2019

Approaches to the Search of Platinum Anticancer Agents: Derivatizing Current Drugs and Incorporating HDAC Inhibition

Chao Feng

University of the Pacific, fengchaopacific@gmail.com

Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds

Part of the Chemistry Commons

Recommended Citation
https://scholarlycommons.pacific.edu/uop_etds/3637

This Dissertation is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been accepted for inclusion in University of the Pacific Theses and Dissertations by an authorized administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.
APPROACHES TO THE SEARCH OF PLATINUM ANTICANCER AGENTS: DERIVATIZING CURRENT DRUGS AND INCORPORATING HDAC INHIBITION

by

Chao Feng

A Dissertation Submitted to the

Graduate School

In Partial Fulfillment of the

Requirements for the Degree of

DOCTOR OF PHILOSOPHY

Thomas J. Long School of Pharmacy and Health Sciences
Pharmaceutical and Chemical Sciences

University of the Pacific
Stockton, CA

2019
APPROACHES TO THE SEARCH OF PLATINUM ANTICANCER AGENTS: DERIVATIZING CURRENT DRUGS AND INCORPORATING HDAC INHIBITION

by

Chao Feng

APPROVED BY:

Dissertation Advisor: Qinliang Zhao, Ph.D.

Committee Member: Yi Chen, Ph.D.

Committee Member: Liang Xue, Ph.D.

Committee Member: Jianhua Ren, Ph.D.

Committee Member: Jerry Tsai, Ph.D.

Department Chairs: Jianhua Ren, Ph.D.; Jerry Tsai, Ph.D.

Dean of Graduate School: Thomas Naehr, Ph.D.
APPROACHES TO THE SEARCH OF PLATINUM ANTICANCER AGENTS:
DERIVATIZING CURRENT DRUGS AND INCORPORATING HDAC INHIBITION

Copyright 2019

by

Chao Feng
ACKNOWLEDGMENTS

First, and most of all, I would like to thank my Ph.D. advisor Dr. Qinliang Zhao for her endless support during the past five years. Thank her for accepting me as an engineering background student and for giving me the freedom to explore different projects. She is a strong woman, mother, professor, and scientist, and always inspire me of solving problems, not only in research but also in life.

I would like to thank my Ph.D. committee members. Dr. Yi Chen (Newave Pharmaceuticals Inc.) has been guiding me through my whole project. Some of the chemicals were purchased and all the HDAC inhibition screening were conducted with his generous support. Without his help, I could not have learned this much and might not have been able to pursue my career in the pharmaceutical industry. I would like to thank Dr. Liang Xue for his great help with the DNA binding assay and suggestions on biostudies. I would like to thank Dr. Jianhua Ren for allowing me to use mass spectrometers in her lab. I would like to thank Dr. Jerry Tsai for chairing my qualifying exam and aiding me in the course work. I would like to thank all the committee members for being flexible with my defense schedules.

I would also like to thank Prof. O. David Sparkman for teaching me all the knowledge about mass spectrometry and giving me the opportunity to work at pacific mass spectrometry facility. I would like to thank Dr. Andy Franz for his great help in all the NMR, especially the long-hour platinum NMR measurements. I would like to thank Dr. Xin Guo for his help and discussion in cell culture study. I would like to thank Dr. Dingben Chen for helping me with the organic molecule synthesis and purification. I would also like to thank Dr. Brett William and Ms. Susan McCann for taking care of all the paper works and chemical supplies.
I would also like to thank all my colleagues at the University of the Pacific. My labmate, Dr. Michael B. Pastor for being with me in the lab for the first four years and always helping me with my research, English and my life in the United States. Yuntao Zhang for tons of help in mass spectrometry analysis and daily life. Yingbo Huang for all the work and great help in cell culture studies. I would also like to thank Dan Shao. She has been with me and participated in all my projects. I appreciate all her help as a great partner. I would like to thank Ethan Liu for editing my dissertation. I would also like to thank all other members of Dr. Qinliang Zhao’s research group.

Lastly, I would like to thank my parents. Without their support and encouragement, I could not be here to finish my Ph.D.
Platinum-based anticancer drugs, such as cisplatin, carboplatin, and oxaliplatin, have been approved for clinical use worldwide for decades. Despite their enormous success, their widespread application is hindered by either cross-resistance or toxic side effects, including nephrotoxicity and neurotoxicity. The need to overcome these drawbacks has stimulated the search for new platinum-based drugs.

This dissertation will start with the accidental discovery of cisplatin, followed by an introduction of other platinum-based anticancer agents, including the action mechanism, general structures, and development history. Picoplatin is a newer generation of platinum-based anticancer agent. The bulky 2-methylpyridine as a non-leaving group on picoplatin could reduce the detoxification effect caused by thiol-containing species, such as glutathione and metallothionein, thus may grant picoplatin the ability to overcome cisplatin resistance. A convenient synthesis route for picoplatin derivatives has been developed. 11 new picoplatin derivatives have been designed by varying the bulkiness of the non-leaving amine group. All complexes have been characterized by different instrumentations, including MS, $^1$H NMR, $^{13}$C NMR, $^{195}$Pt NMR, HMQC, X-ray crystallography, and elemental analysis. Different bioassays, such as DNA binding, cell viability, and cellular accumulation, have been applied to evaluate their efficacy on cisplatin-sensitive ovarian cancer cell line A2780 and cisplatin-resistant ovarian
cancer cell line A2780cis. The newly designed picoplatin derivatives show comparable efficacy with that of picoplatin and less resistance compared with cisplatin. The study of picoplatin derivatives laid the foundation toward the research of bifunctional platinum-based anticancer agents by incorporating histone deacetylase (HDAC) inhibition.

Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are a pair of important enzymes in epigenetic regulation. They work in harmony to acetylate and deacetylate histone lysine residues, resulting in a more relaxed or more condensed chromatin structure, respectively. HDAC has been found to be overexpressed in some cancer cells. Since 2006, 5 HDAC inhibitors (HDACi) have entered clinical use for cancer treatment. 19 new HDACi with additional coordination sites on the phenyl cap have been designed, synthesized, and evaluated. A few of the new HDACi show comparable or even better HDAC inhibition than that of Vorinostat (SAHA, the first FDA approved HDACi).

A logical design would involve the installation of HDACi on the platinum center as a non-leaving group ligand. When the bifunctional drug reaches the cancer cell, the synergistic effect could be maintained as the relaxed chromatin structure makes DNA more susceptible to be attacked by the platinum centers, thus increase the anticancer activity and possibly selectivity toward cancer cells. 6 Pt-HDACi conjugates have been designed and synthesized. Dual functions of the new Pt-HDACi have been confirmed by DNA electrophoresis assay and HDAC inhibition assay. One of the Pt-HDACi (CF-101) shows comparable cytotoxicity with cisplatin and less resistance, which could be used as the lead compound for further structural modification and in vivo studies.
TABLE OF CONTENTS

LIST OF TABLES ......................................................................................................................... 10

LIST OF FIGURES ...................................................................................................................... 11

LIST OF ABBREVIATIONS ......................................................................................................... 13

Chapter 1: Platinum Anticancer Agents ...................................................................................... 15

1.1 The Discovery of Cisplatin .................................................................................................. 15

1.2 Action Mechanism of Cisplatin ......................................................................................... 17

1.3 General Structure of Platinum Anticancer Agents ............................................................. 19

1.4 Clinically Approved Platinum Anticancer Agents ............................................................... 21

Chapter 2: Picoplatin Derivatives .............................................................................................. 24

2.1 Introduction ......................................................................................................................... 24

2.2 Preparation of Picoplatin Derivatives ............................................................................... 26

2.3 Bioassay Protocols ............................................................................................................. 35

2.4 Results and Discussion ...................................................................................................... 37

2.5 Conclusions ....................................................................................................................... 45

Chapter 3: HDAC Inhibitors ................................................................................................... 47

3.1 Introduction ......................................................................................................................... 47

3.2 Preparation of HDAC Inhibitors ....................................................................................... 51

3.3 HDAC Inhibition and Cell Viability Study ......................................................................... 80

3.4 Conclusions ....................................................................................................................... 83
Chapter 4: Pt-HDACi Conjugates

4.1 Introduction

4.2 Design of Pt-HDACi Conjugates

4.3 Preparation of Pt-HDACi Conjugates

4.4 Results and Discussion

4.5 Conclusions

References

APPENDIX A: SYNTHESIS SCHEME

APPENDIX B: NMR SPECTRA DATA

APPENDIX C: MASS SPECTRA DATA

APPENDIX D: X-RAY DATA

APPENDIX E: BIOSTUDY DATA
LIST OF TABLES

Table

2.1 Cytotoxic activities of cisplatin, Pt-1, Pt-3, and Pt-4 in cell lines A2780 and A2780cis. ..... 43

2.2 Cellular accumulation of platinum from cisplatin, Pt-1, Pt-3, and Pt-4 in A2780 and A2780cis. * ................................................................................................................................. 44

3.1 HDAC1 inhibition and cell viability for compound CF-L01 to CF-L12. * ........................................ 81

3.2 HDAC1 inhibition of CF-L13 to CF-L19 .......................................................................................... 83

4.1 $^{195}$Pt NMR shifts of monodentate Pt-HDACi and its corresponding picoplatin derivatives. ........................................ 97

4.2 HDAC1 inhibition of Pt-HDACi conjugates and their corresponding free ligands. ......... 99

4.3 Cell viability IC$_{50}$ values of Pt-HDACi in four different cancer cell lines. ................... 101

4.4 Cellular accumulation of platinum from cisplatin, Pt-HDACi in four different cancer cell lines. (treated at 10µM for 24 h). ........................................................................................................ 102
LIST OF FIGURES

Figure

1.1 NIH-registered clinical trials involving cisplatin as of 2019. The numbers only reflect those trials that are recruiting and active, not recruiting. ......................................................... 16

1.2 Action mechanism of cisplatin. ......................................................... 18

1.3 General structure of platinum anticancer agents. ......................... 20

1.4 The family tree of platinum anticancer agents. ................................. 22

2.1 Crystal structure of picoplatin ......................................................... 24

2.2 Summary of picoplatin derivatives ................................................ 28

2.3 DNA gel electrophoresis of picoplatin derivatives ................................ 38

2.4 The DNA binding yield of picoplatin derivatives. (confidence interval: 95%, p<0.01) ........ 39

2.5 DMF % by volume effect on cell viability study of A2780 and A2780cis. ......................... 40

2.6 Preliminary cell viability screening of picoplatin derivatives in two ovarian cell lines at two concentrations. (a) A2780 with 5 µM, (b) A2780 with 20 µM, (c) A2780cis with 5 µM, (d) A2780cis with 20 µM. ............................................................... 41

2.7 IC$_{50}$ curve of cisplatin, Pt-1, Pt-3, and Pt-4 in (a) A2780 and (b) A2780cis cell lines. .............. 42

2.8 Cellular accumulation of platinum from cisplatin, Pt-1, Pt-3, and Pt-4 in A2780 and A2780cis cell lines. (treated at 10µM for 24 h) **** p≤0.0001, *** p≤0.001. ......................................................... 45

3.1 Roles of histone acetyltransferases (HATs) and histone deacetylases (HDACs) in regulating histone proteins (right), and HDACs in deacetylation mechanism (left). ............................................. 48

3.2 (a) X-ray crystal structure of SAHA bound to an HDAC-like protein. (b) Molecular structure of SAHA. ................................................................. 49

3.3 Clinically approved HDAC inhibitors with approving agency, year of approval, therapeutic indication, and administration route. ...................................................... 50

3.4 Structures of HDAC inhibitors (CF-L01 to CF-L12) ..................................... 51

3.5 Structures of HDAC inhibitors (CF-L13 to CF-L17). ..................................... 53
3.6 Structures of HDAC inhibitors CF-L18 and CF-L19. .......................................................... 54

4.1 HDACi-based hybrid agents in clinical trials. $^{6,150,146}$ ......................................................... 86

4.2 Pt-HDACi hybrid molecule reported by Marmion’s team.$^{113,151}$ .............................................. 87

4.3 The design logic of Pt-HDACi conjugates. ................................................................................. 88

4.4 Pt-HDACi hybrid molecules (bidentate binding) designed in current research. ................. 90

4.5 Pt-HDACi hybrid molecules (bidentate binding) designed in current research. ................. 90

4.6 The stacked $^1$H NMR spectra of CF-L13 (top, blue trace) and CF-102 (bottom, red trace). 98

4.7 DNA gel electrophoresis of CF-101, CF-102, CF-103 and CF-104, reference to cisplatin and SAHA......................................................................................................................... 98

4.8 The DNA binding yields of Pt-HDACi conjugates. (confidence interval: 95%, p<0.1) ........ 99

4.9 IC$_{50}$ curve of SAHA, cisplatin, and Pt-HDACi in (a) HCT-116, (b)A549, (c)A2780 and (d) A2780cis cell lines. .................................................................................................................. 100

4.10 Cellular accumulation of platinum from cisplatin, Pt-HDACi in four different cancer cell lines. (treated at 10µM for 24 h) **** p≤0.0001, *** p≤0.001, * p≤0.1, ns p >0.1.............. 102

4.11 Preliminary cell viability screening of Pt-13, Pt-14, and Pt-15 in two different ovarian cell lines at two different concentrations. (a) A2780 with 5 µM, (b) A2780 with 20 µM, (c) A2780cis with 5 µM, (d) A2780cis with 20 µM.................................................................................................................. 104
LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>Acetonitrile</td>
</tr>
<tr>
<td>CID</td>
<td>Collision-induced dissociation</td>
</tr>
<tr>
<td>CHCl₃</td>
<td>Chloroform</td>
</tr>
<tr>
<td>COSY</td>
<td>Homonuclear Correlation Spectroscopy</td>
</tr>
<tr>
<td>DART</td>
<td>Direct Analysis in Real Time</td>
</tr>
<tr>
<td>DCM</td>
<td>Dichloromethane</td>
</tr>
<tr>
<td>DMF</td>
<td>Dimethylformamide</td>
</tr>
<tr>
<td>DIEA</td>
<td>N,N-Diisopropylethylamine</td>
</tr>
<tr>
<td>DI</td>
<td>Deionized</td>
</tr>
<tr>
<td>Equiv</td>
<td>Equivalent</td>
</tr>
<tr>
<td>Et₂O</td>
<td>Diethyl Ether</td>
</tr>
<tr>
<td>ESI</td>
<td>Electrospray Ionization</td>
</tr>
<tr>
<td>EtOH</td>
<td>Ethanol</td>
</tr>
<tr>
<td>EtOAc</td>
<td>Ethyl Acetate</td>
</tr>
<tr>
<td>HMBC</td>
<td>Heteronuclear Multiple-Bond Correlation spectroscopy</td>
</tr>
<tr>
<td>HATU</td>
<td>1-[Bis(dimethylamino)methylene]-1H-1,2,3- triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate</td>
</tr>
<tr>
<td>MS</td>
<td>Mass Spectrometry</td>
</tr>
<tr>
<td>m-CPBA</td>
<td>meta-Chloroperoxybenzoic acid</td>
</tr>
<tr>
<td>MeOH</td>
<td>Methanol</td>
</tr>
<tr>
<td>NMP</td>
<td>N-Methyl-2-pyrrolidone</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>NMR</td>
<td>Nuclear Magnetic Resonance</td>
</tr>
<tr>
<td>PE</td>
<td>Petroleum Ether</td>
</tr>
<tr>
<td>rt</td>
<td>Room Temperature, 25 °C (also RT)</td>
</tr>
</tbody>
</table>
Chapter 1: Platinum Anticancer Agents

1.1 The Discovery of Cisplatin

Over 50 years ago, Dr. Barnett Rosenberg, a biophysicist at Michigan State University, was applying an electrical field to bacteria in order to investigate whether it could affect the cell division. Because platinum is inert and was thought to have no biological effect in the study, Dr. Rosenberg and his group added platinum electrodes in the growth chamber containing *E. coli*. Once the current was on, the *E.coli* stopped dividing and kept growing as very long filaments (up to 300 times long as normal length), which was quite abnormal. When the power/current was off, the *E.coli* began to divide again. They spent two years trying to understand why the electrical field had such a powerful effect on *E. coli* division. It turned out that this effect was not due to the electrical field but rather the compound formed with platinum that was released from the electrode that blocked cell division. Dr. Rosenberg and his team spent another two years to identify the active complex and later named it cisplatin.\(^1\) It turns out that cisplatin was originally synthesized by the Italian chemist Michele Peyrone in 1845 and named as Peyrone’s chloride.\(^2,^3\) Later, cisplatin was approved by the US Food and Drug Administration (FDA) for cancer treatment in 1978. It is the first metal-based anticancer reagent for worldwide clinical use. Before that time, all the chemicals for cancer treatment were either natural products or synthetic organic compounds. Since then, cisplatin became the gold standard for new metal-containing drug design.\(^4,^5\) As of 2019, there are still close to 1,000 clinical trials involving cisplatin all over the world (Figure 1.1).\(^6\)
Figure 1.1 NIH-registered clinical trials involving cisplatin as of 2019. The numbers only reflect those trials that are recruiting and active, not recruiting.\(^6\)

The first rapid way to synthesize cisplatin was developed by S. C. Dhara in 1970 (Scheme 1).\(^7\)\(^8\)\(^9\) \(\text{K}_2\text{PtCl}_4\) was first converted to \(\text{K}_2\text{PtI}_4\) in aqueous solution with an excess of KI. Two equivalents of ammonium hydroxide were added to the dark brown solution of \(\text{K}_2\text{PtI}_4\) and yielded a yellow precipitate \(\text{cis-}[\text{Pt(NH}_3\text{)}_2\text{I}_2]\). Iodide ligands were then removed by 2 equiv \(\text{AgNO}_3\), yielding \(\text{cis-}[\text{Pt(NH}_3\text{)}_2(\text{H}_2\text{O})_2]^{2+}\). Finally, isometrically pure cisplatin was made by adding excess KCl. The key intermediate during the Dhara synthesis was \(\text{K}[\text{Pt(NH}_3\text{)}\text{I}_3]\). The stronger \textit{trans} effect of iodide with respect to chloride ensures that the next \(\text{NH}_3\) ligand would substitute the position \textit{trans} to an iodide, which affords the \textit{cis} isomer. Cisplatin can be purified by recrystallization in hot water containing either 0.1 M \text{HCl} or 0.9 \% \text{NaCl} solution.\(^10\)\(^11\) The high chloride concentration helps to stabilize the cisplatin during the recrystallization process.
1.2 Action Mechanism of Cisplatin

Cisplatin has been widely used for different types of cancer treatment, including testicular, ovarian, cervical, breast, bladder, head and neck, esophageal, lung cancer, mesothelioma brain tumors, and neuroblastoma.\(^{12}\) It is administered intravenously to the patients as a short-term infusion in saline solution. Numerous experiments have been designed and conducted by scientists to study the cisplatin action mechanism. The general mechanism involves four key steps (Figure 1.2), including (i) cellular uptake, (ii) aquation/activation, (iii) DNA binding, and (iv) apoptosis.\(^{13}\) Once the cisplatin is administered to the bloodstream, it remains unchanged and neutral due to the high concentration of chloride (~ 100 mM).\(^ {9}\) However, cisplatin is still susceptible to be attacked by plasma proteins, particularly those containing thiol groups, such as albumin, which lead to the deactivation of cisplatin, causing side effects including nephrotoxicity and neurotoxicity.\(^ {4,9,14}\) There are two main pathways in the cellular uptake process, either by passive diffusion due to the concentration difference or active transport by membrane proteins, such as copper transporter proteins.\(^ {15,16,17}\) The relative importance of
these two pathways remains to be determined. Once cisplatin enters the cell, intracellular chloride concentration is decreased (below 20 mM) and chlorine ligands on cisplatin can be easily substituted by water molecules.\textsuperscript{18} This process is called aquation/activation. However, such activation is suppressed in the bloodstream due to the high chloride concentration. The positively charged Pt-water complex ion could be attracted to the negatively charged DNA, where the water molecules coordinated to the Pt center could be substituted by the most nucleophilic N7 position on guanine and adenine.\textsuperscript{19} The major DNA binding product is the 1,2-d(GpG) intrastrand cross-link adduct (65%), which causes the distortion of DNA.\textsuperscript{20,21} If the cell cannot repair the damage, it will go apoptosis. One of the main mechanisms during the cell apoptosis from platinum treatment is the inhibition of RNA polymerases transcription past platinum lesions.\textsuperscript{22}

Figure 1.2 Action mechanism of cisplatin.\textsuperscript{13}
However, some cancers are intrinsically resistant to cisplatin or acquire resistance during the treatment, either by the lowered uptake efficiency, increased detoxification in the cytoplasm, or resistance mediated after DNA binding.\textsuperscript{1,13} As cisplatin is a highly polar compound compared with other small molecule drugs, the uptake process is relatively slow and influenced by many other factors, like Na\textsuperscript{+} and K\textsuperscript{+} concentrations, and transporter expression. The resistance of cisplatin during the uptake process is mainly due to the low uptake efficiency rather than increased cisplatin efflux, which is a common resistance mechanism for most natural product-based drugs.\textsuperscript{15} It has been reported that downregulation of membrane transporters is one of the reasons.\textsuperscript{1} However, the detailed molecular mechanism involved in the cisplatin uptake is still poorly understood. Another reason for cisplatin resistance is the increased detoxification caused by the raised concentration of thiol-containing species in the cytoplasm of cancer cells, such as glutathione and metallothioneins. Because cisplatin is easier to bind to sulfur-containing species, the resulting conjugation is more readily exported from the cancer cells.\textsuperscript{23–25} After the platinum-DNA adducts are formed, cells can survive by either through increased DNA repair or tolerance mechanism. Many cisplatin-resistant cancer cell lines have shown increased DNA repair capacity compared to the sensitive cell lines, like testicular cancer. The major DNA repair pathway involved in the removal of platinum-DNA lesions is nucleotide excision repair.\textsuperscript{26} The increased tolerance could also come from the loss of DNA mismatch repair,\textsuperscript{27,28} bypass of DNA adducts,\textsuperscript{29,30} or decreased apoptosis.\textsuperscript{31}

### 1.3 General Structure of Platinum Anticancer Agents

Although cisplatin is a very effective anticancer drug, it is highly toxic to kidneys (nephrotoxicity),\textsuperscript{1,32} which have driven chemists and biologists to make safer platinum agents to overcome the toxicity and the cisplatin resistance. In designing new platinum-based anticancer
agents, there are a few moieties that could be modified (Figure 1.3). Typically, there are three different types of ligands (L, R, and X) that could be incorporated onto the coordination environment of the Pt core. Ligands L, the “non-leaving group” ligands which typically contain nitrogen donors, bind to platinum tightly and stay unchanged in the final platinum-DNA adducts.

![Diagram of platinum anticancer agents](image)

**Figure 1.3 General structure of platinum anticancer agents.**

Modification of the L ligands would affect the nature of the platinum-DNA adducts, therefore changing the resistance profile. The leaving group ligands X, commonly halides and carboxylates, are labile and could be replaced through ligand substitution. Modification of ligands X can change the aquation/activation kinetics and therefore changing toxicity profile. The axial ligands R only present in tetravalent platinum complexes and will dissociate after biological reduction. They could be used for tumor targeting by incorporating a functional R group aiming for specific cancer cells. Any modification of these three types of ligands will cause the change of lipophilicity and solubility, and both of these properties are very important in
terms of drug design. Ongoing research mainly focuses on reducing the toxic side effects of cisplatin, combating the drug resistance by modifying the ligands or improving the delivery technique.

1.4 Clinically Approved Platinum Anticancer Agents

Since the discovery of the first platinum drug cisplatin, another six platinum drugs (Figure 1.4) have been approved for clinical use in the USA and other countries. Carboplatin, as the second-generation Pt-based drug, was approved by FDA in 1989 and primarily used to treat ovarian cancer.\textsuperscript{12,37} It contains the same non-leaving group as cisplatin, but a different leaving group. The bidentate 1,1-cyclobutanedicarboxylate ligand that binds to Pt is tighter due to the chelation effect, resulted in a much slower aquation/activation rate compared with cisplatin.\textsuperscript{38,39} Because of the slower activation rate, carboplatin is much more gentle to off-target biological nucleophiles and thus has a lower toxicity profile.\textsuperscript{40,41} Therefore, carboplatin can be administered at a higher dosage than cisplatin. Although carboplatin is less toxic than cisplatin, it exhibits the same cross-resistance to cisplatin since they share the same non-leaving group, which results in the same platinum DNA-adducts as cisplatin.\textsuperscript{42,43}

Oxaliplatin mainly used for colorectal cancer treatment, is the third generation of platinum-based anticancer drugs and gained FDA approval in 2002.\textsuperscript{12,37} Like carboplatin, oxaliplatin has a chelating ligand (oxalate) as the leaving group, which are less susceptible to aquation. However, it has a different non-leaving group (1R,2R-diaminocyclohexane), which shows different sensitivity to cancer cell lines compared to cisplatin and carboplatin.\textsuperscript{42} The accumulation of oxaliplatin seems to be less dependent on copper transporters, but more on organic cation transporters, which are normally overexpressed in colon cancer.\textsuperscript{44,45} Oxaliplatin is the first clinically approved platinum drug that can overcome cisplatin resistance.
Figure 1.4 The family tree of platinum anticancer agents.

Nedaplatin is a second-generation analog that shares the same non-leaving group as cisplatin and carboplatin, but has a different chelating leaving group (glycolate) compared to carboplatin. The glycolate contributes to nedaplatin’s higher water solubility than cisplatin and lower nephrotoxicity than cisplatin and carboplatin.\textsuperscript{46} Nedaplatin was approved in Japan in 1995 and was primarily used for small cell lung cancer and non-small cell lung cancer.\textsuperscript{12,37}
Heptaplatin, approved by South Korea in 1999, is used for gastric cancer treatment.\textsuperscript{12,37} It possesses malonate as a chelating leaving group and bidentate 2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine as the non-leaving group. The advantage of heptaplatin is the lower toxic side effects.\textsuperscript{47}

Lobaplatin, approved by China in 2003, is used for chronic myelogenous leukemia, breast cancer, and small cell lung cancer.\textsuperscript{12,13,37} It has an S-lactate as the leaving group and a R, R and S, S racemic mixture as the non-leaving group ligand. Therefore, lobaplatin is a mixture of diastereomers.\textsuperscript{48}

Miriplatin, approved by Japan in 2009, is used for hepatocellular carcinoma. It has the same non-leaving group as oxaliplatin and contains myristates as the leaving group, which makes miriplatin a lipophilic complex. It can be easily suspended in ethyl esters of iodized fatty acids. The advantage of miriplatin suspension is the reduced toxicities in normal liver and the whole body.\textsuperscript{49}

There are a few platinum anticancer agents that have entered clinical trials but not approved yet, such as satraplatin (an orally active prodrug),\textsuperscript{50} picoplatin (overcome cisplatin resistance),\textsuperscript{51} prolindac (AP5346, water-soluble biocompatible polymer for advanced delivery),\textsuperscript{52} and et al. Detailed discussion about picoplatin will be included in Chapter 2.
Chapter 2: Picoplatin Derivatives

2.1 Introduction

Numerous studies have indicated that the platinum detoxification by thiol-containing species, such as glutathione and metallothionein, is one of the main reasons for cisplatin resistance.\textsuperscript{23–25} The rationality of the design for a platinum drug containing a bulky ligand is that the bulky ligand could reduce the possibility of platinum binding to thiols which led to the invention of picoplatin (\textit{cis}-aminodichloro(2-methylpyridine) platinum (II)).\textsuperscript{51,53–55}

Figure 2.1 Crystal structure of picoplatin.
As shown in Figure 2.1, picoplatin contains a 2-methylpyridine (2-picoline) as one of the non-leaving groups. The pyridine ring is approximately perpendicular to the square planar coordination plane of platinum, leaving the methyl group on 2-picoline pointing to the axial position of the platinum. This provides the steric hindrance that prevents the thiols from attacking the platinum, therefore reducing the drug detoxification. Picoplatin was shown to be less reactive to thiol-containing species than cisplatin and also exhibited a slower aquation rate than cisplatin.\textsuperscript{56,57} The steric methyl group on the pyridine ring significantly affects the substitution kinetics of the picoplatin complex.

Picoplatin initially came from the collaboration between the Institute of Cancer and Johnson Matthey/AnorMed.\textsuperscript{53} Preclinical studies have shown that picoplatin has antitumor properties in cisplatin-resistant ovarian cancer cells and lung cancer cell lines.\textsuperscript{58} Studies have shown that cisplatin sensitive ovarian cancer cells (A2780) that were transfected to overexpress metallothionein has around 7-fold higher resistance to cisplatin, whereas there is no appreciable resistance to picoplatin.\textsuperscript{59} Picoplatin also retains anticancer activity in cells with overexpressed drug resistance proteins and cell lines possessing acquired resistance to oxaliplatin.\textsuperscript{60–62} A phase I clinical trial study of picoplatin started in 1997 and the drug was well tolerated with neutropenia as the common side effect.\textsuperscript{37} In a phase II clinical trial study, picoplatin was evaluated against platinum pretreated ovarian cancers and small cell lung cancers.\textsuperscript{63–65} In a phase III trial study launched in 2007 with 399 participants, picoplatin was used as a second-line treatment for small cell lung cancer, sponsored by Poniard Pharmaceuticals.\textsuperscript{55} There are also other clinical trial studies involving picoplatin as a treatment for different types of cancer.

Picoplatin with potent activity toward cancer cells and advantage over cisplatin-resistance cancer cells due to its steric feature presented us great potential to further fine-tune its structural
properties. Thus, we set our goal to synthesize families of picoplatin derivatives by varying the bulkiness of the non-leaving amine group. In this chapter, synthesis, characterization and various bioassay studies of picoplatin derivatives will be described in detail, followed by results and discussion.

2.2 Preparation of Picoplatin Derivatives

General procedures. The synthesis was conducted in a regular wet-lab setting in the Chemistry Department, University of the Pacific. All reagents were purchased from commercial vendors and used without further purification. NMR spectra were recorded using a JEOL 600 MHz spectrometer. $^1$H NMR data are reported as follows: chemical shift in ppm relative to the residual solvent peaks, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, br = broad signal). MS spectra were recorded using JEOL DART/ESI-AccuTOF spectrometer, Varian 320 ESI-MS spectrometer or Thermal ESI-LTQ MS spectrometer. Elemental analysis was performed by Atlantic Microlab, Inc. X-ray structures were collected on Beamline 11.3.1 at the Advanced Light Source, Lawrence Berkeley National Lab using monochromatic radiation ($\lambda = 0.7749 \text{ Å}$)

![Diagram](image)

Scheme 2.1 Synthesis of Picoplatin.
A rapid way to synthesize picoplatin was developed in our lab by modifying the methods in literature and patent. The synthesis scheme was shown in Scheme 2.1. The key intermediate $K[PtCl_3(2\text{-picoline})]$ (TCPP) was synthesized in anhydrous N-methyl-2-pyrrolidone (NMP) and further purified from anhydrous dimethylformamide (DMF). The yield of TCPP could reach 90%. The crystal structure is given in Appendix D. The bulky methyl group on the pyridine ring is crucial to the formation of the monosubstituted Pt intermediate. Picoplatin was then directly synthesized from TCPP in water by adding ammonium hydroxide without adding any other buffer. The purification process is quite straightforward without any use of chromatography. Using TCPP as the key intermediate, more than 10 picoplatin derivatives have been successfully synthesized and isolated (Scheme 2.2). They all secured 2-picoline as one non-leaving group and another non-leaving group, including primary amines, secondary amines, cycloalkyl amines, cyclic amines, pyridine, and benzylamine (Figure 2.2). According to the trans
effect theory, all derivatives should have a *cis* configuration, which was confirmed in most of the derivatives by X-ray crystallography (Appendix D).

Figure 2.2 Summary of picoplatin derivatives.
K[PtCl₃(2-picoline)] (TCPP). To a mixture of potassium tetrachloroplatinate (II) fine powder, K₂PtCl₄ (1.0 g, 2.41 mmol, 1.0 equiv) in anhydrous NMP (6 mL) was added a solution of 2-picoline (261 µL, 0.464 mmol, 1.1 equiv) in 1 mL NMP at a rate of 20% every 20 min. The reaction was stirred at 65 °C for around 2 h after the complete addition of 2-picoline and stopped after all K₂PtCl₄ has dissolved. Byproduct KCl and a trace amount of unreacted K₂PtCl₄ are removed by vacuum filtration. Dichloromethane (DCM) was added to the filtrate to precipitate/crush out the product as a yellow solid. After the solids settled down, the supernatant was decanted, and the process was repeated three times to help to remove most NMP solvent. The solid was collected via vacuum filtration and washed with DCM, which was then dried overnight. The crude product was further purified by dissolving it in anhydrous DMF (~3-5 mL) and insoluble salts were removed by filtration. DCM was then added to the filtrate to induce product formation. After the solids settled down, the supernatant was decanted, and the process was repeated three times to help to remove most DMF solvent. The solid was collected via vacuum filtration and washed with DCM, which was then dried overnight to afford a yellow solid (0.94g, yield: 90%). ¹H NMR (600 MHz, D₂O): δ 8.82 (dd, J = 6.0, 1.1 Hz, 1H), 7.72 (td, J = 7.8, 1.6 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.26 (t, J = 6.7 Hz, 1H), 3.18 (s, 3H). ¹³C NMR (151 MHz, D₂O): δ 161.41, 153.56, 139.00, 126.97, 123.55, 26.02. ¹⁹⁵Pt NMR (129 MHz, D₂O): δ 1781.63. ESI-MS: m/z value of the most abundant isotope peak of C₆H₇Cl₃NPt, [M]⁺ calcd 393.9267, found 393.9. Crystals were obtained by vapor diffusion crystallization set-up with ether diffusing into a methanol solution.

PtCl₂(2-picoline)(NH₃) (Pt-1, picoplatin). To a solution of TCPP (120 mg, 0.277 mmol, 1.0 equiv) in H₂O (1 mL) was added 6 M NH₄OH (231µL, 1.38 mmol, 5.0 equiv) and stirred at 45 °C in dark. A light-yellow solid started to precipitate out after 10 min. The light-yellow solid was collected via vacuum filtration after 1 h of stirring and washed with cold water and acetone. The
final product was dried under vacuum overnight (43.6 mg, yield: 42%). $^1$H NMR (600 MHz, DMF-d$_7$) δ 9.05 (d, J = 5.7 Hz, 1H), 7.88 (t, J = 7.7 Hz, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.35 (t, J = 6.6 Hz, 1H), 4.41 (s, 2H), 3.18 (s, 3H). $^{13}$C NMR (151 MHz, DMF-d$_7$): δ 162.84, 155.27, 139.13, 127.31, 123.91, 26.82. $^{195}$Pt NMR (129 MHz, DMF-d$_7$): δ -2042.86. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_6$H$_{10}$Cl$_2$N$_2$PtNa, [M+Na]$^+$ calcd 398.9747, found 398.9662.

Crystals were obtained by vapor diffusion crystallization set-up using MeOH and ether.

**PtCl$_2$(2-picoline)((CH$_3$)$_2$NH)** (Pt-2). To a solution of TCPP (100 mg, 0.23 mmol, 1.0 equiv) in H$_2$O (1 mL) was added dimethylamine with a mass percentage of 40% in water (87.6µL, 0.69 mmol, 3.0 equiv) and stirred at 45 °C in dark for 1 h. A light-yellow solid that formed was collected via vacuum filtration and washed with cold water, acetone and DCM. The product was dried under vacuum overnight (37 mg, yield: 40 %). $^1$H NMR (600 MHz, DMF-d$_7$) δ 9.16 (d, J = 5.6 Hz, 1H), 7.93 (t, J = 7.5 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.42 (t, J = 6.5 Hz, 1H), 5.89 (s, 1H), 3.21 (s, 3H), 2.60 (d, J = 5.7 Hz, 3H), 2.54 (d, J = 5.7 Hz, 3H). $^{13}$C NMR (151 MHz, DMF-d$_7$): δ 162.71, 154.97, 139.48, 127.79, 124.44, 44.29, 44.19, 26.91. $^{195}$Pt NMR (129 MHz, DMF-d$_7$): δ -2088.57. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_8$H$_{14}$Cl$_2$N$_2$PtNa, [M+Na]$^+$ calcd 427.0061, found 427.0079. Anal. calcd for C$_8$H$_{14}$Cl$_2$N$_2$Pt: C, 23.77; H, 3.49; N, 6.93%. Found: C, 23.92; H, 3.45; N, 6.69%. Crystals were obtained by slow evaporation of a saturated DMF solution.

**PtCl$_2$(2-picoline)((CH$_3$)$_2$CHNH$_2$)** (Pt-3). Following the same synthesis procedure as Pt-2, the reaction afforded a light-yellow solid (yield: 20 %). $^1$H NMR (600 MHz, DMF-d$_7$) δ 9.05 (d, J = 5.8 Hz, 1H), 7.89 (td, J = 7.7, 1.2 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.38 (t, J = 6.7 Hz, 1H), 3.18 (s, 3H), 3.12 (m, 1H), 1.33 (d, J = 6.5 Hz, 3H), 1.26 (d, J = 6.5 Hz, 3H). $^{13}$C NMR (151 MHz, DMF-d$_7$): δ 162.87, 155.21, 139.24, 127.54, 124.16, 48.65, 26.84, 23.65, 23.45. $^{195}$Pt NMR (129 MHz, DMF-d$_7$): δ 162.57.
MHz, DMF-d$_7$): $\delta$ -2101.25. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_9$H$_{16}$Cl$_2$N$_2$PtNa, [M+Na]$^+$ calcd 427.0218, found 441.0277. Anal. calcd for C$_9$H$_{16}$Cl$_2$N$_2$Pt: C, 25.85; H, 3.86; N, 6.70%. Found: C, 26.08; H, 3.72; N, 6.64%. Crystals were obtained by vapor diffusion crystallization set-up using MeOH and ether.

**PtCl$_2$(2-picoline)(cyclopropylamine) (Pt-4).** To a solution of TCPP (125 mg, 0.288 mmol, 1.0 equiv) in anhydrous DMF (3 mL) was added cyclopropylamine (16.5 mg, 20.0 µL, 0.288 mmol, 1.0 equiv). The resulting mixture was stirred at 65 °C for 20 h. An insoluble byproduct was removed by filtration and DMF in the filtrate was removed under reduced pressure (40-45 °C, 125 rpm). The residual was then dissolved in acetone (0.5mL), filtered and purified by preparative alumina TLC (DCM/Acetone =3/1). The gel band containing the product was scratched off, dissolved in acetone, filtered, concentrated to dryness, and triturated twice with Et$_2$O. A light-yellow product was collected via centrifugation, and dried under vacuum overnight (23 mg, yield: 19 %). $^1$H NMR (600 MHz, DMF-d$_7$) $\delta$ 9.14 (d, $J$ = 5.8 Hz, 1H), 7.90 (td, $J$ = 7.8, 1.4 Hz, 1H), 7.59 (d, $J$ = 7.9 Hz, 1H), 7.39 (t, $J$ = 6.6 Hz, 1H), 5.17 (s, 2H), 3.23 (s, 3H), 2.37 – 2.31 (m, 1H), 0.50 – 0.46 (m, 2H), 0.45 – 0.41 (m, 2H). $^{13}$C NMR (151 MHz, DMF-d$_7$): $\delta$ 162.87, 155.42, 139.28, 127.41, 123.98, 30.76, 26.94, 6.80, 6.78. $^{195}$Pt NMR (129 MHz, DMF-d$_7$): $\delta$ -2084.60. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_9$H$_{14}$Cl$_2$N$_2$PtNa, [M+Na]$^+$ calcd 439.0061, found 439.0069. Anal. calcd for C$_9$H$_{14}$Cl$_2$N$_2$Pt: C, 25.97; H, 3.39; N, 6.73%. Found: C, 26.17; H, 3.27; N, 6.75%. Crystals of the final product were obtained by slow evaporation of a saturated DMF solution.

**PtCl$_2$(2-picoline)(cyclobutylamine) (Pt-5).** Following the same synthesis procedure as Pt-4, the reaction led to a light-yellow solid as the final product (yield: 20 %). $^1$H NMR (600 MHz, DMF-d$_7$) $\delta$ 9.05 (d, $J$ = 5.3 Hz, 1H), 7.90 (t, $J$ = 7.7 Hz, 1H), 7.59 (d, $J$ = 7.5 Hz, 1H), 7.39 (t, $J$ =
6.6 Hz, 1H), 5.32 (d, J = 49.5 Hz, 2H), 3.46 – 3.38 (m, 1H), 3.19 (s, 3H), 2.16 (m, 2H), 1.97 (m, 2H), 1.55 (m, 2H). $^{13}$C NMR (151 MHz, DMF-d$_7$): δ 162.86, 155.34, 139.26, 127.49, 124.11, 52.74, 30.88, 30.81, 26.94, 14.38. $^{195}$Pt NMR (129 MHz, DMF-d$_7$): δ -2104.26. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_{10}$H$_{16}$Cl$_2$N$_2$PtNa, [M+Na]$^+$ calcd 453.0218, found 453.0271. Anal. calcd for C$_{10}$H$_{16}$Cl$_2$N$_2$Pt: C, 27.92; H, 3.75; N, 6.51%. Found: C, 28.05; H, 3.78; N, 6.30%. Crystals were obtained by vapor diffusion crystallization set-up using DCM and ether.

**PtCl$_2$(2-picoline)(cyclopentylamine) (Pt-6).** A light-yellow solid (yield: 14 %) as the product was obtained by following the same synthesis procedure as Pt-4. $^1$H NMR (600 MHz, DMF-d$_7$) δ 9.07 (d, J = 5.1 Hz, 1H), 7.89 (t, J = 7.4 Hz, 1H), 7.58 (d, J = 7.5 Hz, 1H), 7.39 (t, J = 6.1 Hz, 1H), 5.12 (s, 2H), 3.26 (m, 1H), 3.20 (s, 3H), 2.08 (m, 1H), 1.98 (m, 1H), 1.65 (m, 4H), 1.49 (m, 2H). $^{13}$C NMR (151 MHz, DMF-d$_7$): δ 162.86, 155.21, 139.22, 127.50, 124.10, 58.64, 34.03, 33.99, 26.87, 24.70, 24.62. $^{195}$Pt NMR (129 MHz, DMF-d$_7$): δ -2099.05. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_{11}$H$_{18}$Cl$_2$N$_2$PtNa, [M+Na]$^+$ calcd 467.0375, found 467.0442. Anal. calcd for C$_{11}$H$_{18}$Cl$_2$N$_2$Pt: C, 29.74; H, 4.08; N, 6.31%. Found: C, 29.85; H, 3.93; N, 6.31%. Crystals were obtained by vapor diffusion crystallization set-up using DCM and ether.

**PtCl$_2$(2-picoline)(cyclohexylamine) (Pt-7).** The same synthesis procedure as Pt-4 was applied, led to the formation of a light-yellow solid, which was further purified by preparative alumina TLC (DCM/EtOAc =1/1). (yield: 23 %). $^1$H NMR (600 MHz, DMF-d$_7$) δ 9.05 (d, J = 5.2 Hz, 1H), 7.88 (t, J = 7.4 Hz, 1H), 7.57 (d, J = 7.7 Hz, 1H), 7.38 (t, J = 6.3 Hz, 1H), 5.07 (s, 2H), 3.18 (s, 3H), 2.72 (m, 1H), 2.52 m, 1H), 2.26 (d, J = 11.2 Hz, 1H), 1.72 (m, 1H), 1.67 (d, J = 12.8 Hz, 1H), 1.54 (d, J = 12.3 Hz, 1H), 1.30 – 1.16 (m, 4H), 1.03 (m, 1H). $^{13}$C NMR (151
MHz, DMF-d7): δ 162.85, 155.27, 139.18, 127.49, 124.11, 55.74, 34.53, 34.32, 26.82, 26.31, 25.91, 25.84. 195Pt NMR (129 MHz, DMF-d7): δ -2093.93. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C12H20Cl2N2PtNa, [M+Na]+ calcd 481.0532, found 481.0679.

Anal. calcd for C12H20Cl2N2Pt (0.5 H2O): C, 30.82; H, 4.53; N, 6.00%. Found: C, 31.02; H, 4.60; N, 5.89%. Crystals were obtained by vapor diffusion crystallization set-up using DCM and ether.

**PtCl2(2-picoline)(azetidine) (Pt-8).** To a solution of TCPP (150 mg, 0.346 mmol, 1.0 equiv) in anhydrous DMF (3 mL) was added azetidine (19.7 mg, 23.3 µL, 0.346 mmol, 1.0 equiv), and the resulting solution was stirred at 65 °C for 20 h. The insoluble byproducts were removed by filtration. DMF in the filtrate was concentrated under reduced pressure (40-45 °C, 125 rpm) until only ~0.5 mL was left. The residual was triturated twice with H2O (2.0 mL), decanted, and lyophilized to remove water. The crude product was washed with EtOAc (~1 mL) and Et2O (5 mL) twice, collected via centrifugation, and dried under vacuum overnight to afford a light-yellow solid (26 mg, yield: 18 %). 1H NMR (600 MHz, DMF-d7) δ 9.08 (d, J = 5.4 Hz, 1H), 7.93 (t, J = 7.6 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.41 (t, J = 6.6 Hz, 1H), 6.84 (br, 1H), 3.93 (m, 1H), 3.78 (m, 1H), 3.56 – 3.47 (m, 2H), 3.14 (s, 3H), 2.52 (m, 1H), 2.08 (m, 1H). 13C NMR (151 MHz, DMF-d7): δ 162.43, 155.02, 139.45, 127.65, 124.38, 53.93, 53.65, 26.84, 22.56. 195Pt NMR (129 MHz, DMF-d7): δ -2139.23. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C9H14Cl2N2PtNa, [M+Na]+ calcd 439.0061, found 438.9988. Anal. calcd for C9H14Cl2N2Pt: C, 25.97; H, 3.39; N, 6.73%. Found: C, 26.13; H, 3.40; N, 6.51%. Crystals were obtained by vapor diffusion crystallization set-up using DCM and ether.

**PtCl2(2-picoline)(pyrrolidine) (Pt-9).** Following the same synthesis procedure as Pt-8, the reaction led to the formation of a light-yellow crude product, which was purified by preparative
silica TLC (DCM/MeOH =20/1). The gel band containing the product was scratched off, dissolved in anhydrous DMF, filtered, and concentrated to ~0.5 mL. EtOAc was added to precipitate/crush out the final light-yellow product, which was then collected via centrifugation, washed with Et2O, and dried under vacuum overnight (yield: 31 %). 1H NMR (600 MHz, DMF-d7) δ 9.13 (d, J = 5.5 Hz, 1H), 7.91 (t, J = 7.6 Hz, 1H), 7.61 (d, J = 7.7 Hz, 1H), 7.40 (t, J = 6.4 Hz, 1H), 5.89 (br, 1H), 3.21 (s, 3H), 3.18 (m, 2H), 3.04 (m, 1H), 2.83 (m, 1H), 1.66 (m, 4H). 13C NMR (151 MHz, DMF-d7): δ 162.64, 155.05, 139.35, 127.63, 124.36, 52.94, 52.85, 27.02, 24.22, 24.17 (shown in HMQC spectrum). 195Pt NMR (129 MHz, DMF-d7): δ -2095.61. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C10H16Cl2N2PtNa, [M+Na]+ calcd 453.0218, found 453.0123. Anal. calcd for C10H16Cl2N2Pt: C, 27.92; H, 3.75; N, 6.51%. Found: C, 28.00; H, 3.57; N, 6.46%. Crystals were obtained by vapor diffusion crystallization set-up (DCM/Ether).

PtCl2(2-picoline)(piperidine) (Pt-10). Following the same synthesis procedure as Pt-8, Pt-10 was obtained as a light-yellow solid (yield: 35%). 1H NMR (600 MHz, DMF-d7) δ 9.12 (d, J = 5.3 Hz, 1H), 7.91 (t, J = 7.5 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.41 (t, J = 6.3 Hz, 1H), 5.60 (br, 1H), 3.41 – 3.31 (m, 2H), 3.20 (s, 3H), 3.02 (m, 1H), 2.82 (m, 1H), 1.65 (m, 2H), 1.56 (m, 1H), 1.47 (m, 2H), 1.33 (m, 1H). 13C NMR (151 MHz, DMF-d7): δ 162.73, 154.91, 139.32, 127.67, 124.37, 54.17, 54.06, 26.98, 26.94, 26.81, 24.33. 195Pt NMR (129 MHz, DMF-d7): δ -2122.03. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C11H18Cl2N2PtNa, [M+Na]+ calcd 467.0375, found 467.0235. Anal. calcd for C11H18Cl2N2Pt: C, 29.74; H, 4.08; N, 6.31%. Found: C, 30.16; H, 4.19; N, 6.13%. Crystals were obtained by vapor diffusion crystallization set-up using MeOH and ether.
**PtCl\(_2\)(2-picoline)(pyridine)** (Pt-11). Using the same synthesis procedure as Pt-9, a light-yellow solid was obtained (yield: 18%). \(^1\)H NMR (600 MHz, DMF-d\(_7\)) δ 9.22 (d, \(J = 5.4\) Hz, 1H), 8.92 (d, \(J = 5.4\) Hz, 2H), 8.04 (t, \(J = 7.7\) Hz, 1H), 7.93 (t, \(J = 7.4\) Hz, 1H), 7.60 (d, \(J = 7.8\) Hz, 1H), 7.57-7.53 (m, 2H), 7.43 (t, \(J = 6.6\) Hz, 1H), 3.19 (s, 3H). \(^{13}\)C NMR (151 MHz, DMF-d\(_7\)): δ 162.32, 154.46, 153.96 (2), 140.14, 139.95, 128.03, 127.53 (2), 124.76, 26.46. \(^{195}\)Pt NMR (129 MHz, DMF-d\(_7\)): δ -1979.29. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C\(_{11}\)H\(_{12}\)Cl\(_2\)N\(_2\)PtNa, [M+Na]\(^+\) calcd 460.9905, found 460.9798. Anal. calcd for C\(_{11}\)H\(_{12}\)Cl\(_2\)N\(_2\)Pt: C, 30.15; H, 2.76; N, 6.39%. Found: C, 29.88; H, 2.63; N, 6.10%. Crystals were obtained by vapor diffusion crystallization set-up using MeOH and hexanes.

**PtCl\(_2\)(2-picoline)(benzylamine)** (Pt-12). The same synthesis procedure as Pt-8 was applied to afford a light-yellow crude product (yield: 26%). \(^1\)H NMR (600 MHz, DMF-d\(_7\)) δ 8.59 (d, \(J = 5.7\) Hz, 1H), 7.83 (t, \(J = 7.6\) Hz, 1H), 7.50 (m, 3H), 7.37 (m, 3H), 7.23 (t, \(J = 6.5\) Hz, 1H), 5.57 (d, \(J = 41.6\) Hz, 2H), 3.97 (m, 1H), 3.90 (m, 1H), 3.05 (s, 3H). \(^{13}\)C NMR (151 MHz, DMF-d\(_7\)): δ 162.76, 154.81, 139.29, 139.05, 130.15, 129.39, 128.67, 127.30, 123.82, 50.80, 26.70. (The \(^{13}\)C peak signals between 127.30 and 130.15 ppm represent 6 aromatic \(^{13}\)C, shown in HMQC NMR spectrum) \(^{195}\)Pt NMR (129 MHz, DMF-d\(_7\)): δ -2095.60. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C\(_{13}\)H\(_{16}\)Cl\(_2\)N\(_2\)PtNa, [M+Na]\(^+\) calcd 489.0219, found 489.0150. Anal. calcd for C\(_{13}\)H\(_{16}\)Cl\(_2\)N\(_2\)Pt: C, 33.49; H, 3.46; N, 6.01%. Found: C, 33.76; H, 3.52; N, 5.83%. Crystals were obtained by vapor diffusion crystallization set-up using a solvent pair of EtOH and cyclohexane.

### 2.3 Bioassay Protocols

#### 2.3.1 DNA binding assay
DNA binding study was performed at Dr. Liang Xue’s lab in the Chemistry Department, University of the Pacific. The complex was dissolved in DI water
(200 µM) and stirred for 2 h at rt in a darkroom. The complex (20 µM) was then incubated with phosphate buffer (10 µM, pH = 6) and single-strand DNA (5' TCTCCTTCTGGTCTCTTCTC 3', 10 µM) at 37 °C for 5 hrs. Water was removed by lyophilization. The resulting sample was then dissolved in 30% glycerol (20 µL volume, 20 mM concentration) and loaded (5 µL) on a 22.5% of polyacrylamide gel (200 V for 25 h). SYBR green II was used as a stain solution. The staining time was 30-40 min. The gel was destained in deionized water (DI) for 1 min and scanned at 450 nm.

2.3.2 Cell viability assay. Cell viability study was performed in the School of Pharmacy, University of the Pacific in collaboration with Dr. Xin Guo’s lab. Two cell lines, ovarian cancer cell line A2780 (cisplatin sensitive) and A2780cis (cisplatin-resistant), were purchased from Sigma Aldrich and used as the screening cell lines. They have shown different morphologies, with round shape morphology for A2780 and fibroblastic morphology for A2780cis (Appendix E). The cells were seeded (10,000) and cultured for 12 h on 96-well plates (UltraCruz® Tissue Culture Plate, catalog: sc-204447). The cell medium is RPMI-1640 with 2 mM Glutamine and 10% Foetal Bovine Serum (FBS). After the test compounds were dosed, the incubation (5% CO2, 95% humidity, 37°C) of cells was continued for 72 h. Blank and solvent controls were incubated under the same conditions. MTS assay purchased from Promega was used to quantify viable cells which are capable to reduce the tetrazolium compounds into a colored formazan product.69 The incubation time is 3 h and then the absorbance at 490 nm was recorded using a 96-well plate reader. The data was processed using GraphPad Prism 7. To maintain the cisplatin resistance of A2780cis, cisplatin as a 1 µM solution in the same medium was added every 2 passages.70,71
2.3.3 Cellular accumulation assay. The cellular uptake study of platinum complexes was conducted using a Thermal ICP-OES instrument (iCAP 6000 series) in our lab at the Chemistry Department, University of the Pacific. Standard calibration curve of Pt in the same nitric acid matrix as the sample, measured at 214.4 nm using a series of dilutions from 1000 ppm stock solution in 5% nitric acid was obtained before the sample measurement. A2780 and A2780cis were cultured at the School of Pharmacy and $10^6$ cells were seeded in 6-wells tissue culture plates (UltraCruz® Tissue Culture Plate, catalog: sc-204443) with 2 mL cell culture (5% CO₂, 95% humidity, 37°C). The culture was removed after 24 h and replaced by new cell culture with a 10μM platinum compound and continue to incubate for 24 h. The cell culture was removed using a pipette and washed three times with phosphate-buffered saline (PBS buffer, 2 mL each wash). Parallel experiments under the same condition except adding platinum compounds were used for cell counting. Concentrated HNO₃ (70%, 1 mL/well) was used to digest the samples. After 2 h, the digested sample was diluted 10 times using DI (0.6 mL to 5.4 mL DI), which was then injected to ICP-OES directly. Wells without cell seeding was used as the blank control. Three independent replicates were conducted for every experiment. After subtracting the values from the blank control, the platinum content was quantified to nanogram Pt per $10^6$ cells.²²,⁷³

2.4 Results and Discussion

2.4.1 DNA binding study. Since DNA is the biological target of platinum-based anticancer agents and 1,2-d(GpG) intrastrand cross-link adduct is the main product. A single strand 20mer DNA with two adjacent guanines in the middle (5' TCTCCTTCTGGTCTTTCTC 3')⁷⁴ as the binding site was selected and prepared by Dr. Liang Xue’s lab for initial screening.
Figure 2.3 DNA gel electrophoresis of picoplatin derivatives.

In the DNA gel electrophoresis graph of Figure 2.3, the bottom darker spot is the pure DNA and the top spot is the Pt-DNA adduct, which has been confirmed by mass spectrometry (Appendix E). Since the molecular weight of Pt-DNA adduct formed with each picoplatin derivative is quite close to that of cisplatin, the separation difference of all Pt-DNA adducts is negligibly small like cisplatin, thus all the Pt-DNA adducts were aligned in the gel electrophoresis. Quantitative study with three runs for each complex has been conducted (Appendix E) and the summary is shown in Figure 2.4. Not surprisingly, cisplatin is still the most efficient one in terms of binding yield. Complexes Pt-4, Pt-5, and Pt-6 showed comparable binding efficiency with Pt-1 (picoplatin). In order to further exam these complexes, a cell viability study was performed.
2.4.2 Cell viability study. Before performing the cell viability study, the toxicity of the formulation solvent needed to be evaluated. Dimethyl sulfoxide (DMSO) is the most commonly used formulation solvent in cell viability studies. However, it does not work for platinum-containing agents as the nucleophilic sulfur atom on the DMSO will bind to platinum and deactivate the complex. As initiated by other researchers, DMF was applied to formulate our platinum compound. Different amount of DMF have been used in the literature, ranging from 0.1% to 1.0% by volume. Initially, 1% DMF was chosen, however, most of the cells died before adding any of the platinum complexes. A detailed study was performed to evaluate the percentage of DMF by volume toxicity effect on cell viability, shown in Figure 2.5. The figure demonstrated that DMF at higher concentration does possess higher toxicity toward cells. In order to reduce solvent toxicity but at the same time formulate/dissolve the platinum complex, 0.25 % DMF was chosen in the following studies.
Preliminary cell viability screening of picoplatin derivatives in A2780 and A2780cis cell lines was performed at two different concentrations of 5 µM, and 20 µM (Figure 2.6). It is very clear that the A2780 cell line is more sensitive to all complexes. In A2780 cell line, Pt-4, Pt-5, Pt-6, Pt-11, and Pt-12 shows comparable cell viability to cisplatin and picoplatin (Pt-1), while the rest are less toxic. In A2780cis cell line, Pt-4, Pt-5, Pt-6, Pt-11, and Pt-12 have comparable cell viability to picoplatin and even better than that of cisplatin. Overall, the picoplatin derivatives bearing a cycloalkyl amine as the non-leaving group showed promising activity, while cyclic amines as the non-leaving group have less efficacy. Pyridine ring (Pt-11) and benzyamine (Pt-12) as non-leaving groups also showed better efficacy. The study demonstrated that the steric feature and ring constraints of the ligands on the platinum agents played an important role in its efficacy toward cancer cells. Pt-1, Pt-3, and Pt-4, representing a reference and samples with potent efficacy, were used for more detailed study.
Figure 2.6 Preliminary cell viability screening of picoplatin derivatives in two ovarian cell lines at two concentrations. (a) A2780 with 5 µM, (b) A2780 with 20 µM, (c) A2780cis with 5 µM, (d) A2780cis with 20 µM.

The IC₅₀ values of **Pt-1**, **Pt-3**, and **Pt-4** against A2780 and A2780cis were reported in Figure 2.7 and summarized in Table 2.1. Cisplatin is used as the reference compound. Directly dissolving the compound in 0.25% or 25% DMF did not work. The pre-formulation strategy was applied in the study. A test compound is first dissolved in pure DMF and then diluted with 3× volume of the cell culture media to reach 25% DMF by volume. A series of dilution was done using cell culture media containing 25% DMF by volume to obtain the stock solution. The stock
solution was further diluted 100× using pure cell culture media to obtain the working solution (0.25% DMF by volume), which was directly added to the 96-well plates (200 µL).

Figure 2.7 IC$_{50}$ curve of cisplatin, Pt-1, Pt-3, and Pt-4 in (a) A2780 and (b) A2780cis cell lines.
Table 2.1 Cytotoxic activities of cisplatin, Pt-1, Pt-3, and Pt-4 in cell lines A2780 and A2780cis.

<table>
<thead>
<tr>
<th>IC$_{50}$ (µM)</th>
<th>A2780</th>
<th>A2780cis</th>
<th>Resistance factor (R$_f$)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin</td>
<td>1.42 ± 0.13</td>
<td>12.26 ± 0.59</td>
<td>8.63</td>
</tr>
<tr>
<td>Pt-1</td>
<td>4.40 ± 0.50</td>
<td>12.85 ± 1.59</td>
<td>2.92</td>
</tr>
<tr>
<td>Pt-3</td>
<td>11.59 ± 1.05</td>
<td>23.13 ± 4.35</td>
<td>2.00</td>
</tr>
<tr>
<td>Pt-4</td>
<td>4.43 ± 0.48</td>
<td>14.81 ± 2.08</td>
<td>3.34</td>
</tr>
</tbody>
</table>

*Resistance factor (R$_f$) is defined as IC$_{50}$(A2780cis)/IC$_{50}$(A2780)

Although Pt-1 (picoplatin) and Pt-4 are less toxic than cisplatin in cisplatin sensitive cell line A2780, they show comparable IC$_{50}$ value with cisplatin in A2780cis. As expected, cisplatin shows a high resistance factor (R$_f$) of 8.63, which is consistent with the literature data.$^{70,71}$ Both Pt-1 (picoplatin) and Pt-4 have a much smaller resistance factor, indicating a low cross-resistance to cisplatin. Pt-3 has a very similar formula and structure as those of Pt-4 but less cytotoxic in both A2780 and A2780cis cell lines. In order to further understand the nuance of biological action among these complexes, a cellular accumulation study was conducted.

2.4.3 Cellular accumulation study. Intracellular accumulation is one of the key factors affecting the cytotoxicity of platinum-based anticancer agents. To examine the accumulation level of platinum in A2780 and A2780cis cell lines, cisplatin, Pt-1, Pt-3, and Pt-4 were chosen for the study. The test compounds, each at 10 µM, were incubated with the cancer cell lines for 24 h and the platinum level was measured by ICP-OES. Data from Figure 2.8 and Table 2.2 demonstrated that significant difference was observed among the four compounds, with cisplatin being the simplest and smallest platinum agent but having low cellular accumulation. Picoplatin derivatives with more organic components and higher molecular weight, especially Pt-1 and Pt-4, were easier to accumulate in both cell lines than cisplatin. Therefore, the structural feature of the platinum agents played a significant role in the platinum accumulation levels in cells.
However, there is no linear relationship between the bulkiness of the complex and the level of cellular accumulation. Even a minor change in the structure could lead to huge difference in cellular uptake, such as Pt-3 and Pt-4. The only difference between Pt-3 and Pt-4 is on one of the non-leaving groups, being isopropylamine on Pt-3 and cyclopropylamine with ring strain on Pt-4. However, the cellular accumulation levels of Pt-4 in both cell lines are nearly doubled in comparison to those of Pt-3. Therefore, a trivial structural variation, such as with or without ring strain, could significantly alter its activity toward cancer cells.

The accumulation levels of platinum in A2780cis are significantly lower than that in A2780 for all four compounds, which explains the decreasing cytotoxicity of these compounds in A2780cis. The research provided strong support for the proposed hypothesis where cancer cells could grow resistance to platinum drugs possibly by downregulation of membrane transporter, or more readily exportation of detoxified conjugation from cells. Pt-1 and Pt-4 are much easier to accumulate in both A2780 and A2780cis cell lines, however, the IC$_{50}$ values (Table 2.1) are not smaller than that of cisplatin in A2780, indicating the enhanced cytotoxicity of cisplatin in A2780 is not due to the significantly low cellular accumulation of cisplatin. The higher cellular accumulation of Pt-1 and Pt-4 in A2780cis may contribute to their low IC$_{50}$ values (Table 2.1), which are comparable to that of cisplatin.

<table>
<thead>
<tr>
<th>Mean (ng Pt/10$^6$ cell)</th>
<th>A2780</th>
<th>A2780cis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin</td>
<td>59.59 ± 1.62</td>
<td>10.28 ± 0.41</td>
</tr>
<tr>
<td>Pt-1</td>
<td>121.80 ± 0.94</td>
<td>29.89 ± 1.35</td>
</tr>
<tr>
<td>Pt-3</td>
<td>55.35 ± 2.64</td>
<td>21.77 ± 2.49</td>
</tr>
<tr>
<td>Pt-4</td>
<td>103.50 ± 3.18</td>
<td>51.82 ± 5.17</td>
</tr>
</tbody>
</table>

*treated at 10µM for 24 h
2.5 Conclusions

A convenient synthesis route for picoplatin derivatives have been established and 11 picoplatin derivatives have been synthesized and characterized. The bulky methyl group on 2-picoline is crucial for the formation of monosubstituted product TCPP, while TCPP is the key intermediate leading to the success of all picoplatin derivatives. The solvent involved in the last step of the synthesis is either protic solvent H₂O or anhydrous aprotic solvent DMF. If the non-leaving group is a small amine and the product formation is quick, H₂O with mild reaction temperature (~45 °C) would be applied, otherwise, anhydrous DMF with moderate reaction temperature (~65 °C) is the first choice. The stronger trans effect of the chloride than that of the pyridine on TCPP led to the successful synthesis of the picoplatin derivatives, all in cis configuration confirmed by solid-state structural analysis.
Three bioassays were used to evaluate the efficacy of picoplatin derivatives, including DNA binding assay, cell viability assay, and cellular accumulation assay. The DNA gel electrophoresis shows that the picoplatin derivatives have comparable binding efficiency with picoplatin. Cell viability studies show that derivatives with cycloalkyl amines with ring strain as non-leaving group exhibits better efficacy, while that with cyclic amines as non-leaving group shows less efficacy. \textbf{Pt-11} with pyridine ring and \textbf{Pt-12} with benzylamine as non-leaving groups also show better efficacy. Cellular accumulation study shows a higher level of platinum content in the A2780 cell line than that of A2780cis, which may be one of the explanations for the cisplatin resistance in A2780cis cell line.

The study of picoplatin derivatives laid the foundation for the search of platinum-based anticancer agents through structural attenuation.
Chapter 3: HDAC Inhibitors

3.1 Introduction

It is well known that DNA is wrapped around histone proteins to form chromatin. As shown in Figure 3.1, the positively charged lysine residue of histone protein has strong ionic interaction with the negatively charged DNA, resulting in a more condensed chromatin structure.\textsuperscript{82,83} Histone acetylase (HAT) is an enzyme that can add an acetyl group on the lysine residue, thereby neutralizing the positive charge and forming a relaxed chromatin structure. The more open structure allows transcription factors to access the gene, thereby promoting the gene expression. On the other hand, histone deacetylase (HDAC) is an enzyme that can remove the acetyl group from the acetylated lysine residue and restore the positive charge, therefore returning to the condensed chromatin structure. Deacetylation of the histone proteins will cause gene silencing. The acetylation status is controlled by HAT and HDAC enzyme families and is one of the most extensively studied epigenetic process.\textsuperscript{83,84,85}

There are eighteen HDACs that have been identified in humans and are subdivided into four classes, including class I HDACs (HDAC 1, 2, 3 and 8), class II HDACs (HDAC 4, 5, 6, 7, 9 and 10), class III HDACs (SIRT 1, 2, 3, 4, 5, 6 and 7) and class IV HDACs (HDAC 11).\textsuperscript{86,87} It has been reported that many HDACs are overexpressed in different types of cancers, including HDAC1 in the prostate,\textsuperscript{88} gastric,\textsuperscript{89} colon\textsuperscript{90} and breast cancers\textsuperscript{91}, HDAC2 in colorectal,\textsuperscript{90,92} cervical\textsuperscript{93} and gastric cancer,\textsuperscript{94} HDAC3 in colon cancer\textsuperscript{90} and HDAC6 in breast cancer.\textsuperscript{95} On the other hand, knockdown of individual HDACs overexpressed in cancers could suppress cell growth.\textsuperscript{90,92,93,96} It also has been shown that overexpressed HDAC suppress the expression of cancer suppressor genes in many tumors, and HDAC inhibitors (HDACi) could restore the
expression of cancer-suppressive genes and induce apoptosis.\textsuperscript{86,97–103} Therefore, HDAC has become a promising biological target for cancer treatment.\textsuperscript{83,86,104,105}

Figure 3.1 Roles of histone acetyltransferases (HATs) and histone deacetylases (HDACs) in regulating histone proteins (right), and HDACs in deacetylation mechanism (left).\textsuperscript{82,83}

Most HDACs have a catalytic zinc domain, as shown in the left part of Figure 3.1.\textsuperscript{82,83} The zinc cofactor acts as a Lewis acid, which interacts with the oxygen atom of the acetyl group and catalyzes its hydrolysis. If there is a stronger chelator that could bind to the catalytic zinc center, the deacetylation would be inhibited, resulting in a more relaxed chromatin structure.

The design of HDACi was originally derived from the understanding of the co-crystal structure between a bacterial homolog of histone deacetylase-like protein and hydroxamic acid Trichostain A.\textsuperscript{106} The scaffold was also based on mimics of acetylated lysine. The first FDA approved HDACi is Vorinostat (SAHA). As shown in Figure 3.2 b, it consists of three main
domains: a surface binding domain (cap), a hydrocarbon linker motif, and a zinc-binding group (ZBG). All components are necessary for a new HDAC inhibitor to function effectively. A recent study on the X-ray crystal structure of SAHA bound to an HDAC-like protein discovered an internal cavity adjacent to the zinc-binding domain (Figure 3.2 a), which hinted for additional hydrophobic moiety in the newer HDACi design.

![Figure 3.2 (a) X-ray crystal structure of SAHA bound to an HDAC-like protein.](image1)

(b) Molecular structure of SAHA.

To date, five HDAC inhibitors shown in Figure 3.3 have entered clinical use, with four approved by US FDA and one approved by the China Food and Drug Administration (CFDA). Vorinostat, belinostat, and panobinostat all have hydroximic acids as the zinc-binding group. The depsipeptides romidepsin is more like a prodrug and the disulfide bond in romidepsin would be reduced and release the active thiol group acting as the zinc-binding group. Chidamide has ortho-aminoanilide as the zinc-binding group. There are many kinds of HDAC inhibitors, including short-chain alkanoic acids, hydroxamic acids, cyclic peptides, and other macrocycles, ortho-aminoanilides, et al. As most clinically studied and approved HDAC inhibitors are hydroxamic acids and ortho-aminoanilides derivatives, and their synthesis is more
straightforward while compared to cyclic peptides, we will focus on HDAC inhibitors with hydroxamic acids and *ortho*-aminoamides in the following study.

Figure 3.3 Clinically approved HDAC inhibitors with approving agency, year of approval, therapeutic indication, and administration route.¹⁰⁸
3.2 Preparation of HDAC Inhibitors

As shown in Figure 3.4, 12 HDAC inhibitors have been synthesized and characterized in our lab. They shared the same cap domain, 2-methyl pyridine, but have variations on the linkage between the cap domain and linker, the linker length, and the zinc-binding group. The linkage between the cap domain and linker could be an ether bond or a reversed amide bond. Convenience in their synthesis is the main reason in choosing these linkages. The second variation is the linker length, with 5 or 6 carbons, which is the appropriate length approved by various bioassays. The third variation is the zinc-binding group, including hydroxamic acid, ortho-aminoamilide and ortho-aminoamilide possessing a C-5 phenyl group that could occupy the internal cavity illustrated in Figure 3.2 a. The general synthesis scheme is shown in Scheme 3.1. Structures of HDAC inhibitors CF-L13 to CF-L19 are shown in Figure 3.5 and Figure 3.6. CF-L13 to CF-L17 were designed based on the results of structural activity relationship study of CF-L01 to CF-L12. CF-L18 and CF-L19 were designed by modifying
Panobinostat. The detailed synthesis scheme of each individual HDAC inhibitor is included in Appendix A.

Scheme 3.1 Synthesis routes of HDAC inhibitors (CF-L01 to CF-L12).
Figure 3.5 Structures of HDAC inhibitors (CF-L13 to CF-L17).
General procedures. Refer to part 2.2 in Chapter 2.

Synthesis of $N$-hydroxy-6-((2-methylpyridin-4-yl)oxy)hexanamide (CF-L01)

6-((2-methylpyridin-4-yl)oxy)hexanoic acid (CF-L01-1). Oxepan-2-one (414.0 mg, 3.63 mmol, 1.25 equiv) in DMSO (1 mL) was added dropwise to a stirred suspension of fine KOH powder (570.8 mg, 10.2 mmol, 3.5 equiv) in DMSO (5 mL) at 75 °C. After 30 min, 4-bromo-2-methylpyridine (500 mg, 2.91 mmol, 1.0 equiv) in DMSO (1 mL) was added to the reaction mixture which was stirred for 2 days at 75 °C. After the reaction mixture cooled down, anhydrous EtOH was added and concentrated $\text{H}_2\text{SO}_4$ was used to adjust the pH to 1-2. The
compound CF-L01-1 was detected by DART-AccuTOF MS and directly used for the following step without further purification.

**Ethyl-6-((2-methylpyridin-4-yl)oxy)hexanoate (CF-L01-2).** The mixture from previous step was refluxed overnight. EtOH was removed under reduced pressure. The reaction mixture was extracted with EtOAc and water three times. NaHCO$_3$ solution was used to neutralize the mixture. The organic layers were combined, washed with brine twice and then dried over anhydrous Na$_2$SO$_4$. After filtration, EtOAc was removed under reduced pressure and the crude product was purified by silica gel chromatography (DCM/MeOH=50/1) to afford colorless oil (533 mg, yield: 73%). $^1$H NMR (600 MHz, CDCl$_3$): δ 8.27 (d, J = 5.9 Hz, 1H), 6.65 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 5.9, 2.5 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.98 (t, J = 6.4 Hz, 2H), 2.50 (s, 3H), 2.31 (t, J = 7.5 Hz, 3H), 1.79 (m, 2H), 1.68 (m, 2H), 1.48 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H). $^{13}$C NMR (151 MHz, CDCl$_3$): δ 173.62, 165.96, 159.56, 149.56, 109.70, 107.93, 67.75, 60.38, 34.24, 28.67, 25.59, 24.67, 24.19, 14.33. DART-AccuTOF MS: m/z calcd C$_{14}$H$_{22}$NO$_3$ [M+H]$^+$ 252.1600, found 252.1517.

**N-hydroxy-6-((2-methylpyridin-4-yl)oxy)hexanamide (CF-L01).** To a solution of CF-L01-2 (340.0 mg, 1.35 mmol, 1.0 equiv) in DCM and MeOH (1:2 ratio, 12 mL) at 0 °C, hydroxylamine (50 wt% in water, 1.2 mL, 20.29 mmol, 15.0 equiv) was added, following by fine NaOH powder (541.0 mg, 13.5 mmol, 10.0 equiv). The solution was stirred at 0 °C for 30 min, and then allowed to warm to rt and stirred overnight. The solvent was removed under reduced pressure. Minimum H$_2$O was added to the residual and insoluble particles were removed by filtration. HCl (conc. 1-2 M) was used to adjust the pH of the aqueous filtrate until a white solid precipitated out from the mixture which was cooled in a cold water bath. The product was collected through filtration, washed by cold water and dried overnight to afford a white solid
(257 mg, yield: 80%). $^1$H NMR (600 MHz, CD$_3$OD): δ 8.19 (d, J = 6.0 Hz, 1H), 6.85 (d, J = 2.3 Hz, 1H), 6.80 (dd, J = 6.0, 2.5 Hz, 1H), 4.07 (t, J = 6.4 Hz, 2H), 2.47 (s, 3H), 2.13 (t, J = 7.4 Hz, 2H), 1.82 (m, 2H), 1.69 (m, 2H), 1.50 (m, 2H). $^{13}$C NMR (151 MHz, CD$_3$OD): δ 172.77, 167.98, 160.58, 150.08, 111.05, 109.47, 69.13, 33.62, 29.61, 26.51, 26.38, 23.56. DART-AccuTOF MS: m/z calcd C$_{12}$H$_{19}$N$_2$O$_3$ [M+H]$^+$ 239.1396, found 239.1376. HPLC: 99.5%.

**Synthesis of N-hydroxy-7-((2-methylpyridin-4-yl)oxy)heptanamide (CF-L02)**

Oxocan-2-one (CF-L02-1). To a solution of m-CPBA (14.98g, 66.86 mmol, <77% purity, 1.50 equiv) in DCM (150mL) was added cycloheptanone (5.0 g, 44.58 mmol, 1.0 equiv) under 0 °C and the resulting reaction was stirred for 10 minutes. The reaction mixture was allowed to warm to rt and stirred for 5-6 days. The reaction mixture was cooled to 0 °C for ~30 min and white precipitates were removed by vacuum filtration. The filtrate was washed with saturated NaHCO$_3$, followed by brine twice. The organic layer was dried over anhydrous Na$_2$SO$_4$, filtered and concentrated under reduced pressure to yield a light-yellow liquid, which was confirmed by $^1$H NMR (crude yield: 89%), and used for the next step without further purification.

7-((2-methylpyridin-4-yl)oxy)heptanoic acid (CF-L02-2). CF-L02-1 (761.9 mg, 5.94 mmol, 1.0 equiv) in DMSO (1 mL) was added dropwise to a stirred suspension of fine KOH powder (1167.3 mg, 20.8 mmol, 3.5 equiv) in DMSO (7 mL) at 75 °C. After 30 min of stirring, 4-bromo-2-methylpyridine (1.07 g, 6.24 mmol, 1.0 equiv) in DMSO (1 mL) was added to the reaction mixture, which was stirred for 2 days at 75 °C. After the reaction mixture cooled down, anhydrous EtOH was added and concentrated H$_2$SO$_4$ was added to adjust the pH to 1 to 2. The
compound **CF-L02-2** was detected by DART-AccuTOF MS and used for the following step without further purification.

**Ethyl-7-((2-methylpyridin-4-yl)oxy)heptanoate (CF-L02-3).** Following the same synthesis procedure as **CF-L01-2**, a colorless oil was obtained as the product (yield: 54%). $^1$H NMR (600 MHz, CDCl$_3$): $\delta$ 8.27 (d, $J = 5.9$ Hz, 1H), 6.65 (d, $J = 2.4$ Hz, 1H), 6.62 (dd, $J = 5.9$, 2.5 Hz, 1H), 4.10 (q, $J = 7.1$ Hz, 2H), 3.97 (t, $J = 6.5$ Hz, 2H), 2.50 (s, 3H), 2.29 (t, $J = 7.5$ Hz, 2H), 1.77 (m, 2H), 1.64 (m, 2H), 1.45 (m, 2H), 1.37 (m, 2H), 1.23 (t, $J = 7.1$ Hz, 3H). $^{13}$C NMR (151 MHz, CDCl$_3$): $\delta$ 173.77, 165.96, 159.59, 149.64, 140.84, 109.68, 107.91, 65.89, 60.32, 34.29, 28.85, 28.78, 25.70, 24.88, 24.26, 14.34. DART-AccuTOF MS: m/z calcd C$_{15}$H$_{23}$NO$_3$ [M+H]$^+$ 266.1756, found 266.1662.

**N-hydroxy-7-((2-methylpyridin-4-yl)oxy)heptanamide (CF-L02).** A white solid product was obtained following the same synthesis procedure as **CF-L01** (yield: 80%). $^1$H NMR (600 MHz, CDCl$_3$): $\delta$ 8.17 (d, $J = 5.9$ Hz, 1H), 6.82 (d, $J = 2.3$ Hz, 1H), 6.77 (dd, $J = 5.9$, 2.5 Hz, 1H), 4.05 (t, $J = 6.4$ Hz, 2H), 2.46 (s, 3H), 2.10 (t, $J = 7.4$ Hz, 2H), 1.79 (m, 2H), 1.65 (m, 2H), 1.49 (m, 2H), 1.40 (m, 2H). $^{13}$C NMR (151 MHz, CD$_3$OD): $\delta$ 172.90, 167.74, 160.78, 150.44, 110.92, 109.31, 69.09, 33.67, 29.81, 29.78, 26.67, 26.63, 23.77. DART-AccuTOF MS: m/z calcd C$_{13}$H$_{21}$N$_2$O$_3$ [M+H]$^+$ 253.1552, found 253.1449. HPLC: 99.5%.

**Synthesis of N$^1$-hydroxy-N$^7$-((2-methylpyridin-4-yl)heptanediamide (CF-L03)**

**Ethyl-7-((2-methylpyridin-4-yl)amino)-7-oxoheptanoate (CF-L03-1).** To a solution of ethyl hydrogen pimelate (870.3 mg, 4.62 mmol, 1.0 equiv) in anhydrous DMF (15 mL) was added DIEA (2.4 mL, 13.87 mmol, 3.0 equiv) and HATU (2.2 g, 5.78 mmol, 1.25 equiv). The resulting mixture was stirred for 30 min, followed by the addition of 4-amino-2-picoline (500
mg, 4.62 mmol, 1.0 equiv) and stirring for another 24 h. H₂O (~30 mL) was then added and the mixture was extracted with EtOAc twice. The combined organic layers were washed with brine three times, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (DCM; DCM/MeOH=50/1 to 20/1) to afford a white powder (720 mg, yield: 56%). ¹H NMR (600 MHz, CDCl₃): δ 8.94 (br, 1H), 8.25 (d, J = 5.9 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.40 (dd, J = 5.9, 1.9 Hz, 1H), 4.08 (q, J = 7.1 Hz, 2H), 2.48 (s, 3H), 2.38 (t, J = 7.4 Hz, 2H), 2.27 (t, J = 7.4 Hz, 2H), 1.68 (m, 2H), 1.61 (m, 2H), 1.35 (m, 2H), 1.21 (t, J = 7.1 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃): δ 173.99, 173.05, 157.99, 147.82, 147.39, 113.62, 111.73, 77.37, 77.16, 76.95, 60.45, 37.19, 34.09, 28.53, 24.83, 24.51, 23.21, 14.26. DART-AccuTOF MS: m/z calcd C₁₅H₂₃N₂O₃ [M+H]+ 279.1709, found 279.1889.

N¹-hydroxy-N⁷-(2-methylpyridin-4-yl)heptanediamide (CF-L03). The same synthesis procedure as CF-L01 was applied, resulting a white solid as the product (yield: 72%). ¹H NMR (600 MHz, DMSO-d₆): δ 10.33 (s, 1H), 10.15 (s, 1H), 8.67 (br, 1H), 8.25 (d, J = 5.6 Hz, 1H), 7.44 (d, J = 1.7 Hz, 1H), 7.34 (dd, J = 5.6, 2.0 Hz, 1H), 2.39 (s, 3H), 2.32 (t, J = 7.4 Hz, 2H), 1.94 (t, J = 7.4 Hz, 2H), 1.56 (m, 2H), 1.50 (m, 2H), 1.26 (m, 2H). ¹³C NMR (151 MHz, DMSO-d₆): δ 172.36, 169.03, 158.51, 149.55, 146.05, 111.91, 110.52, 36.35, 32.13, 28.17, 24.89, 24.55, 24.28, 24.27. DART-AccuTOF MS: m/z calcd C₁₃H₂₀N₃O₃ [M+H]+ 266.1505, found 266.1407. HPLC: 98.7%

Synthesis of N¹-hydroxy-N⁸-(2-methylpyridin-4-yl)octanediamide (CF-L04)

Methyl-8-((2-methylpyridin-4-yl)amino)-8-oxooctanoate (CF-L04-1). To a solution of 8-methoxy-8-oxooctanoic acid (870.3 mg, 4.62 mmol, 1.0 equiv) in anhydrous DMF (15 mL) was added DIEA (2.4 mL, 13.87 mmol, 3.0 equiv) and HATU (2.2 g, 5.78 mmol, 1.25 equiv).
The resulting mixture was stirred for 30 min, 4-amino-2-picoline (500 mg, 4.62 mmol, 1.0 equiv) was then added and the resulting mixture was stirred for 24 h. H2O (~30 mL) was added and the mixture was extracted with EtOAc twice. The combined organic layers were washed with brine three times, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (DCM; DCM/MeOH=50/1 to 20/1) to afford a white powder (550 mg, yield: 43%). 1H NMR (600 MHz, CDCl3): δ 8.68 (s, 1H), 8.26 (d, J = 5.9 Hz, 1H), 7.62 (d, J = 1.9 Hz, 1H), 7.42 (dd, J = 5.9, 2.1 Hz, 1H), 3.64 (s, 3H), 2.50 (s, 3H), 2.39 (t, J = 7.5 Hz, 2H), 2.29 (t, J = 7.4 Hz, 2H), 1.68 (m, 2H), 1.60 (m, 2H), 1.37 – 1.29 (m, 4H). 13C NMR (151 MHz, CDCl3): δ 174.51, 173.10, 158.18, 147.74, 147.62, 113.62, 111.74, 77.37, 77.16, 76.95, 51.65, 37.45, 34.03, 28.74, 28.73, 25.01, 24.72, 23.44. DART-AccuTOF MS: m/z calcd C15H23N2O3 [M+H]+ 279.1709, found 279.1669.

N1-hydroxy-N8-(2-methylpyridin-4-yl)octanamide (CF-L04). Following the same synthesis procedure as CF-L01, a white solid was obtained as the final product (yield: 69%). 1H NMR (600 MHz, DMSO-d6): δ 10.34 (s, 1H), 10.17 (s, 1H), 8.67 (br, 1H), 8.25 (d, J = 5.6 Hz, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.34 (dd, J = 5.6, 2.0 Hz, 1H), 2.38 (s, 3H), 2.32 (t, J = 7.4 Hz, 2H), 1.93 (t, J = 7.4 Hz, 2H), 1.56 (m, 2H), 1.48 (m, 2H), 1.30 – 1.21 (m, 4H). 13C NMR (151 MHz, DMSO-d6): δ 172.42, 169.10, 158.50, 149.55, 146.07, 111.92, 110.53, 36.46, 32.23, 28.37, 28.34, 25.01, 24.73, 24.29. DART-AccuTOF MS: m/z calcd C14H22N3O3 [M+H]+ 280.1661, found 280.1621. HPLC: 98.2%

Synthesis of N-(2-aminophenyl)-6-((2-methylpyridin-4-yl)oxy)hexanamide (CF-L05)

6-((2-methylpyridin-4-yl)oxy)hexanoic acid (CF-L05-1). Following the same synthesis procedure as CF-L01-1, CF-L05-1 could be synthesized and used for the next step without
further purification. Alternatively, CF-L05-1 can be synthesized and purified via basic hydrolysis of CF-L01-2. More specifically, CF-L01-2 (798 mg, 3.18 mmol, 1.0 equiv) was dissolved in a 30 mL mixed solution of THF and MeOH (1:1 ratio), followed by the addition of NaOH (1.27 g, 31.8 mmol, 10.0 equiv) in H2O (7.5 mL). The mixture was stirred at rt overnight, concentrated under reduced pressure, and extracted with EtOAc twice. The organic layer was discarded and the insoluble particles in aqueous phase were removed by filtration. HCl solution (conc 1-2 M) was used to adjust the pH of the aqueous filtrate until a white solid precipitated out under cold water bath. Liquid nitrogen could also be applied to induce the precipitate formation if there are no precipitates formed while using cold water bath alone. The product was collected through filtration, washed by cold water and dried overnight to afford a white powder (384 mg, yield: 35%).

1H NMR (600 MHz, DMSO-d6): δ 8.21 (d, J = 5.8 Hz, 1H), 6.80 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 5.8, 2.5 Hz, 1H), 4.00 (t, J = 6.5 Hz, 2H), 2.38 (s, 3H), 2.22 (t, J = 7.4 Hz, 2H), 1.70 (m, 2H), 1.55 (m, 2H), 1.40 (m, 2H).

13C NMR (600 MHz, DMSO-d6): δ 174.43, 164.83, 159.40, 150.02, 109.15, 107.80, 67.28, 33.62, 28.12, 25.03, 24.21, 24.08. DART-AccuTOF MS: m/z calcd C12H18NO3 [M+H]+ 224.1287, found 224.1238.

N-(2-aminophenyl)-6-((2-methylpyridin-4-yl)oxy)hexanamide (CF-L05). To a solution of CF-L05-1 (907 mg, 4.06 mmol, 1.0 equiv) in anhydrous DMF (15 mL) was added DIEA (2.11 mL, 12.19 mmol, 3.0 equiv) and HATU (1.93 g, 5.08 mmol, 1.25 equiv). The solution was stirred for 30 min, followed by the addition of o-phenylenediamine (461 mg, 4.26 mmol, 1.05 equiv). The resulting mixture was stirred for another 24 h. H2O (~30 mL) was added and the mixture was extracted with EtOAc twice. The combined organic layers were washed with brine three times, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by basic alumina gel chromatography.
(DCM/MeOH=30/1) to afford a white powder (535 mg, yield: 42%). $^1$H NMR (600 MHz, CD$_3$OD): $\delta$ 8.17 (d, J = 5.9 Hz, 1H), 7.07 (dd, J = 7.8, 1.5 Hz, 1H), 7.02 (td, J = 7.7, 1.5 Hz, 1H), 6.85 (dd, J = 8.0, 1.4 Hz, 1H), 6.83 (d, J = 2.3 Hz, 1H), 6.78 (dd, J = 5.9, 2.5 Hz, 1H), 6.71 (td, J = 7.6, 1.3 Hz, 1H), 4.08 (t, J = 6.4 Hz, 2H), 2.49 – 2.42 (m, 5H), 1.86 (m, 2H), 1.80 (m, 2H), 1.59 (m, 2H). $^{13}$C NMR (151 MHz, CD$_3$OD): $\delta$ 174.86, 167.72, 160.79, 150.46, 143.30, 128.24, 127.08, 125.16, 119.50, 118.55, 110.94, 109.33, 69.00, 37.06, 29.71, 26.66, 26.65, 23.78.

DART-AccuTOF MS: m/z calcd C$_{18}$H$_{24}$N$_3$O$_2$ [M+H]$^+$ 314.1869, found 314.1916. HPLC: 98.5%.

Synthesis of N-(2-aminophenyl)-7-((2-methylpyridin-4-yl)oxy)heptanamide (CF-L06)

7-((2-methylpyridin-4-yl)oxy)heptanoic acid (CF-L06-1). Following the same synthesis procedure as CF-L02-2, CF-L06-1 was synthesized and used for the next step without further purification. Alternatively, CF-L06-1 could be synthesized and purified via basic hydrolysis of CF-L02-2, following a similar synthesis procedure as CF-L05-1, yielding a white powder (yield: 48%). $^1$H NMR (600 MHz, CD$_3$OD): $\delta$ 8.21 (d, J = 6.1 Hz, 1H), 6.90 (d, J = 2.4 Hz, 1H), 6.85 (dd, J = 6.1, 2.5 Hz, 1H), 4.09 (t, J = 6.4 Hz, 2H), 2.49 (s, 3H), 2.29 (t, J = 7.4 Hz, 2H), 1.81 (m, 2H), 1.64 (m, 2H), 1.50 (m, 2H), 1.42 (m, 2H). $^{13}$C NMR (151 MHz, CD$_3$OD): $\delta$ 178.27, 168.46, 160.21, 149.46, 111.29, 109.73, 69.50, 35.37, 29.91, 29.77, 26.69, 26.16, 23.20.

DART-AccuTOF MS: m/z calcd C$_{13}$H$_{20}$NO$_3$ [M+H]$^+$ 238.1443, found 238.1369.

N-(2-aminophenyl)-7-((2-methylpyridin-4-yl)oxy)heptanamide (CF-L06). The same synthesis procedure as CF-L05 was applied to afford a white solid (yield: 43%). $^1$H NMR (600 MHz, CD$_3$OD): $\delta$ 8.17 (d, J = 5.9 Hz, 1H), 7.07 (dd, J = 7.8, 1.5 Hz, 1H), 7.02 (td, J = 7.6, 1.5 Hz, 1H), 6.84 (dd, J = 8.0, 1.4 Hz, 1H), 6.82 (d, J = 2.3 Hz, 1H), 6.77 (dd, J = 5.9, 2.5 Hz, 1H), 6.70 (td, J = 7.5, 1.3 Hz, 1H), 4.07 (t, J = 6.4 Hz, 2H), 2.45 – 2.42 (m, 5H), 1.83 (m, 2H), 1.76
(m, 2H), 1.52 (m, 4H). $^{13}$C NMR (151 MHz, CD$_3$OD): $\delta$ 175.00, 167.75, 160.77, 150.45, 143.29, 128.23, 127.06, 125.18, 119.51, 118.56, 110.94, 109.32, 69.12, 37.12, 29.95, 29.82, 26.91, 26.76, 23.78. DART-AccuTOF MS: m/z calcd C$_{19}$H$_{26}$N$_3$O$_2$ [M+H]$^+$ 328.2025, found 328.1901. HPLC: 98.8%.

Synthesis of $N^1$-(2-aminophenyl)-$N^7$-(2-methylpyridin-4-yl)heptanediamide (CF-L07).

7-((2-methylpyridin-4-yl)amino)-7-oxoheptanoic acid (CF-L07-1). A similar synthesis procedure as CF-L05-1 was applied to afford a white solid (yield: 58%). $^1$H NMR (600 MHz, DMSO-d$_6$): $\delta$ 12.03 (br, 1H), 10.16 (s, 1H), 8.25 (d, $J = 5.6$ Hz, 1H), 7.44 (d, $J = 1.8$ Hz, 1H), 7.34 (dd, $J = 5.6$, 1.9 Hz, 1H), 2.39 (s, 3H), 2.32 (t, $J = 7.4$ Hz, 2H), 2.20 (t, $J = 7.4$ Hz, 2H), 1.57 (m, 2H), 1.51 (m, 2H), 1.29 (m, 2H). $^{13}$C NMR (151 MHz, DMSO-d$_6$): $\delta$ 174.44, 172.35, 158.50, 149.53, 146.06, 111.92, 110.52, 36.35, 33.55, 28.13, 24.56, 24.27, 24.26. DART-AccuTOF MS: m/z calcd C$_{13}$H$_{19}$N$_2$O$_3$ [M+H]$^+$ 251.1396, found 251.1322.

$N^1$-(2-aminophenyl)-$N^7$-(2-methylpyridin-4-yl)heptanediamide (CF-L07). A similar synthesis procedure as CF-L05 was used to afford a white solid (yield: 48%). $^1$H NMR (600 MHz, CD$_3$OD): $\delta$ 8.23 (d, $J = 5.8$ Hz, 1H), 7.51 (d, $J = 2.0$ Hz, 1H), 7.45 (dd, $J = 5.8$, 2.0 Hz, 1H), 7.06 (dd, $J = 7.9$, 1.5 Hz, 1H), 7.01 (ddd, $J = 8.0$, 7.4, 1.5 Hz, 1H), 6.84 (dd, $J = 8.0$, 1.3 Hz, 1H), 6.69 (td, $J = 7.4$, 1.5 Hz 1H), 2.46 (s, 3H), 2.43 (td, $J = 7.4$, 3.2 Hz, 4H), 1.76 (m, 4H), 1.49 (m, 2H). $^{13}$C NMR (151 MHz, CD$_3$OD): $\delta$ 175.26, 174.93, 160.04, 149.95, 148.42, 143.30, 128.25, 127.12, 125.11, 119.48, 118.52, 114.19, 112.44, 37.83, 36.95, 29.72, 26.62, 26.13, 23.89. DART-AccuTOF MS: m/z calcd C$_{19}$H$_{25}$N$_4$O$_2$ [M+H]$^+$ 341.1978, found 341.1893. HPLC: 99.3%.

Synthesis of $N^1$-(2-aminophenyl)-$N^8$-(2-methylpyridin-4-yl)octanediadime (CF-L08).
**8-((2-methylpyridin-4-yl)amino)-8-oxooctanoic acid (CF-L08-1).** The same synthesis procedure as **CF-L05-1** was applied to afford a white solid (yield: 65%). $^1$H NMR (600 MHz, DMSO-d$_6$): δ 12.03 (br, 1H), 10.14 (s, 1H), 8.25 (d, J = 5.6 Hz, 1H), 7.44 (s, 1H), 7.34 (dd, J = 5.6, 0.5 Hz, 1H), 2.39 (s, 3H), 2.32 (t, J = 7.4 Hz, 2H), 2.19 (td, J = 7.4, 1.0 Hz, 2H), 1.57 (m, 2H), 1.49 (m, 2H), 1.28 (m, 4H). $^{13}$C NMR (151 MHz, DMSO-d$_6$): δ 174.47, 172.40, 158.48, 149.50, 146.09, 111.93, 110.53, 36.45, 33.62, 28.32, 28.31, 24.69, 24.36, 24.25. DART-AccuTOF MS: m/z calcd C$_{14}$H$_{21}$N$_2$O$_3$ [M+H]$^+$ 265.1552, found 265.1545.

**$N^1$-(2-aminophenyl)-$N^8$-(2-methylpyridin-4-yl)octanediamide (CF-L08).** Similar synthesis procedure as **CF-L05** was applied to synthesize **CF-L08**. A white solid was obtained as the final product (yield: 51%). $^1$H NMR (600 MHz, CD$_3$OD): δ 8.23 (d, J = 5.8 Hz, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.45 (dd, J = 5.8, 2.1 Hz, 1H), 7.07 (dd, J = 7.8, 1.5 Hz, 1H), 7.01 (m, 1H), 6.84 (dd, J = 8.0, 1.4 Hz, 1H), 6.70 (td, J = 7.6, 1.4 Hz, 1H), 2.46 (s, 3H), 2.41 (m, 4H), 1.81 – 1.64 (m, 4H), 1.51 – 1.39 (m, 4H). $^{13}$C NMR (151 MHz, CD$_3$OD): δ 175.37, 175.04, 159.95, 149.81, 148.54, 143.28, 128.24, 127.10, 125.15, 119.51, 118.54, 114.20, 112.45, 37.96, 37.11, 29.96, 29.92, 26.82, 26.28, 23.81. DART-AccuTOF MS: m/z calcd C$_{20}$H$_{27}$N$_4$O$_2$ [M+H]$^+$ 355.2134, found 355.2068. HPLC: 98.7%

**Synthesis of $N$-(4-amino-[1,1'-biphenyl]-3-yl)-6-((2-methylpyridin-4-yl)oxy)hexanamide (CF-L09).**

**$N$-(4-amino-[1,1'-biphenyl]-3-yl)-6-((2-methylpyridin-4-yl)oxy)hexanamide (CF-L09).** The same synthesis procedure as **CF-L05** was used to afford **CF-L09-1**, which then underwent boc deprotection using 4M HCl in dioxane and EtOH (1:1 ratio) and purified by silca gel chromatography (DCM/MeOH=20/1, 10/1) to afford a white powder (yield: 63%). $^1$H NMR
(600 MHz, CD$_3$OD): $\delta$ 8.14 (d, J = 5.9 Hz, 1H), 7.50 (dd, J = 8.3, 1.1 Hz, 2H), 7.40 (d, J = 2.1 Hz, 1H), 7.34 (t, J = 7.8 Hz, 2H), 7.30 (dd, J = 8.3, 2.1 Hz, 1H), 7.22 (m, 1H), 6.91 (d, J = 8.3 Hz, 1H), 6.79 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 5.9, 2.5 Hz, 1H), 4.04 (t, J = 6.4 Hz, 2H), 2.47 (t, J = 7.4 Hz, 2H), 2.42 (s, 3H), 1.86 – 1.77 (m, 4H), 1.58 (m, 2H). $^{13}$C NMR (151 MHz, CD$_3$OD): $\delta$ 174.98, 167.68, 160.72, 150.42, 142.72, 142.01, 132.67, 129.72, 127.39, 127.19, 126.62, 125.41, 125.32, 118.79, 110.93, 109.27, 69.10, 37.18, 29.97, 29.80, 26.86, 26.74, 23.78. DART-AccuTOF MS: m/z calcd C$_{24}$H$_{28}$N$_3$O$_2$ [M+H]$^+$ 390.2182, found 390.2188. HPLC: 96.4%. Crystals were obtained by vapor diffusion crystallization set-up using DCM and ether (Appendix D).

**Synthesis of N-(4-amino-[1,1'-biphenyl]-3-yl)-7-((2-methylpyridin-4-yl)oxy)heptanamide (CF-L10).**

N-(4-amino-[1,1'-biphenyl]-3-yl)-7-((2-methylpyridin-4-yl)oxy)heptanamide (CF-L10). Similar synthesis procedure as **CF-L09** was applied to afford a white powder (yield: 60%). $^1$H NMR (600 MHz, CD$_3$OD): $\delta$ 8.14 (d, J = 5.9 Hz, 1H), 7.51 (dd, J = 8.3, 1.1 Hz, 2H), 7.40 (d, J = 2.1 Hz, 1H), 7.34 (t, J = 7.8 Hz, 2H), 7.30 (dd, J = 8.3, 2.2 Hz, 1H), 7.22 (t, J = 7.4 Hz, 1H), 6.91 (d, J = 8.3 Hz, 1H), 6.78 (d, J = 2.3 Hz, 1H), 6.73 (dd, J = 5.9, 2.5 Hz, 1H), 4.02 (t, J = 6.4 Hz, 2H), 2.45 (t, J = 7.4 Hz, 2H), 2.42 (s, 3H), 1.84 – 1.71 (m, 4H), 1.56 – 1.44 (m, 4H). $^{13}$C NMR (151 MHz, CD$_3$OD): $\delta$ 175.10, 167.69, 160.72, 150.40, 142.76, 142.01, 132.66, 129.73, 127.39, 127.19, 126.62, 125.41, 125.32, 118.79, 110.93, 109.27, 69.10, 37.11, 29.69, 26.67, 26.63, 23.77. DART-AccuTOF MS: m/z calcd C$_{25}$H$_{30}$N$_3$O$_2$ [M+H]$^+$ 404.2338, found 404.2333. HPLC: 97.4%. Crystals were obtained by vapor diffusion crystallization set-up using DCM and ether (Appendix D).
Synthesis of \( N^1-(4\text{-amino-[1,1'\text{-biphenyl}-3-yl]}-N^7-(2\text{-methylpyridin-4-yl})\text{heptanediamide} \) (CF-L11).

\( N^1-(4\text{-amino-[1,1'\text{-biphenyl}-3-yl]}-N^7-(2\text{-methylpyridin-4-yl})\text{heptanediamide} \) (CF-L11). The same synthesis procedure as CF-L07 was used to afford CF-L11-1, which then underwent boc deprotection using 4M HCl in dioxane and MeOH (1:1 ratio) and purified by silca gel chromatography (DCM/MeOH=20/1, 10/1) to afford a white powder (yield: 64%). \(^1\)H NMR (600 MHz, CD\(_3\)OD): \( \delta \) 8.19 (d, \( J = 5.8 \) Hz, 1H), 7.52 – 7.49 (m, 3H), 7.45 (dd, \( J = 5.8, 2.1 \) Hz, 1H), 7.39 (d, \( J = 2.2 \) Hz, 1H), 7.34 (t, \( J = 7.8 \) Hz, 2H), 7.30 (dd, \( J = 8.3, 2.2 \) Hz, 1H), 7.22 (m, 1H), 6.90 (d, \( J = 8.3 \) Hz, 1H), 2.48 – 2.42 (m, 7H), 1.77 (m 4H), 1.50 (m, 2H). \(^{13}\)C NMR (151 MHz, CD\(_3\)OD): \( \delta \) 175.26, 175.07, 159.71, 149.47, 148.77, 142.78, 142.00, 132.65, 129.72, 127.38, 127.18, 126.67, 125.51, 125.23, 118.73, 114.25, 112.50, 37.82, 36.99, 29.72, 26.56, 26.06, 23.63. DART-AccuTOF MS: m/z calcd C\(_{25}\)H\(_{28}\)N\(_4\)O\(_2\) [M+H]\(^+\) 417.2291, found 417.2231. HPLC: 98.0%

Synthesis of \( N^1-(4\text{-amino-[1,1'\text{-biphenyl}-3-yl]}-N^8-(2\text{-methylpyridin-4-yl})\text{octanediamide} \) (CF-L12).

\( N^1-(4\text{-amino-[1,1'\text{-biphenyl}-3-yl]}-N^8-(2\text{-methylpyridin-4-yl})\text{octanediamide} \) (CF-L12). The same synthesis procedure as CF-L11 was applied to afford a white powder (yield: 51%). \(^1\)H NMR (600 MHz, CD\(_3\)OD): \( \delta \) 8.21 (d, \( J = 5.8 \) Hz, 1H), 7.52 – 7.48 (m, 3H), 7.43 (dd, \( J = 5.8, 2.1 \) Hz, 1H), 7.38 (d, \( J = 2.2 \) Hz, 1H), 7.34 (t, \( J = 7.8 \) Hz, 2H), 7.30 (dd, \( J = 8.3, 2.1 \) Hz, 1H), 7.22 (m, 1H), 6.91 (d, \( J = 8.3 \) Hz, 1H), 2.45 (m, 5H), 2.40 (t, \( J = 7.5 \) Hz, 2H), 1.78 – 1.69 (m, 4H), 1.49 – 1.41 (m, 4H). \(^{13}\)C NMR (151 MHz, CD\(_3\)OD): \( \delta \) 175.35, 175.16, 159.98, 149.87, 148.45, 142.75, 142.00, 132.70, 129.72, 127.38, 127.19, 126.66, 125.48, 125.29, 118.77, 114.19,
112.43, 37.96, 37.17, 29.97, 29.91, 26.79, 26.28, 23.85. DART-AccuTOF MS: m/z calcd C_{26}H_{31}N_{4}O_{2} [M+H]^+ 431.2447, found 431.2401. HPLC: 97.7%

Synthesis of N\textsuperscript{1}-hydroxy-N\textsuperscript{8}-(pyridin-4-yl)octanediamide (CF-L13).

Methyl 8-oxo-8-(pyridin-4-ylamino)octanoate (CF-L13-1). The same synthesis procedure as CF-L04-1 was used to afford a white solid (yield: 46%). \(^1\)H NMR (600 MHz, CD\textsubscript{3}Cl): \(\delta\) 8.73 (s, 1H), 8.44 (d, \(J = 5.9\) Hz, 2H), 7.56 (d, \(J = 6.2\) Hz, 2H), 3.65 (s, 3H), 2.37 (t, \(J = 7.5\) Hz, 2H), 2.29 (t, \(J = 7.4\) Hz, 2H), 1.70 (m, 2H), 1.60 (m, 2H), 1.37 – 1.29 (m, 4H). \(^{13}\)C NMR (151 MHz, CD\textsubscript{3}Cl): \(\delta\) 174.45, 172.66, 150.26, 145.99, 113.81, 51.66, 37.56, 34.01, 28.77, 28.73, 25.12, 24.71. DART-AccuTOF MS: m/z calcd C_{14}H_{21}N_{2}O_{3} [M+H]^+ 265.1552, found 265.1523.

\(^{N}\)\textsuperscript{1}-hydroxy-\(^{N}\)\textsuperscript{8}-(pyridin-4-yl)octanediamide (CF-L13). A similar synthesis procedure as CF-L04 afforded a white solid (yield: 39%). \(^1\)H NMR (600 MHz, DMSO-d\textsubscript{6}): \(\delta\) 10.33 (s, 1H), 10.24 (s, 1H), 8.67 (s, 1H), 8.39 (dd, \(J = 4.8, 1.5\) Hz, 2H), 7.55 (dd, \(J = 4.8, 1.6\) Hz, 2H), 2.33 (t, \(J = 7.5\) Hz, 2H), 1.93 (t, \(J = 7.4\) Hz, 2H), 1.60 – 1.54 (m, 2H), 1.51 – 1.45 (m, 2H), 1.31 – 1.22 (m, 4H). \(^{13}\)C NMR (151 MHz, DMSO-d\textsubscript{6}): \(\delta\) 172.49, 169.09, 150.30, 145.76, 113.04, 36.46, 32.23, 28.36, 28.34, 25.00, 24.68. DART-AccuTOF MS: m/z calcd C_{13}H_{20}N_{3}O_{3} [M+H]^+ 266.1505, found 266.1467. HPLC: 99.0%

Synthesis of \(^{N}\)\textsuperscript{1}-(4-(aminomethyl)phenyl)-\(^{N}\)\textsuperscript{8}-hydroxyoctanediamide hydrogen chloride (CF-L14).

Methyl-8-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)amino)-8-oxooctanoate (CF-L14-1). The same synthesis procedure as CF-L04-1 afforded the crude product, which was further purified by recrystallization using EtOAc and hexanes and yielded a white powder (82%).
1H NMR (600 MHz, DMSO-d6): δ 9.81 (s, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.31 (t, J = 6.0 Hz, 1H), 7.13 (d, J = 8.4 Hz, 2H), 4.05 (d, J = 6.1 Hz, 2H), 3.57 (s, 3H), 2.28 (m, 4H), 1.54 (m, 4H), 1.39 (s, 9H), 1.30 – 1.24 (m, 4H). 13C NMR (151 MHz, DMSO-d6): δ 173.33, 171.05, 155.74, 137.93, 134.65, 127.28, 118.94, 77.68, 51.15, 43.00, 36.27, 33.22, 28.31, 28.25, 28.22, 24.94, 24.31.

DART-AccuTOF MS: m/z calcd C_{21}H_{33}N_{2}O_{5} [M+H]+ 393.2390, found 393.2334. McLafferty rearrangement and decarboxylation occurred during the DART-AccuTOF mass spectrometry measurement.

**tert-butyl (4-(8-(hydroxyamino)-8-oxooctanamido)benzyl)carbamate (CF-L14-2).** To a solution of CF-L14-1 (1.35 g, 3.4 mmol, 1.0 equiv) in DCM and MeOH (1:2 ratio, 24 mL) at 0 °C, hydroxylamine (50 wt% in water, 3.04 mL, 51.6 mmol, 15.0 equiv) was added, followed by addition of a fine NaOH powder (1.38 g, 34.4 mmol, 10.0 equiv). The solution was stirred at 0 °C for 30 min, and then allowed to warm to rt and stirred overnight. Solvent was removed under reduced pressure to yield a white solid. H2O (10 mL) was added to the residual and the solid product was insoluble. HCl (conc 1-2 M) was added to adjust the pH to ~9 while stirring. The product was collected through vacuum filtration, washed by cold water and dried overnight. The aqueous filtrate was washed with EtOAc three times, dried over Na2SO4, filtered and concentrated under reduced pressure to yield a white solid. All white solids were combined and recrystallized from EtOAc (~30-50 mL, not completely soluble) to afford a white powder (1.35 g, yield: quantitative). 1H NMR (600 MHz, DMSO-d6): δ 10.19 (br, 1H), 7.54 (d, J = 8.3 Hz, 2H), 7.34 (t, J = 5.8 Hz, 1H), 7.12 (d, J = 8.4 Hz, 2H), 4.04 (d, J = 5.8 Hz, 2H), 2.27 (t, J = 7.4 Hz, 2H), 1.85 (t, J = 7.4 Hz, 2H), 1.55 (m, 2H), 1.44 (m, 2H), 1.38 (s, 9H), 1.30 – 1.18 (m, 4H). 13C NMR (151 MHz, DMSO-d6): δ 171.29, 167.62, 155.77, 138.13, 134.54, 127.23, 118.98, 77.68, 43.03, 36.27, 32.95, 28.52, 28.43, 28.27, 25.72, 25.18. DART-AccuTOF MS: m/z calcd
C\textsubscript{19}H\textsubscript{32}N\textsubscript{3}O\textsubscript{3} [M-CO\textsubscript{2}+H\textsuperscript{+}] 350.2444, found 350.2405. McLafferty rearrangement and decarboxylation occurred during the DART-AccuTOF mass spectrometry measurement. ESI-AccuTOF MS: m/z calcd C\textsubscript{20}H\textsubscript{31}N\textsubscript{3}O\textsubscript{5}Na [M+Na\textsuperscript{+}] 416.2161, found 416.2060.

\textit{N}\textsuperscript{1}-(4-(aminomethyl)phenyl)-\textit{N}\textsuperscript{8}-hydroxyoctanediamide hydrogen chloride (CF-L14). To a mixture of insoluble CF-L14-2 (700 mg, 1.78 mmol, 1.0 equiv) in anhydrous DCM (3 mL), 1 M HCl in anhydrous EtOAc (9 mL) was added. The mixture was stirred overnight. The organic liquid was removed using centrifuge and the product was washed with dry Et\textsubscript{2}O three times and dried overnight to afford a white powder (yield: quantitative). \textsuperscript{1}H NMR (600 MHz, DMSO-d\textsubscript{6}): \(\delta 10.43 \text{ (s, 1H)}, 10.20 \text{ (s, 1H)}, 8.68 \text{ (br, 1H)}, 8.49 \text{ (s, 3H)}, 7.64 \text{ (d, } J = 8.6 \text{ Hz, 2H)}, 7.40 \text{ (d, } J = 8.6 \text{ Hz, 2H)}, 3.91 \text{ (q, } J = 5.4 \text{ Hz, 2H)}, 2.31 \text{ (t, } J = 7.5 \text{ Hz, 2H)}, 1.94 \text{ (t, } J = 7.4 \text{ Hz, 2H)}, 1.56 \text{ (m, 2H)}, 1.47 \text{ (m, 2H)}, 1.32 – 1.20 \text{ (m, 4H)}. \textsuperscript{13}C NMR (151 MHz, DMSO-d\textsubscript{6}): \(\delta 171.53, 169.22, 139.61, 129.48, 128.27, 118.88, 41.78, 36.31, 32.40, 28.40, 28.38, 25.05, 25.01. ESI-AccuTOF MS: m/z calcd C\textsubscript{15}H\textsubscript{24}N\textsubscript{3}O\textsubscript{3} [M+H\textsuperscript{+}] 294.1818, found 294.1769. HPLC: 95.1%

Synthesis of \textit{N}\textsuperscript{1}-(4-(2-aminoethyl)phenyl)-\textit{N}\textsuperscript{8}-hydroxyoctanediamide hydrogen chloride (CF-L15).

\textit{Methyl-8-((4-((tert-butoxycarbonyl)amino)ethyl)phenyl)amino)-8-oxooctanoate (CF-L15-1)}. The same synthesis procedure as CF-L14-1 afforded a white powder (83%). \textsuperscript{1}H NMR (600 MHz, DMSO-d\textsubscript{6}): \(\delta 9.77 \text{ (s, 1H)}, 7.48 \text{ (d, } J = 8.5 \text{ Hz, 2H)}, 7.08 \text{ (d, } J = 8.5 \text{ Hz, 2H)}, 6.84 \text{ (t, } J = 5.6 \text{ Hz, 1H)}, 3.57 \text{ (s, 3H)}, 3.09 \text{ (m, 2H)}, 2.62 \text{ (m, 2H)}, 2.31 – 2.23 \text{ (m, 4H)}, 1.62 – 1.47 \text{ (m, 4H)}, 1.36 \text{ (s, 9H)}, 1.31 – 1.25 \text{ (m, 4H)}. \textsuperscript{13}C NMR (151 MHz, DMSO-d\textsubscript{6}): \(\delta 173.34, 170.99, 155.50, 137.43, 133.91, 128.71, 119.05, 77.46, 51.15, 41.61, 36.29, 34.92, 33.23, 28.31, 28.26, 28.23, 24.98, 24.32. DART-AccuTOF MS: m/z calcd C\textsubscript{22}H\textsubscript{38}N\textsubscript{2}O\textsubscript{5} [M+H\textsuperscript{+}] 407.2546,
found 407.2519. McLafferty rearrangement and decarboxylation occurred during the DART-AccuTOF mass spectrometry measurement.

**tert-butyl (4-(8-(hydroxyamino)-8-oxooctanamido)phenethyl)carbamate (CF-L15-2).**

Similar synthesis procedure as **CF-L14-2** was applied and afforded a white powder (96%).

$^1$H NMR (600 MHz, DMSO-$d_6$): $\delta$ 10.25 (br, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.07 (d, J = 8.5 Hz, 2H), 6.87 (t, J = 5.5 Hz, 1H), 3.08 (m, 2H), 2.61 (m, 2H), 2.26 (t, J = 7.4 Hz, 2H), 1.80 (t, J = 7.4 Hz, 2H), 1.59 – 1.49 (m, 2H), 1.47 – 1.39 (m, 2H), 1.36 (s, 9H), 1.27 – 1.20 (m, 4H).

$^{13}$C NMR (151 MHz, DMSO-$d_6$): $\delta$ 171.27, 167.24, 155.52, 137.66, 133.76, 128.66, 119.12, 77.45, 41.63, 36.24, 34.92, 33.35, 28.55, 28.33, 28.28, 26.08, 25.28. DART-AccuTOF MS: m/z calcd C$_{20}$H$_{34}$N$_3$O$_3$ [M-CO$_2$+H]$^+$ 364.2600, found 364.2589. McLafferty rearrangement and decarboxylation occurred during the DART-AccuTOF mass spectrometry measurement. ESI-AccuTOF MS: m/z calcd C$_{21}$H$_{33}$N$_3$O$_3$Na [M+Na]$^+$ 430.2318, found 430.2265.

$N^1$-(4-(2-aminoethyl)phenyl)-$N^8$-hydroxyoctanediamide hydrogen chloride (CF-L15). The same synthesis procedure as **CF-L14** produced a white powder (yield: quantitative).

$^1$H NMR (600 MHz, DMSO-$d_6$): $\delta$ 10.49 (s, 1H), 10.12 (s, 1H), 8.27 (s, 3H), 7.57 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 2.94 (m, 2H), 2.85 (m, 2H), 2.29 (t, J = 7.4 Hz, 2H), 1.94 (t, J = 7.4 Hz, 2H), 1.54(m, 2H), 1.47 (m, 2H), 1.33 – 1.17 (m, 4H).

$^{13}$C NMR (151 MHz, DMSO-$d_6$): $\delta$ 171.26, 169.19, 138.13, 131.75, 128.74, 119.28, 39.99, 36.30, 32.33, 32.23, 28.40, 28.39, 25.08, 25.05. DART-AccuTOF MS: m/z calcd C$_{16}$H$_{26}$N$_3$O$_3$ [M+H]$^+$ 308.1974, found 308.1907. ESI-AccuTOF MS: m/z calcd C$_{16}$H$_{26}$N$_3$O$_3$ [M+H]$^+$ 308.1974, found 308.1961. HPLC: 95.4%

**Synthesis of 4-(((2-aminoethyl)amino)methyl)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide hydrogen chloride (CF-L16).**
**Methyl-7-(4-formylbenzamido)heptanoate (CF-L16-1).** Similar synthesis procedure as CF-L03-1 led to a crude product, which was purified by silica gel chromatography (DCM/EtOAc=1/1) to afford a white powder (yield: 88%). $^1$H NMR (600 MHz, CDCl$_3$): δ 10.05 (s, 1H), 7.91 (s, 4H), 6.44 (s, 1H), 3.64 (s, 3H), 3.44 (dt, J = 7.2, 6.1 Hz, 2H), 2.30 (t, J = 7.4 Hz, 2H), 1.68 – 1.52 (m, 4H), 1.42 – 1.31 (m, 4H). $^{13}$C NMR (151 MHz, CDCl$_3$): δ 191.69, 174.29, 166.53, 140.09, 138.19, 129.92, 127.73, 51.61, 40.27, 34.00, 29.44, 28.79, 26.66, 24.82. DART-AccuTOF MS: m/z calcd C$_{16}$H$_{22}$NO$_4$ [M+H]$^+$ 292.1549, found 292.1541.

**Methyl-7-((4-(((2-((tert-butoxycarbonyl)amino)ethyl)amino)methyl)benzamido)heptanoate (CF-L16-2).** To a solution of CF-L16-1 (635 mg, 2.18 mmol, 1.0 equiv) in MeOH (15 mL) was added tert-butyl (2-aminoethyl)carbamate (366.7 mg, 1.05 mmol, 1.05 equiv) and stirred at rt overnight. Fine NaBH$_4$ powder (123.7 mg, 3.27 mmol, 1.5 equiv) was added in portions at 0 °C. After complete addition, the reaction mixture was stirred for 1 h at rt. MeOH was removed under reduced pressure. The residual was extracted with EtOAc and H$_2$O twice. The combined organic layers were washed with brine three times, dried over anhydrous Na$_2$SO$_4$, filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (DCM; DCM/MeOH=10/1) to afford a white powder (500 mg, yield: 53%). $^1$H NMR (600 MHz, DMSO-d$_6$): δ 8.36 (t, J = 5.6 Hz, 1H), 7.77 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 6.74 (t, J = 5.4 Hz, 1H), 3.71 (s, 2H), 3.57 (s, 3H), 3.23 (q, J = 6.7 Hz, 2H), 3.02 (q, J = 6.0 Hz, 2H), 2.51 (t, J = 6.5 Hz, 2H), 2.29 (t, J = 7.4 Hz, 2H), 1.51 (m, 4H), 1.36 (s, 9H), 1.32 – 1.25 (m, 4H). $^{13}$C NMR (151 MHz, DMSO-d$_6$): δ 173.33, 165.94, 155.62, 144.10, 132.98, 127.54, 126.95, 77.44, 52.23, 51.13, 48.38, 39.95 (shown in HMQC spectrum), 39.06, 33.22, 28.96, 28.23, 28.20, 26.13, 24.38. DART-AccuTOF MS: m/z calcd C$_{23}$H$_{38}$N$_3$O$_5$ [M+H]$^+$ 436.2812, found 436.2709.
tert-butyl (2-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)benzyl)amino)ethyl)carbamate (CF-L16-3). To a solution of CF-L16-2 (150 mg, 0.34 mmol, 1.0 equiv) in DCM and MeOH (1:2 ratio, 12 mL) at 0 °C, hydroxylamine (50 wt% in water, 0.30 mL, 5.17 mmol, 15.0 equiv) was added, following by fine NaOH powder (138 mg, 3.44 mmol, 10.0 equiv). The solution was stirred at 0 °C for 30 min, and then allowed to warm to rt and stirred overnight. Solvent was removed under reduced pressure to yield a white solid. H₂O (2.5 mL) was added to the residual and the insoluble solid was removed by filtration. HCl solution (conc 1-2 M) was added to adjust the pH and no precipitates formed. The mixture was extracted with EtOAc three times, dried over Na₂SO₄, filtered and concentrated under reduced pressure to yield a white solid. The crude product was recrystallized from EtOAc to afford a white powder (100 mg, yield: 67%). ¹H NMR (600 MHz, DMSO-d₆): δ 10.33 (br, 1H), 8.66 (br, 1H), 8.36 (t, J = 5.6 Hz, 1H), 7.77 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 6.74 (t, J = 5.4 Hz, 1H), 3.71 (s, 2H), 3.34 (br, 1H), 3.23 (q, J = 6.6 Hz, 2H), 3.02 (q, J = 6.2 Hz, 2H), 2.52 (t, J = 6.5 Hz, 2H), 1.94 (t, J = 7.4 Hz, 2H), 1.49 (m, 4H), 1.37 (s, 9H), 1.31 – 1.24 (m, 4H). %). ¹³C NMR (151 MHz, DMSO-d₆): δ 169.09, 165.96, 155.64, 144.15, 132.98, 127.55, 126.97, 77.46, 52.24, 48.40, 39.97 (shown in HMQC spectrum), 39.12 (shown in HMQC spectrum), 32.24, 29.06, 28.36, 28.25, 26.23, 25.10. DART-AccuTOF MS: m/z calcd C₂₂H₃₇N₄O₅ [M+H]+ 437.2764, found 437.2727

4-(((2-aminooethyl)amino)methyl)-N-((7-(hydroxyamino)-7-oxoheptyl)benzamide hydrogen chloride (CF-L16). Similar synthesis procedure as CF-L14 was applied in this synthesis, which afforded a white powder (yield: 92%). ¹H NMR (600 MHz, DMSO-d₆): δ 7.87 (d, J = 7.8 Hz, 2H), 7.64 (d, J = 7.5 Hz, 2H), 4.24 (s, 2H), 3.30 – 3.14 (m, 6H), 1.93 (t, J = 7.3 Hz, 2H), 1.52 – 1.43 (m, 4H), 1.30 – 1.21 (m, 4H). ¹³C NMR (151 MHz, DMSO-d₆): δ 169.62,
165.76, 135.18, 134.65, 130.06, 127.62, 49.76, 43.91, 39.30 (shown in HMQC spectrum), 35.23, 32.79, 29.09, 28.47, 26.36, 25.25. DART-AccuTOF MS: m/z calcd C_{17}H_{29}N_{4}O_{3} [M+H]^+ 337.2240, found 337.2204. HPLC: 96.4%

**Synthesis of 7-(4-(((2-aminoethyl)amino)methyl)phenoxy)-N-hydroxyheptanamide hydrogen chloride (CF-L17)**

**Ethyl-7-(4-formylphenoxy)heptanoate (CF-L17-1).** To a solution of 4-hydroxybenzaldehyde (1.22 g, 10.0 mmol, 1.0 equiv) in ACN (50 mL) was added ethyl-7-bromoheptanoate (2.37 g, 10.0 mmol, 1.0 equiv) and K_{2}CO_{3} (5.52 g, 40 mmol, 3.0 equiv). The mixture was refluxed overnight. Partial ACN was removed under reduced pressure and the resulting mixture was extracted with EtOAc and H_{2}O three times. The organic layers were combined, washed with brine, dried over anhydrous Na_{2}SO_{4}, and concentrated under reduced pressure to give a yellow crude product. The crude product was dissolved in Et_{2}O and hexane and left in freezer overnight, which afforded a light-yellow product (1.5 g, 54%). \(^1\)H NMR (600 MHz, CDCl_{3}): δ 9.87 (s, 1H), 7.82 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 4.12 (q, J = 7.1 Hz, 2H), 4.03 (t, J = 6.5 Hz, 2H), 2.31 (t, J = 7.5 Hz, 2H), 1.81 (m, 2H), 1.66 (m, 2H), 1.52 – 1.46 (m, 2H), 1.41 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H). \(^{13}\)C NMR (151 MHz, CDCl_{3}): δ 190.93, 173.82, 164.31, 132.11, 129.91, 114.86, 68.35, 60.35, 34.34, 28.98, 28.92, 25.79, 24.94, 14.38. DART-AccuTOF MS: m/z calcd C_{16}H_{25}O_{4} [M+H]^+ 279.1596, found 279.1572.

**Ethyl-7-(4-(((2-((tert-butoxycarbonyl)amino)ethyl)amino)methyl)phenoxy)heptanoate (CF-L17-2).** Similar synthesis procedure as CF-L16-2 was applied to yield crude product, which was further purified by silica gel chromatography (DCM/MeOH=20/1) to afford a white powder (yield: 92%). \(^1\)H
NMR (600 MHz, DMSO-d$_6$): $\delta$ 7.19 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 6.72 (t, J = 5.4 Hz, 1H), 4.04 (q, J = 7.1 Hz, 2H), 3.91 (t, J = 6.5 Hz, 2H), 3.58 (s, 2H), 3.00 (q, J = 6.3 Hz, 2H), 2.49 (m, 2H), 2.28 (t, J = 7.4 Hz, 2H), 2.00 (s, 1H), 1.72 – 1.63 (m, 2H), 1.57 – 1.50 (m, 2H), 1.42 – 1.30 (m, 13H), 1.17 (t, J = 7.1 Hz, 3H).

$^{13}$C NMR (151 MHz, DMSO-d$_6$): $\delta$ 172.85, 157.39, 155.61, 132.71, 129.00, 113.98, 77.41, 67.22, 59.62, 52.08, 48.28, 39.93 (shown in HMQC spectrum), 33.43, 28.54, 28.23, 28.17, 25.20, 24.39, 14.11.

DART-AccuTOF MS: m/z calcd C$_{23}$H$_{39}$N$_2$O$_5$ [M+H]$^+$ 423.2859, found 279.1572.

**tert-butyl (2-((4-((7-(hydroxyamino)-7-oxoheptyl)oxy)benzyl)amino)ethyl)carbamate (CF-L17-3).** Similar synthesis procedure as CF-L16-3 yielded a white wax solid (yield: 75%).

$^1$H NMR (600 MHz, DMSO-d$_6$): $\delta$ 10.34 (br, 1H), 7.19 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 6.72 (t, J = 5.7 Hz, 1H), 3.91 (t, J = 6.5 Hz, 2H), 3.58 (s, 2H), 3.00 (q, J = 6.3 Hz, 2H), 2.48 (t, J = 6.5 Hz, 1H), 1.94 (t, J = 7.4 Hz, 2H), 1.69 – 1.65 (m, 2H), 1.53 – 1.46 (m, 2H), 1.42 – 1.34 (m, 11H), 1.31 – 1.25 (m, 2H).

$^{13}$C NMR (151 MHz, DMSO-d$_6$): $\delta$ 169.05, 157.40, 155.62, 132.71, 129.02, 114.00, 77.43, 67.28, 52.09, 48.29, 39.95 (shown in HMQC spectrum), 33.20, 28.62, 28.34, 28.25, 25.27, 25.07. DART-AccuTOF MS: m/z calcd C$_{21}$H$_{36}$N$_3$O$_5$ [M+H]$^+$ 410.2655, found 410.2661.

**7-(4-(((2-aminoethyl)amino)methyl)phenoxy)-N-hydroxyheptanamide hydrogen chloride (CF-L17).** Similar synthesis procedure as CF-L16 afforded a white solid (yield: 92%).

$^1$H NMR (600 MHz, D$_2$O): $\delta$ 7.46 (d, J = 6.0 Hz, 2H), 7.06 (d, J = 6.5 Hz, 2H), 4.28 (s, 2H), 4.08 (t, J = 5.5 Hz, 2H), 3.44 (m, 4H), 2.16 (t, J = 6.8 Hz, 2H), 1.76 (m, 2H), 1.59 (m, 2H), 1.44 (m, 2H), 1.35 (m, 2H).

$^{13}$C NMR (151 MHz, D$_2$O): $\delta$ 159.40, 131.71, 122.68, 115.53, 100.00, 68.69, 51.21, 43.48, 35.57, 35.55, ESI-AccuTOF MS: m/z calcd C$_{16}$H$_{28}$N$_3$O$_3$ [M+H]$^+$ 310.2131, found 310.2125 HPLC: 95.2%.
Synthesis of \((E)\)-\(N\)-hydroxy-3-(4-((2-(pyridin-4-yl)ethyl)amino)methyl)phenyl)acrylamide (CF-L18). Similar synthesis procedure as CF-L16-2 produced a crude product CF-L18-1, which was used directly for the following step. Similar synthesis procedure as CF-L01 was applied to afford a light yellow solid (overall yield: 28%). \(^1\)H NMR (600 MHz, CD\(_3\)OD): \(\delta\) 8.44 (d, \(J = 6.1\) Hz, 2H), 7.56 (m, 3H), 7.41 (d, \(J = 8.1\) Hz, 2H), 7.32 (d, \(J = 6.1\) Hz, 2H), 6.47 (d, \(J = 15.8\) Hz, 1H), 3.93 (s, 2H), 3.00 (m, 2H), 2.93 (dd, \(J = 8.4, 6.4\) Hz, 2H).

Synthesis of \((E)\)-3-(4-(1-(3,4-diaminophenethyl)pyrrolidin-2-yl)phenyl)-\(N\)-hydroxyacrylamide (CF-L19).

4-acetamidophenethyl acetate (CF-L19-1). To a solution of 2-(4-aminophenyl)ethan-1-ol (2.74 g, 19.97 mmol, 1.0 equiv) in DCM (50 mL) was added TEA (8.09 g, 11.1 mL, 79.9 mmol, 4.0 equiv) and Ac\(_2\)O (6.12 g, 59.92 mmol, 3.0 equiv). The reaction mixture was stirred under 0 °C for 45 min and then rt for overnight. The reaction was monitored by silica gel TLC (DCM/MeOH=10/1). The mixture was washed by water and brine twice, dried over anhydrous Na\(_2\)SO\(_4\), concentrated under reduced pressure to afford a light-yellow solid as a crude product, which was further purified by recrystallization (EtOAc/Cyclohexane) to afford a white solid (3.55 g, yield: 80%). \(^1\)H NMR (600 MHz, CDCl\(_3\)): \(\delta\) 7.76 (s, 1H), 7.43 (d, \(J = 8.4\) Hz, 2H), 7.13 (d, \(J = 8.4\) Hz, 2H), 4.23 (t, \(J = 7.1\) Hz, 2H), 2.88 (t, \(J = 7.1\) Hz, 2H), 2.14 (s, 3H), 2.02 (s, 3H). \(^{13}\)C NMR (151 MHz, CDCl\(_3\)): \(\delta\) 171.23, 168.69, 136.67, 133.76, 129.42, 120.23, 65.02, 34.56, 24.54, 21.07. DART-AccuTOF MS: m/z calcd C\(_{12}\)H\(_{16}\)NO\(_3\) [M+H]\(^+\) 222.1130, found 222.0921.

4-acetamido-3-nitrophenethyl acetate (CF-L19-2). To a solution of CF-L19-1 (2.0 g, 9.04 mmol, 1.0 equiv) in DCM (25 mL) was added Ac\(_2\)O (1.85 g, 1.71 mL, 18.08 mmol, 2.0 equiv) and cooled at 0 °C. Fuming HNO\(_3\) (0.9 mL, 18.08 mmol, 2.0 equiv) was added to the
mixture and stirred for 1 h. The reaction was monitored by silica TLC (PE/EtOAc=1/1) and another portion of fuming HNO$_3$ was added if there was still starting material left. The mixture was poured into water and stirred for 30 min, after which the mixture was extracted with DCM three times. The combined organic layers were washed with water twice, dried over anhydrous Na$_2$SO$_4$, concentrated under reduced pressure to yield a yellow solid. The crude product was dissolved in minimum Et$_2$O and left in the freezer for recrystallization. The recrystallized product was collected through vacuum filtration and washed with hexane to afford a bright-yellow solid (2.03 g, yield: 84%). $^1$H NMR (600 MHz, CDCl$_3$): $\delta$ 10.24 (s, 1H), 8.69 (d, $J = 8.7$ Hz, 1H), 8.06 (d, $J = 2.1$ Hz, 1H), 7.50 (dd, $J = 8.7$, 2.2 Hz, 1H), 4.28 (t, $J = 6.7$ Hz, 2H), 2.96 (t, $J = 6.6$ Hz, 2H), 2.28 (s, 3H), 2.03 (s, 3H). $^{13}$C NMR (151 MHz, CDCl$_3$): $\delta$ 170.95, 169.09, 136.66, 136.37, 133.73, 133.55, 125.74, 122.51, 64.09, 34.13, 25.70, 20.98. DART-AccuTOF MS: m/z calcd C$_{12}$H$_{15}$N$_2$O$_5$ [M+H]$^+$ 267.0981, found 267.0953.

2-(4-amino-3-nitrophienyl)ethan-1-ol (CF-L19-3). To a solution of CF-L19-2 (1.8 g, 6.76 mmol, 1.0 equiv) in MeOH (20 mL) was added 10 M NaOH (1.35 mL, 13.52 mmol, 2.0 equiv) and stirred for 15 min. The reaction was monitored by silica gel TLC (PE/EtOAc=1/1) and another portion of NaOH was added if there was still starting material left. MeOH was removed under reduced pressure and the residue was extracted by DCM/H$_2$O three times. The combined organic layers were washed with water twice, dried over anhydrous Na$_2$SO$_4$, concentrated under reduced pressure to afford bright red crystals (1.03 g, yield: 84%). $^1$H NMR (600 MHz, DMSO-d$_6$): $\delta$ 7.79 (d, $J = 1.9$ Hz, 1H), 7.34 – 7.23 (m, 3H), 6.94 (d, $J = 8.7$ Hz, 1H), 4.60 (t, $J = 5.2$ Hz, 1H), 3.55 (dt, $J = 6.7$, 5.3 Hz, 2H), 2.61 (t, $J = 6.7$ Hz, 2H). $^{13}$C NMR (151 MHz, DMSO-d$_6$): $\delta$ 144.74, 137.15, 129.93, 126.96, 124.43, 119.06, 61.72, 37.36. DART-AccuTOF MS: m/z calcd C$_8$H$_{11}$N$_2$O$_3$ [M+H]$^+$ 183.0770, found 183.0764.
4-(2-bromoethyl)-2-nitroaniline (CF-L19-4). CF-L19-3 (1.0 g, 5.49 mmol, 1.0 equiv) was dissolved in 48% HBr solution (30 mL) and refluxed for 6 h. The reaction was monitored by silica gel TLC (PE/EtOAc=1/1). After the reaction mixture cooled down, it was poured into a beaker with 30 mL H2O, neutralized with saturated NaHCO3, extracted with DCM three times. The combined organic layers were washed with water twice, dried over anhydrous Na2SO4, concentrated under reduced pressure to afford an orange oil. The crude product was further purified by silica gel chromatography (EtOAc/PE=1/10-1/5) to afford a yellow oil, from which orange crystals formed after being left in the freezer overnight (1.0 g, yield: 74%). 1H NMR (600 MHz, CDCl3): δ 7.97 (d, J = 2.1 Hz, 1H), 7.23 (dd, J = 8.5, 2.1 Hz, 1H), 6.78 (d, J = 8.5 Hz, 1H), 6.04 (s, 2H), 3.53 (t, J = 7.2 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H). 13C NMR (151 MHz, CDCl3): δ 143.75, 136.51, 132.07, 127.76, 125.77, 119.19, 37.81, 32.93. DART-AccuTOF MS: m/z calcd C8H10BrN2O2 [M+H]+ 244.9926, found 244.9903.

tert-butyl 2-(4-bromophenyl)pyrrolidine-1-carboxylate (CF-L19-5). To a solution of 2-(4-bromophenyl)pyrrolidine (2.0 g, 8.84 mmol, 1.0 equiv) in THF (30 mL), 1 M NaOH (9.73 mL, 9.73 mmol, 1.1 equiv) and 1 M Boc2O in THF (9.29 mL, 9.29 mmol, 1.05 equiv) was added. NMR spectra of the precursors were shown in Appendix B and couldn’t differentiate enantiomers. The mixture was stirred at rt overnight. THF was removed under reduced pressure and the residual was extracted with EtOAc three times. The combined organic layers were washed with brine twice, dried over anhydrous Na2SO4, concentrated under reduced pressure to yield an oily crude product, which was further purified by silica gel chromatography (DCM) to afford a white solid (2.5 g, 87%). 1H NMR (600 MHz, DMSO-d6): δ 7.49 (d, J = 7.3 Hz, 2H), 7.13 (d, J = 7.4 Hz, 2H), 4.80 - 4.63 (m, 1H), 3.57 – 3.38 (m, 2H), 2.36 – 2.14 (m, 1H), 1.79 (m, 2H), 1.70 – 1.60 (m, 1H), 1.38 – 1.11 (s, 9Hs). (two sets of signals indicate two diastereomers).
13C NMR (151 MHz, DMSO-d6): δ 153.44, 153.30, 144.70, 143.86, 130.96, 130.88, 127.75, 127.66, 119.24, 119.19, 78.48, 78.15, 59.69, 46.99, 46.81, 35.48, 34.27, 28.11, 27.79, 23.02, 22.72 (two sets of signals indicate two diastereomers). DART-AccuTOF MS: m/z calcd C15H21BrNO2 [M+H]+ 326.0756, found 326.0659. McLafferty rearrangement and decarboxylation occur during the DART-AccuTOF mass spectrometry measurement.

**tert-butyl (E)-2-(4-(3-methoxy-3-oxoprop-1-en-1-yl)phenyl)pyrrolidine-1-carboxylate (CF-L19-6).** To a solution of CF-L19-5 (1.63 g, 5.0 mmol, 1.0 equiv) in anhydrous ACN (20 mL) was added Pd(OAc)2 (56 mg, 0.25 mmol, 0.05 equiv), TEA (2.1 mL, 15 mmol, 3.0 equiv) and methyl acrylate (1.29 g, 15 mmol, 3.0 equiv) under argon. The mixture was stirred at 90 °C for 20 h. All solvent was removed under reduced pressure and the residual was extracted with EtOAc three times. The combined organic layers were washed with brine twice, dried over anhydrous Na2SO4, concentrated under reduced pressure to yield an oily crude product, which was further purified by silica gel chromatography (DCM; DCM/EtOAc=20/1) to afford a white solid (850 mg, yield: 51%). 1H NMR (600 MHz, CDCl3): δ 7.67 (d, J = 15.8 Hz, 1H), 7.45 (d, J = 7.7 Hz, 2H), 7.18 (s, 2H), 6.41 (d, J = 15.8 Hz, 1H), 4.93 – 4.75 (m, 1H), 3.78 (s, 3H), 3.58 – 3.30 (m, 2H), 2.32 (m, 1H), 1.97 – 1.74 (m, 3H), 1.44 – 1.16 (s, 9H). 13C NMR (151 MHz, CDCl3): δ 167.61, 154.54, 144.88, 144.70, 132.86, 128.38, 128.11, 126.17, 126.03, 117.27, 117.16, 79.47, 61.23, 60.65, 51.74, 47.48, 47.19, 36.02, 34.86, 28.59, 28.23, 23.71, 23.33. (two sets of signals indicate two diastereomers). DART-AccuTOF MS: m/z calcd C19H26NO4 [M+H]+ 332.1862, found 332.1769.

**Methyl (E)-3-(4-(pyrrolidin-2-yl)phenyl)acrylate hydrogen chloride (CF-L19-7).** Following the same synthesis procedure as CF-L14 afforded a white powder (yield: 86%). 1H NMR (600 MHz, D2O): δ 7.57 (m, 3H), 7.45 (d, J = 8.2 Hz, 2H), 6.44 (d, J = 16.1 Hz, 1H), 4.64
(m, 1H), 3.74 (s, 3H), 3.51 – 3.42 (m, 2H), 2.48 – 2.41 (m, 1H), 2.28 – 2.22 (m, 1H), 2.21 – 2.12 (m, 2H). $^{13}$C NMR (151 MHz, D$_2$O): δ 169.55, 144.69, 136.71, 134.89, 128.94, 128.03, 118.11, 62.80, 52.30, 45.50, 30.18, 23.48. DART-AccuTOF MS: m/z calcd C$_{14}$H$_{18}$NO$_2$ [M+H]$^+$ 232.1338, found 232.1262.

**Methyl (E)-3-(4-(1-(4-amino-3-nitrophenethyl)pyrrolidin-2-yl)phenyl)acrylate (CF-L19-8).** To a solution of CF-L19-4 (450 mg, 1.84 mmol, 1.0 equiv) in ACN (25 mL) was added CF-L19-7 (761 mg, 1.84 mmol, 1.0 equiv) and K$_2$CO$_3$ (761 mg, 5.5 mmol, 3.0 equiv). The resulting mixture was refluxed overnight. Partial ACN was removed under reduced pressure and the resulting mixture was extracted with EtOAc and H$_2$O three times. The organic layers were combined, washed with brine, dried over anhydrous Na$_2$SO$_4$, and concentrated under reduced pressure to give a yellow crude product. The crude product was further purified by silica gel chromatography (DCM, DCM/EtOAc=10/1), which afforded a yellow product (500 mg, 69%).

$^1$H NMR (600 MHz, DMSO-d$_6$): δ 7.67 (d, J = 2.0 Hz, 1H), 7.61 (d, J = 16.0 Hz, 1H), 7.56 (d, J = 8.2 Hz, 2H), 7.29 (s, 2H), 7.24 (d, J = 8.2 Hz, 2H), 7.15 (dd, J = 8.7, 2.1 Hz, 1H), 6.90 (d, J = 8.6 Hz, 1H), 6.55 (d, J = 16.0 Hz, 1H), 3.71 (s, 3H), 3.33 – 3.27 (m, 2H), 2.61 – 2.51 (m, 3H), 2.29 – 2.21 (m, 2H), 2.12 – 2.05 (m, 1H), 1.84 – 1.73 (m, 2H), 1.49 – 1.41 (m, 1H). $^{13}$C NMR (151 MHz, DMSO-d$_6$): δ 166.72, 146.94, 144.69, 144.44, 136.82, 132.60, 129.85, 128.30, 127.69, 127.62, 123.93, 119.00, 117.03, 68.77, 55.04, 52.86, 51.41, 34.91, 32.89, 22.32. DART-AccuTOF MS: m/z calcd C$_{22}$H$_{26}$N$_3$O$_4$ [M+H]$^+$ 396.1923, found 396.1859.

**Methyl (E)-3-(4-(1-(3,4-diaminophenethyl)pyrrolidin-2-yl)phenyl)acrylate (CF-L19-9).** To a solution of CF-L19-8 (450 mg, 1.14 mmol, 1.0 equiv) in EtOH/H$_2$O (2/1; 20 mL) was added an iron powder (638 mg, 11.4 mmol, 10.0 equiv) and NH$_4$Cl (305 mg, 5.7 mmol, 5.0 equiv). The reaction mixture was refluxed for 1-2 h and monitored by silica gel TLC
(DCM/MeOH=20/1). All iron powder was removed via gravity filtration and EtOH was removed under reduced pressure. The residual was extracted with DCM three times. The organic layers were combined, washed with brine, dried over anhydrous Na$_2$SO$_4$, and concentrated under reduced pressure to give a brown solid (225 mg yield: 54%), which was confirmed by DART-AcuTOF MS and used for the following step without further purification. DART-AcuTOF MS: m/z calcd C$_{22}$H$_{28}$N$_3$O$_2$ [M+H]$^+$ 366.2180, found 366.2117.

(\(E\))-3-(4-(1-(3,4-diaminophenethyl)pyrrolidin-2-yl)phenyl)-N-hydroxyacrylamide (CF-L19). To a solution of CF-L19-9 (200 mg, 0.547 mmol, 1.0 equiv) in DCM/MeOH (1/2, 12 mL) at 0 °C, hydroxylamine (50 wt% in water, 0.484mL, 8.21 mmol, 15.0 equiv) was added, followed by fine NaOH powder (219 mg, 5.47 mmol, 10.0 equiv). The solution was stirred at 0 °C for 30 min and then allowed to warm to rt and stirred overnight. The solvent was removed under reduced pressure. H$_2$O (2.5 mL) was added to the residual and the insoluble solid was removed by filtration. HCl (conc. 1-2 M) was added to adjust the pH (~9) and the mixture was extracted with EtOAc three times, dried over Na$_2$SO$_4$ and filtered. The EtOAc volume was reduced under reduced pressure and hexanes were added to induce the formation of the product. The organic solvent was removed using a centrifuge and the product was washed with dry Et$_2$O three times and dried overnight to afford a brown powder (50 mg, yield: 25%). $^1$H NMR (600 MHz, DMSO-d$_6$): δ 10.73 (s, 1H), 9.03 (s, 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 15.7 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 6.42 (d, J = 15.8 Hz, 1H), 6.35 (d, J = 7.7 Hz, 1H), 6.23 (d, J = 1.9 Hz, 1H), 6.10 (dd, J = 7.8, 1.9 Hz, 1H), 4.27 (s, 4H), 3.33 – 3.31 (m, 1H), 3.31 – 3.24 (m, 1H), 2.55 (m, 1H), 2.48 (m, 1H), 2.38 – 2.32 (m, 1H), 2.25 (m, 1H), 2.19 – 2.06 (m, 2H), 1.87 – 1.73 (m, 2H), 1.51 (m, 1H). ESI-AcuTOF MS: m/z calcd C$_{21}$H$_{27}$N$_4$O$_2$ [M+H]$^+$ 367.2134, found 367.2010.
3.3 HDAC Inhibition and Cell Viability Study

Two bioassays have been used to evaluate the HDAC inhibitors synthesized in our lab. The HDAC1 inhibition study was conducted by contract research organization Nanosyn, Inc, at Santa Clara, CA with the support from Newave Pharmaceutical. Inc. The cell viability study was performed at the School of Pharmacy in collaboration with Dr. Xin Guo’s lab, University of the Pacific. Colon cancer cell line HCT-116 (ATCC) and lung cancer cell line A549 (ATCC) were used for cytotoxicity evaluation. IC$_{50}$ curves can be found in Appendix E. As all of the compounds synthesized in this project are organic molecules, the formulation solvent is DMSO. Please refer to section 2.3 for more experimental details.
Table 3.1 HDAC1 inhibition and cell viability for compound **CF-L01 to CF-L12**.

![Diagram showing SAHA and CF-L01 to CF-L12](Image)

<table>
<thead>
<tr>
<th>Compd</th>
<th>X</th>
<th>n</th>
<th>R₂</th>
<th>HDAC1 inhibition IC₅₀ (µM)</th>
<th>HCT-116 viability IC₅₀ (µM)</th>
<th>A549 viability IC₅₀ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAHA</td>
<td>H</td>
<td>6</td>
<td>O</td>
<td>0.04</td>
<td>1.05</td>
<td>4.42</td>
</tr>
<tr>
<td>CF-L01</td>
<td>1/₂-O 1/₂</td>
<td>5</td>
<td>H</td>
<td>1.74</td>
<td>17.46</td>
<td>N/A</td>
</tr>
<tr>
<td>CF-L02</td>
<td>1/₂-O 1/₂</td>
<td>6</td>
<td>H</td>
<td>0.17</td>
<td>2.67</td>
<td>9.56</td>
</tr>
<tr>
<td>CF-L03</td>
<td>H</td>
<td>5</td>
<td>O</td>
<td>0.11</td>
<td>&gt;50</td>
<td>N/A</td>
</tr>
<tr>
<td>CF-L04</td>
<td>H</td>
<td>6</td>
<td>O</td>
<td>0.04</td>
<td>3.59</td>
<td>13.30</td>
</tr>
<tr>
<td>CF-L05</td>
<td>1/₂-O 1/₂</td>
<td>5</td>
<td>H</td>
<td>&gt;10</td>
<td>&gt;50</td>
<td>N/A</td>
</tr>
<tr>
<td>CF-L06</td>
<td>1/₂-O 1/₂</td>
<td>6</td>
<td>H</td>
<td>4.34</td>
<td>30.16</td>
<td>37.05</td>
</tr>
<tr>
<td>CF-L07</td>
<td>H</td>
<td>5</td>
<td>2-3</td>
<td>0.45</td>
<td>4.45</td>
<td>5.93</td>
</tr>
<tr>
<td>CF-L08</td>
<td>H</td>
<td>6</td>
<td>2-3</td>
<td>1.79</td>
<td>17.45</td>
<td>&gt;50</td>
</tr>
<tr>
<td>CF-L09</td>
<td>1/₂-O 1/₂</td>
<td>5</td>
<td>H</td>
<td>0.07</td>
<td>6.20</td>
<td>20.09</td>
</tr>
<tr>
<td>CF-L10</td>
<td>1/₂-O 1/₂</td>
<td>6</td>
<td>H</td>
<td>0.03</td>
<td>1.98</td>
<td>43.99</td>
</tr>
<tr>
<td>CF-L11</td>
<td>H</td>
<td>5</td>
<td>2-3</td>
<td>0.04</td>
<td>1.13</td>
<td>&gt;50</td>
</tr>
<tr>
<td>CF-L12</td>
<td>H</td>
<td>6</td>
<td>2-3</td>
<td>0.04</td>
<td>2.30</td>
<td>&gt;50</td>
</tr>
</tbody>
</table>

*IC₅₀ values are means of at least three replicates*
HDAC1 inhibition and cell viability data are summarized in Table 3.1. Compound CF-L04, CF-L10, CF-L11, and CF-L12 exhibited comparable HDAC1 inhibition activity with reference compound SAHA. When hydroxamic acid was used as the zinc-binding group (CF-L01 to CF-L04), the linker with 6 carbons has significantly smaller IC_{50} values than those with 5 carbons. The linkage being either ether or reversed amide bond does not significantly alter its inhibition. When ortho-aminoamidelide was used as the zinc-binding group (CF-L05 to CF-L08), the linker with 6 carbons has significantly smaller IC_{50} if an ether bond was used as the linkage while the IC_{50} in an opposite trend was observed when a reversed amide bond was used as the linkage. When ortho-aminoamidelide possessing a C-5 phenyl group was used as the zinc-binding group (CF-L09 to CF-L12), the linker with 6 carbons has smaller IC_{50} if an ether bond was used as the linkage while there is no significant difference when a reversed amide bond was used. It might be due to the additional binding of a C-5 phenyl group to the internal cavity, which weakened the effects of linker length. This also explained the high inhibition potency of CF-L09 to CF-L12.

A similar trend was observed in the HCT-116 colon cancer cell viability study, with CF-L02, CF-L04, CF-L07, and CF-L09 to CF-L12 showing promising IC_{50} value. The inhibition efficiency of CF-L09 to CF-L12 in A549 was low as shown by high IC_{50} values. The overall IC_{50} values are higher in the A549 cell line compared with those in HCT-116, indicating that these compounds might be less effective in treating A549 lung cancer. CF-L02, CF-L04, and CF-L07 are promising HDAC inhibitors for future development. Considering the complexity of synthesis and purification, hydroxamic acid with 6 carbon as linker was used for the design and synthesis of following HDAC inhibitors.
CF-L13 to CF-L17 were synthesized by modifying the cap domain of SAHA while keeping the 6-carbon linker and hydroxamic acid as the zinc-binding group. CF-L18 and CF-L19 were synthesized by modifying Panobinostat. Table 3.2 summarized HDAC1 inhibition. CF-L13 to CF-L17 have comparable efficacy with SAHA, indicating the modification of the cap domain does not affect the HDAC1 inhibition too much. By changing the cap of Panobinostat to pyridine, CF-L18 showed comparable inhibition with SAHA. CF-19 was designed by further increasing the bulkiness and rigidity of the linker. Its HDAC1 inhibition was significantly changed and the IC$_{50}$ value reached to nM molar level (1.1 nM).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HDAC1 IC$_{50}$ (nM)</td>
<td>44.8±5.4</td>
<td>52.3±12.1</td>
<td>51.4±6.9</td>
<td>42.2±3.4</td>
<td>28.3±3.4</td>
<td>15.7±1.2</td>
<td>24.7±7.6</td>
<td>1.1±0.1</td>
</tr>
</tbody>
</table>

### 3.4 Conclusions
19 new HDAC inhibitors have been synthesized, characterized and evaluated by HDAC inhibition assay and cell viability assay. The linker length and zinc-binding group of each inhibitor indeed affected the bioactivity. Modification of the inhibitors directly influences its HDAC inhibition and thus cell viability. The HCT-116 cell line is relative decent model for HDAC1 inhibition screening as the trend is the same as that of HDAC1 enzyme inhibition assay. A549 cell line is less sensitive to the HDAC inhibitors (CF-L01 to CF-L12). The 6-carbon linker demonstrating high efficacy in HDAC inhibition and hydroxamic acid ZBG from convenient synthesis were chosen for further HDAC inhibitor design. Thanks to the bulkiness and higher rigidity of the linker, CF-19 shows the most promising efficacy in HDAC1 inhibition.
Chapter 4: Pt-HDACi Conjugates

4.1 Introduction

As mentioned in Chapter 1, platinum-based anticancer drugs, such as cisplatin, carboplatin, and oxaliplatin, have been approved for worldwide clinical use for decades. Nearly 50% of all cancer therapies involve the use of them as stand-alone treatments or in combination with other drugs.\textsuperscript{1,113,114} However, their widespread application is hindered by either cross-resistance or toxic side effects.\textsuperscript{1} One of the strategies to overcome those drawbacks is to make a newer generation of platinum-based anticancer drugs with multiple functions.\textsuperscript{13} For example, carbohydrates have been conjugated to platinum(II) to achieve targeting glucose receptors since glucose could enhance the uptake by cancer cells.\textsuperscript{115–123} Steroid, such as estrogen, testosterone, and bile acids, have been incorporated with platinum(II), acting as targeting unit that directs the platinum drug to receptors overexpressed with respective tissues.\textsuperscript{123–132} Since the solid-phase peptide synthesis was developed, the research of platinum(II)-peptide conjugates arose, which utilized either the targeting properties of specific peptide sequences\textsuperscript{133,134} or the enhanced cellular uptake properties.\textsuperscript{135–138} Other bioactive agents, such as dichloroacetate,\textsuperscript{139} diclofenac,\textsuperscript{140} curcumin,\textsuperscript{141} and vorinostat\textsuperscript{113} have also been installed onto platinum(II) centers through the leaving group carboxylate to achieve dual functions. Triple and even quadruple action of Pt (IV) prodrugs have been extensively explored by encompassing cyclooxygenases (COX) inhibitors, phosphoinositide-dependent protein kinase (PDK) inhibitor, and HDAC inhibitors.\textsuperscript{12,123}

Since histone deacetylase plays a vital role in the epigenetic pathways and is a clinically approved and validated cancer target, HDAC inhibitors have been extensively involved in many designs of hybrid molecules, aiming to simultaneously target two or more biological targets to achieve the synergistic anticancer activity. There are a few HDACi-based hybrid molecules
currently investigated in clinical trial studies. HDACi can synergize with kinase inhibitors by improving the sensitivity of kinase drugs and inducing apoptosis. CUDC-101 depicted in Figure 4.1 was prepared with a receptor tyrosine kinases (RTK) binding domain as the cap. It is derived from erlotinib, an approved drug for epidermal growth factor receptor (HER) inhibition.\textsuperscript{142} CUDC-907, with a phosphatidylinositol-4,5-bisphosphate (PI3K) binding domain as the cap, has dual PI3K and HDAC inhibition and has entered phase II clinical trial studies.\textsuperscript{6,143} Tinostamustine (EDO-S101) is a \textbf{first-in-class} alkylation deacetylase inhibitor, with the bendamustine pharmacophore as the cap domain.\textsuperscript{144} As a DNA/HDAC bifunctional agent, it shows enhanced anticancer activities, compared with its parent drugs, namely bendamustine and vorinostat.\textsuperscript{145} Domatinostat (4SC-202) is a lysine-specific demethylase 1 (LSD1) and HDAC bifunctional agent while both are crucial in the Wnt and Hedgehog (Hh) pathway. It is mainly employed to target resistant cancer stem cells.\textsuperscript{146} Many different HDAC hybrid molecules have been reported in the literature and for more details, the reader could refer to some nice review papers of this research area.\textsuperscript{146,147–149}
4.2 Design of Pt-HDACi Conjugates

Since both the multifunctional platinum agents and hybrid HDAC inhibitors have DNA and HDAC as their shared biological targets, several Pt-HDACi conjugates have been reported in the literature. The first Pt-HDACi conjugate, shown in Figure 4.2, was reported by Dr. Celine J. Marmion and her research team. The complex is a hybrid molecule of two FDA-approved drugs, cisplatin, and SAHA (vorinostat). Their gel electrophoresis proved the DNA binding function of the hybrid molecule and HDAC1 inhibition assay provided an IC$_{50}$ value of 1143 nM, which is around eightfold less active than the malonic acid precursor. When HDACi is incorporated into the platinum core as the leaving group, the hybrid molecule will eventually
dissociate into two different drugs, which might decrease the efficacy as they have a different pharmacokinetic profile and thus could not achieve enough synergistic effect.

Figure 4.2 Pt-HDACi hybrid molecule reported by Marmion’s team.\textsuperscript{113,151}
A logical design strategy to incorporate the dual function could involve the installation of HDACi on the platinum center as a non-leaving group ligand. When the hybrid molecule reaches the cancer cells, the synergistic effect could be maintained as the relaxed chromatin structure makes DNA more susceptible to attack by the Pt drug. Picoplatin and SAHA derivatives are hybridized to form Pt-HDACi complexes, shown in Figure 4.3. According to the biostudies of HDACi in Chapter 3, **CF-L02**, **CF-L04**, and **CF-L07** exhibited promising HDAC inhibition and cytotoxicity among the first 12 HDACi (Table 3.1). Only **CF-L02** was used to incorporate with
platinum to form Pt-HDACi, **CF-101**, as it was feasible to obtain the pure product for further evaluation. The 2-methyl pyridine cap is crucial to form the desired monodentate product. According to the biostudies of picoplatin derivatives in Chapter 2, **Pt-11** and **Pt-12** showed comparable cell viability to cisplatin and picoplatin in ovarian cancer cell lines A2780 and A2780cis (Figure 2.8). The crystal structural analysis confirmed the *cis* configuration of **Pt-11** and **Pt-12**. HDAC inhibitors, **CF-L13**, **CF-14**, and **CF-15**, have comparable HDACi inhibition with SAHA (Table 3.2). Therefore, **CF-102**, **CF-103**, and **CF-104** were also designed and synthesized by merging **Pt-11** and **Pt-12** with **CF-L13**, **CF-L14**, and **CF-L15**.

Ethylenediamine has been extensively used as the non-leaving group linker for bifunctional platinum agent’s synthesis.\textsuperscript{13} It also showed decent cytotoxicity against A2780 and A2780cis cell lines (Figure 4.10). HDAC inhibitors, **CF-L16** and **CF-17**, have better HDACi inhibition than SAHA (Table 3.2). Therefore, the bidentate Pt-HDACi hybrids (**CF-201**, and **CF-202**) were also synthesized (Figure 4.5) by combing **Pt-13** with **CF-L16** and **CF-L17**.
Figure 4.4 Pt-HDACi hybrid molecules (bidentate binding) designed in current research.

Figure 4.5 Pt-HDACi hybrid molecules (bidentate binding) designed in current research.
4.3 Preparation of Pt-HDACi Conjugates

**General procedures.** Refer to part 2.2 in Chapter 2

![Scheme 4.1 Synthesis of CF-101.](image)

**CF-101.** **CF-L02** (53 mg, 0.21 mmol, 1.0 equiv) dissolved in anhydrous DMF (3.0 mL) was slowly added to a solution of K[PtCl$_3$(NH$_3$)] (75 mg, 0.21 mmol, 1.0 equiv) in anhydrous DMF (3.0 mL). The mixture was stirred at 80 °C for 20 h. The byproducts were removed by filtration and the filtrate was concentrated under reduced pressure (40-45 °C, 125 rpm), which was then purified by preparative silica TLC (DCM/MeOH = 5/1). The gel band containing the product was scratched off, dissolved in anhydrous DMF, filtered, and concentrated to ~0.5 mL. The product was crushed out with the addition of EtOAc. The off-white product was collected via centrifugation, washed with EtOAc (twice), Et$_2$O (three times), and dried under vacuum overnight (30 mg, yield: 23 %). $^1$H NMR (600 MHz, DMF-d$_7$): δ 10.59 (s, 1H), 8.99 (br, 1H), 8.78 (d, J = 5.3 Hz, 1H), 7.16 (s, 1H), 6.95 (s, 1H), 4.36 (s, 3H), 4.17 (t, J = 6.2 Hz, 2H), 3.10 (s, 3H), 2.09 (t, J = 6.7 Hz, 2H), 1.77 (m, 2H), 1.59 (m, 2H), 1.45 (m, 2H), 1.36 (m, 2H). $^{13}$C NMR (151 MHz, DMF-d$_7$): δ 170.53, 166.98, 163.45, 155.73, 112.82, 110.91, 69.77, 33.35, 29.45, 29.29, 26.60, 26.24, 26.21. $^{195}$Pt NMR (129 MHz, DMF-d$_7$): δ -2021.08. ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_{13}$H$_{23}$Cl$_2$N$_3$O$_3$PtNa, [M+Na]$^+$ calcd 558.0646, found
Anal. calc'd for C_{13}H_{23}Cl_{2}N_{3}O_{3}Pt (0.5 H_{2}O): C, 28.67; H, 4.44; N, 7.72%. Found: C, 28.77; H, 4.29; N, 7.45%.

Scheme 4.2 Synthesis of CF-102, CF-103 and CF-104.

**CF-102. CF-L13** (46 mg, 0.173 mmol, 1.0 equiv) dissolved in anhydrous DMF (3.0 mL) was slowly added to a solution of K[PtCl_{3}(2-picoline)] (TPP) (75 mg, 0.173 mmol, 1.0 equiv) in anhydrous DMF (3.0 mL). The mixture was stirred at 80 °C for 20 h. Following the same procedure as **CF-101**, an off-white solid was produced (13 mg, yield: 12%). $^1$H NMR (600 MHz, DMF-d$_7$): δ 10.95 (br, 1H), 10.51 (br, 1H), 9.18 (d, J = 4.9 Hz, 1H), 8.92 (br, 1H), 8.62 (d, J = 5.7 Hz, 2H), 7.91 (t, J = 7.4 Hz, 1H), 7.72 (s, 2H), 7.59 (d, J = 7.7 Hz, 1H), 7.41 (t, J = 6.2 Hz, 1H), 3.17 (s, 3H), 2.44 (m, 2H), 2.05 (t, J = 7.2 Hz, 2H), 1.61 (m, 2H), 1.57 – 1.51 (m, 2H), 1.29 (m, 4H). $^{13}$C NMR (151 MHz, DMF-d$_7$): δ 174.34, 170.60, 162.22, 154.49, 153.75 (2), 148.92,
(129 MHz, DMF-d$_7$): δ -1973.65. AccuTOF MS: m/z value of the most abundant isotope peak of C$_{19}$H$_{26}$Cl$_2$N$_4$O$_3$PtNa, [M+Na]$^+$ calcd 647.0913, found 647.0849. Anal. calcd for C$_{19}$H$_{26}$Cl$_2$N$_4$O$_3$Pt: C, 36.01; H, 4.30; N, 8.85%. Found: C, 35.66; H, 3.90; N, 8.64%.

**CF-103. CF-L14** (57 mg, 0.173 mmol, 1.0 equiv) dissolved in anhydrous DMF (3.0 mL) with DIEA (22.4 mg, 30 µL, 1.0 equiv) was slowly added to a solution of K[PtCl$_3$(2-picoline)] (TCPP) (75 mg, 0.173 mmol, 1.0 equiv) in anhydrous DMF (3.0 mL). The mixture was stirred at 80 °C for 20 h. An off-white solid was obtained by following the same procedure as CF-101 (20 mg, yield: 18%). $^1$H NMR (600 MHz, DMF-d$_7$): δ 10.61 (s, 1H), 10.13 (s, 1H), 8.99 (br, 1H), 8.62 (d, J = 5.1 Hz, 1H), 7.83 (t, J = 7.4 Hz, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 7.6 Hz, 1H), 7.41 (d, J = 8.2 Hz, 2H), 7.24 (t, J = 6.3 Hz, 1H), 5.48 (d, J = 51.9 Hz, 2H), 3.87 (m, 2H), 3.08 (s, 3H), 2.40 (t, J = 7.1 Hz, 2H), 2.08 (t, J = 7.2 Hz, 2H), 1.71 – 1.62 (m, 2H), 1.61 – 1.51 (m, 2H), 1.40 – 1.27 (m, 4H). $^{13}$C NMR (151 MHz, DMF-d$_7$): δ 172.66, 170.64, 162.57, 154.70, 140.16, 138.95, 133.66, 130.43, 127.19, 123.71, 119.98, 50.29, 37.49, 33.31, 29.52, 29.46, 26.62, 26.17(2). $^{195}$Pt NMR (129 MHz, DMF-d$_7$): δ -2096.14. AccuTOF MS: m/z value of the most abundant isotope peak of C$_{21}$H$_{30}$Cl$_2$N$_4$O$_3$PtNa, [M+Na]$^+$ calcd 675.1227, found 675.1182. Anal. calcd for C$_{21}$H$_{30}$Cl$_2$N$_4$O$_3$Pt (H$_2$O): C, 37.60; H, 4.81; N, 8.36%. Found: C, 37.21; H, 4.41; N, 8.13%.

**CF-104. CF-L15** was used as the starting material and the reaction followed the same procedure as CF-103 to afford an off-white solid (yield: 18%). $^1$H NMR (600 MHz, DMF-d$_7$): δ 10.59 (s, 1H), 9.98 (s, 1H), 9.11 (d, J = 5.2 Hz, 1H), 7.89 (t, J = 7.4 Hz, 1H), 7.63 (d, J = 8.1 Hz, 2H), 7.58 (d, J = 8.2 Hz, 1H), 7.39 (t, J = 6.4 Hz, 1H), 7.14 (d, J = 8.2 Hz, 2H), 5.19 (d, J = 61.0 Hz, 2H), 3.20 (s, 3H), 3.02 – 2.94 (m, 2H), 2.90 – 2.79 (m, 2H), 2.37 (t, J = 7.0 Hz, 2H), 2.08 (t,
J = 7.3 Hz, 2H), 1.68 – 1.61 (m, 2H), 1.60 – 1.53 (m, 2H), 1.39 – 1.28 (m, 4H). \( \delta^{13}\text{C} \) NMR (151 MHz, DMF-d7): \( \delta \) 172.45, 170.64, 162.57, 154.96, 139.18, 139.04, 133.96, 129.65, 127.42, 124.09, 120.14, 48.70, 37.52, 36.62, 33.35, 29.57, 29.51, 26.75, 26.22(2). \(^{195}\text{Pt} \) NMR (129 MHz, DMF-d7): \( \delta -2102.74 \). AccuTOF MS: m/z value of the most abundant isotope peak of C\(_{22}\)H\(_{32}\)Cl\(_2\)N\(_4\)O\(_3\)PtNa, [M+Na]\(^+\) calcd 689.1384, found 689.1258. Anal. calcd for C\(_{22}\)H\(_{32}\)Cl\(_2\)N\(_4\)O\(_3\)Pt(H\(_2\)O): C, 38.58; H, 5.01; N, 8.19%. Found: C, 38.35; H, 4.80; N, 7.88%.

**Scheme 4.3 Pt-13, Pt-14, Pt-15 and Pt-16 synthesis**

\[
\begin{array}{c}
2 \text{K}^+ \left[ \begin{array}{c} \text{Cl} \text{Cl} \\
\text{Cl} \text{Cl} \\
\end{array} \right] \rightarrow \text{H}_2\text{O}, \text{rt} \\
\text{Cl} \text{Cl} \text{Cl} \text{Cl} \\
\text{Cl} \text{Pt} \text{N} \text{H} \text{N} \\
\text{H}_2 \text{N} \text{H} \\
\end{array} \rightarrow \\
\text{Pt-13 (73%)} \\
\text{Pt-14 (74%)} \\
\text{Pt-15 (89%)} \\
\text{Pt-16 (76%)}
\end{array}
\]

Scheme 4.3 Synthesis of Pt-13, Pt-14, Pt-15 and Pt-16.

**PtCl\(_2\)(ethylenediamine) (Pt-13).** To a solution of ethylenediamine (18.01 mg, 20.13 \( \mu \)L, 0.30 mmol, 1.25 equiv) in 2 mL of H\(_2\)O was added a solution of potassium tetrachloroplatinate(II), K\(_2\)PtCl\(_4\) (100 mg, 0.241 mmol, 1.0 eq) in 1 mL of H\(_2\)O dropwise. A yellow solid precipitated out after 10-20 min of stirring. The solution continued to stir for additional 5-6 h at rt. The yellow solids were collected via vacuum filtration, washed with cold water, acetone, and ether, and dried under vacuum overnight (yield: 73%). \(^1\text{H} \) NMR (600 MHz, DMSO-d\(_6\)) \( \delta \) 5.29 (s, 4H), 2.23 (s, 4H).
**PtCl$_2$((±)-trans-1,2-cyclohexanediamine) (Pt-14).** The same synthesis procedure as Pt-13 was applied to afford a light-yellow crude product (yield: 74%). $^1$H NMR (600 MHz, DMSO-$d_6$) $\delta$ 6.35 (m, 1H), 6.24 (m, 2H), 5.83 (t, $J = 10.2$ Hz, 1H), 2.34 (m, 2H), 1.95 (d, $J = 12.8$ Hz, 1H), 1.89 (d, $J = 13.8$ Hz, 1H), 1.51 (m, 2H), 1.37 – 1.23 (m, 2H), 1.07 – 0.96 (m, 2H). ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_6$H$_{14}$Cl$_2$N$_2$PtNa, [M+Na]$^+$ calcd 403.0060, found 403.0047.

**PtCl$_2$(phenylenediamine) (Pt-15).** Following the same synthesis procedure as Pt-13 afforded a light-yellow crude product (yield: 89%). $^1$H NMR (600 MHz, DMSO-$d_6$) $\delta$ 7.62 (s, 4H), 7.16 (s, 4H). ESI-AccuTOF MS: m/z value of the most abundant isotope peak of C$_6$H$_8$Cl$_2$N$_2$PtNa, [M+Na]$^+$ calcd 396.9590, found 403.0047.

**PtCl$_2$(2-(aminomethyl)pyridine) (Pt-16).** Following the same synthesis procedure as Pt-13 afforded light-yellow crude product (yield: 76%). $^1$H NMR (600 MHz, DMSO-$d_6$) (one set) $\delta$ 9.07 (ddd, $J = 5.9$, 1.5, 0.7 Hz, 1H), 8.12 (td, $J = 7.7$, 1.6 Hz, 1H), 7.64 (ddd, $J = 7.9$, 1.5, 0.8 Hz, 1H), 7.48 (m, 1H), 6.20 (m, 2H), 4.08 (t, $J = 5.9$ Hz, 2H).

![Scheme 4.4 Synthesis of CF-201 and CF-202.](image-url)
CF-201. To solution of CF-L16 (50 mg, 0.122 mmol, 1.0 equiv) in H₂O (0.8 mL) and acetone (1 mL) was added 1 M NaOH (183 µL, 0.183 mmol, 1.5 equiv). The total volume is around 2 mL. The solution was stirred for 5 min and then added a solution of K₂PtCl₄ (50.7 mg, 0.122 mmol, 1.0 equiv) in H₂O (0.3 mL) dropwise. The solution was stirred for 3.5 h. The light-yellow solid was collected via vacuum filtration, washed with cold water and acetone, dried under vacuum overnight (16 mg, yield: 22%). ¹H NMR (600 MHz, DMF-d₇): δ 10.53 (s, 1H), 8.51 (s, 1H), 7.99 (d, J = 6.6 Hz, 2H), 7.78 (d, J = 6.8 Hz, 2H), 6.63 (s, 1H), 5.47 (s, 2H), 4.50 (d, J = 12.2 Hz, 1H), 4.23 (m, 1H), 3.36 (m, 2H), 2.74 – 2.50 (m, 3H), 2.50 – 2.38 (m, 1H), 2.07 (t, J = 6.9 Hz, 2H), 1.58 (m, 4H), 1.41 – 1.26 (m, 4H).

CF-202. Following the same procedure as CF-201 afforded a light-yellow solid (yield: 23%) ¹H NMR (600 MHz, DMF-d₇): δ 7.57 (d, J = 8.3 Hz, 2H), 6.97 (d, J = 8.3 Hz, 2H), 6.41 (s, 1H), 5.43 (s, 2H), 4.39 (d, J = 13.2 Hz, 1H), 4.07 (dd, J = 13.5, 8.7 Hz, 1H), 4.01 (t, J = 6.3 Hz, 2H), 2.64 (m, 2H), 2.58 (m, 1H), 2.44 (m, 1H), 2.09 (t, J = 7.5 Hz, 2H), 1.82 – 1.69 (m, 2H), 1.60 (m, 2H), 1.52 – 1.42 (m, 2H), 1.37 (m, 2H).

4.4 Results and Discussion

Four bioassays have been used to evaluate the Pt-HDACi complexes. The DNA binding study was performed at Dr. Liang Xue’s lab in the Chemistry Department, University of the Pacific. The HDAC1 inhibition study was conducted by contract research organization Nanosyn, Inc, at Santa Clara, CA with the support from Newave Pharmaeutical Inc. The cell viability study was performed at the pharmacy school with collaboration with Dr. Xin Guo’s lab, University of the Pacific. Colon cancer cell line HCT-116 and lung cancer cell line A549, ovarian cancer cell lines A2780 and A2780cis were used for cytotoxicity evaluation. The cellular uptake study was conducted in our lab at the chemistry department, University of the Pacific.
Since the complexes contain platinum, the formulation solvent is DMF. Please refer to section 2.3 for more experimental details.

**4.4.1 Monodentate Pt-HDACi conjugate. CF-101, CF-102, CF-103, and CF-104** were synthesized as hybrid molecules between picoplatin and SAHA derivatives. Mass spectrometry and NMR have been used to confirm the mass and structures of the desired products. For example, the stacked $^1$H NMR spectra of CF-L13 and CF-102 confirmed the binding of the HDACi to the platinum core (Figure 4.6). Although there is no X-ray data to confirm the *cis* configuration of the Pt-HDACi conjugates, their $^{195}$Pt NMR shifts are very close to their corresponding picoplatin derivatives in a *cis* configuration under the same deuterated NMR solvent (Table 4.1). For example, the $^{195}$Pt NMR shift of CF-101 (-2021.08 ppm) is close to that of Pt-1 (-2042.86 ppm). The $^{195}$Pt NMR shift of CF-102 (-1973.65 ppm) is close to that of Pt-11 (-1979.29 ppm). The $^{195}$Pt NMR shifts of CF-103 (-2096.14 ppm) and CF-104 (-2102.74 ppm) are close to that of Pt-12 (-2095.60 ppm).

<table>
<thead>
<tr>
<th>Compd</th>
<th>CF-101 ppm</th>
<th>CF-102 ppm</th>
<th>CF-103 ppm</th>
<th>CF-104 ppm</th>
<th>Pt-1 ppm</th>
<th>Pt-11 ppm</th>
<th>Pt-12 ppm</th>
</tr>
</thead>
</table>
Figure 4.6 The stacked $^1$H NMR spectra of CF-L13 (top, blue trace) and CF-102 (bottom, red trace).

*DMF-d$_3$, solvent residual at 25 °C

Figure 4.7 DNA gel electrophoresis of CF-101, CF-102, CF-103 and CF-104, reference to cisplatin and SAHA.
The DNA binding study was conducted following the protocol described in section 2.3. As the molecular weight of Pt-DNA adducts formed with Pt-HDACi conjugates is significantly larger than that of cisplatin adduct, the separation difference of Pt-HDACi is bigger than that of cisplatin (Figure 4.7). SAHA was used as the negative control and it showed no binding between DNA and SAHA. Quantitative study with three runs for each complex has also been conducted (Figure 4.8), which demonstrated that CF-101 has a better binding efficacy that other conjugates. The DNA binding studies confirm the function of platinum in the Pt-HDACi conjugates.

Table 4.2 HDAC1 inhibition of Pt-HDACi conjugates and their corresponding free ligands.

<table>
<thead>
<tr>
<th>Pt-HDACi</th>
<th>SAHA</th>
<th>CF-101</th>
<th>CF-102</th>
<th>CF-103</th>
<th>CF-104</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDAC1 IC&lt;sub&gt;50&lt;/sub&gt; (nM)</td>
<td>44.8±5.4</td>
<td>148±35.7</td>
<td>25±4.2</td>
<td>22.5±2.4</td>
<td>32.8±5.5</td>
</tr>
<tr>
<td>Free ligand</td>
<td>SAHA</td>
<td>CF-L02</td>
<td>CF-L13</td>
<td>CF-L14</td>
<td>CF-L15</td>
</tr>
<tr>
<td>HDAC1 IC&lt;sub&gt;50&lt;/sub&gt; (nM)</td>
<td>44.8±5.4</td>
<td>165±31.1</td>
<td>52.3±12.1</td>
<td>51.4±6.9</td>
<td>42.2±3.4</td>
</tr>
</tbody>
</table>
Results from HDAC1 inhibition assay were summarized in Table 4.2. **CF-102, CF-103, and CF-104** showed comparable or even better inhibition efficacy than SAHA. However, **CF-101** exhibited significantly less efficacy than other conjugates. It might be due to the less efficacy of its corresponding free ligand, **CF-L02**. All Pt conjugates showed slightly better HDAC1 inhibition than that of corresponding free ligands. Computational studies could have been applied to further explore the structure-activity relationship.

![Graphs showing IC50 curves](image)

**Figure 4.9** IC50 curve of SAHA, cisplatin, and Pt-HDACi in (a) HCT-116, (b)A549, (c)A2780 and (d) A2780cis cell lines.
Table 4.3 Cell viability IC$_{50}$ values of Pt-HDACi in four different cancer cell lines.

<table>
<thead>
<tr>
<th>IC$_{50}$ (µM)</th>
<th>HCT-116</th>
<th>A549</th>
<th>A2780</th>
<th>A2780cis</th>
<th>Resistance factor$^*$</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAHA</td>
<td>0.81 ± 0.02</td>
<td>3.55 ± 0.18</td>
<td>1.07 ± 0.16</td>
<td>0.40 ± 0.07</td>
<td>N/A</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>6.13 ± 0.31</td>
<td>8.88 ± 0.70</td>
<td>0.97 ± 0.06</td>
<td>4.22 ± 0.21</td>
<td>4.35</td>
</tr>
<tr>
<td>CF-101</td>
<td>5.95 ± 0.44</td>
<td>22.80 ± 3.66</td>
<td>4.22 ± 0.46</td>
<td>3.53 ± 0.58</td>
<td>0.84</td>
</tr>
<tr>
<td>CF-102</td>
<td>14.84 ± 0.39</td>
<td>N/A</td>
<td>30.92 ± 6.64</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>CF-103</td>
<td>21.28 ± 0.96</td>
<td>&gt;50</td>
<td>13.37 ± 0.41</td>
<td>13.39 ± 1.84</td>
<td>1.00</td>
</tr>
<tr>
<td>CF-104</td>
<td>21.46 ± 9.69</td>
<td>&gt;50</td>
<td>14.49 ± 1.44</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

$^*$Resistance factor (R$_f$) is defined as IC$_{50}$(A2780cis)/IC$_{50}$(A2780)

Four solid tumor cancer cell lines, including colon cancer HCT-116, lung cancer A549 and ovarian cancer A2780 and A2780cis, have been used to evaluate the cytotoxicity of the Pt-HDACi conjugates (Figure 4.9). The IC$_{50}$ values are summarized in Table 4.3. Although SAHA showed the best efficacy in terms of cytotoxicity in all four cell lines, it has not been approved for colon, lung and ovarian solid tumors treatment and one of the reasons may be its short elimination half-life (t$_{1/2}$: 1-2 h).$^{153,154}$ Our project focuses on Pt-HDACi conjugates and used for solid tumor treatment. Cisplatin is our reference drug with a much longer elimination half-life and less frequent administration depending on the cancer type. Our complex is more effective on HCT-116 and A2780 cell lines while A549 and A2780cis cell lines are less sensitive to our Pt-HDACi conjugates. Among all the Pt-HDACi conjugates, **CF-101** shows the best efficacy, which is comparable with cisplatin in HCT-116 and A2780cis. **CF-101** also has the lowest resistance factor (0.84) whereas cisplatin has a R$_f$ value of 4.35. Further extending the HDACi away from the platinum core (**CF-102, CF-103, and CF-104**) will decrease the cytotoxicity.
In order to gain more insight, cellular accumulation study was conducted according to the protocol described in section 2.3.3. The test compounds (10 µM) were incubated with the cancer cell lines for 24 h and the platinum level was measured by ICP-OES (Figure 4.10 and Table 4.4).

The higher platinum cellular accumulation of CF-101 than that of cisplatin (*** p≤0.001) in HCT-116 and A2780cis may contribute to the comparable cytotoxicity with cisplatin. The platinum accumulation levels of CF-103 and CF-104 in A549 are significantly lower than that of cisplatin.
cisplatin and **CF-101** (**p ≤ 0.0001**), which explains the decreasing cytotoxicity of these compounds in A549. The platinum accumulation level of **CF-102** in A549 is not significantly different from that of cisplatin and **CF-101** (ns p >0.1), which indicates the low cytotoxicity of **CF-102** is not due to the accumulation. The higher platinum cellular accumulation of **CF-101** in A2780 compared to cisplatin (**p ≤ 0.01**) does not result in higher cytotoxicity. Although the platinum accumulation level of **CF-102** in A2780 is significantly higher than all other test compounds (**p ≤ 0.001**), it shows the lowest cytotoxicity with highest IC50. The higher platinum cellular accumulation of **CF-103** and **CF-104** in A2780 than that of cisplatin (**p ≤ 0.01**) may contribute to the decent cytotoxicity. The lowest IC50 of **CF-101** in A2780cis cell line may derive from the highest platinum cellular level (**p ≤ 0.001**). The platinum accumulation level of **CF-101** (and **CF-103**) in A2780 and A2780cis cell lines are not significantly different (ns p >0.1), which may contribute to the low resistance factor. Overall, **CF-101** shows promising efficacy as a lead compound and further studies should be performed in the future.
4.4.2 **Bidentate Pt-HDACi conjugate.** The monodentate Pt-HDACi complex synthesis involves multiple steps and the purification process is time consuming due to running chromatography. Therefore, four small bidentate platinum complexes (Pt-13, Pt-14, Pt-15, and Pt-16) have been synthesized (Scheme 4.3) and evaluated on A2780 and A2780cis cell lines.

Figure 4.11 Preliminary cell viability screening of **Pt-13, Pt-14, and Pt-15** in two different ovarian cell lines at two different concentrations. (a) A2780 with 5 µM, (b) A2780 with 20 µM, (c) A2780cis with 5 µM, (d) A2780cis with 20 µM.
(Figure 4.11) (Pt-16 was eliminated due to the low solubility). All of them show promising efficacy. Although Pt-14 (PtCl$_2$((±)-trans-1,2-cyclohexanediamine)) shows the best efficacy, it is hard to synthesize the enantiomerically pure ligand with HDAC inhibition. Therefore, only Pt-13 (PtCl$_2$(ethylenediamine)) and Pt-15 (PtCl$_2$(phenylenediamine)) were further explored.

**CF-L16** with ethylenediamine as the binding site was designed and shown even better HDAC1 inhibition (28.3 nM) than SAHA (44.8 nM) (Table 3.2). Therefore, the first bidentate Pt-HDACi was synthesized by combing CF-L16 and Pt-13 together. However, the resulting complex CF-201 (Scheme 4.4) has bad solubility in both aqueous and organic solvents. In order to improve the solubility for biostudies, CF-202 was designed and synthesized by changing the amide bond to an ether bond (Scheme 4.4). However, there is no big change in solubility.

**CF-L19** with a phenylenediamine cap was designed (Figure 3.6) from structure modification of Panobinostat. The tertiary amine will improve the water solubility while sterically hinder the binding with platinum. Although it is a racemic mixture, the HDAC1 IC$_{50}$ has reached nM level (1.1 nM). The enantiomerically pure compound will be obtained and conjugated with platinum soon.

### 4.5 Conclusions

Four new Pt-HDACi conjugates have been synthesized, characterized and evaluated by DNA electrophoresis, HDAC inhibition assay, cell viability assay, and cellular accumulation assay. All the conjugates could bind to DNA and have HDAC inhibition as bifunctional molecules. CF-101 shows promising bioactivity data as the lead compound in HCT-116, A549, A2780, and A2780cis. The lowest IC$_{50}$ of CF-101 in A2780cis cell line may derive from the highest platinum cellular level. The low resistance factor of CF-101 might be due to the similar
platinum accumulation level in A2780 and A2780cis cell. Two bidentate Pt-HDACi conjugates have been synthesized, but biostudies were not conducted due to the low solubility.

In order to further understand how these Pt-HDACi works, more intracellular experiments need to be conducted to confirm the DNA damage and HDAC inhibition. CF-101 could be used as the lead compound for further structural modification and in vivo studies.
References


(10) Hoeschele, J. D.; Butler, T. A.; Roberts, J. A.; Guyer, C. E. Analysis and Refinement of


(45) Alison K. Holzer, Gerald H. Manorek, and S. B. H. Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and


(51) Tang, C. H.; Parham, C.; Shocron, E.; McMahon, G.; Patel, N. Picoplatin Overcomes Resistance to Cell Toxicity in Small-Cell Lung Cancer Cells Previously Treated with


J. Cancer **2002**, *38* (SUPPL. 8), S13–S18.


(73) J. Gilmour Morrison, Peter White, Sophie McDougall, John W. Firth, Steve G. Woolfrey, Martin A. Graham, D. G. Validation of a Highly Sensitive ICP-MS Method for the


Wilson, A. J.; Byun, D. S.; Popova, N.; Murray, L. B.; L’Italien, K.; Sowa, Y.; Arango, D.; Velcich, A.; Augenlicht, L. H.; Mariadason, J. M.


Ping Zhu, Elke Martin, Jorg Mengwasser, Peter Schlag, Klaus-Peter Janssen, and M. G.


(101) Osada, H.; Tatematsu, Y.; Saito, H.; Yatabe, Y.; Mitsudomi, T.; Takahashi, T. Reduced


3941.


(129) Gabano, E.; Ravera, M.; Osella, D. The Drug Targeting and Delivery Approach Applied


(136) Simon P. Wisnovsky, Justin J. Wilson, Robert J. Radford, Mark P. Pereira, Maria R. Chan, Rebecca R. Laposa, Stephen J. Lippard, S. O. K. Targeting Mitochondrial DNA


APPENDIX A: SYNTHESIS SCHEME

Scheme 1. Synthesis of HDAC Inhibitor CF-L01

Reagents and conditions: (a) oxepan-2-one, KOH, DMSO, 75 °C; (b) Concentrated H₂SO₄, EtOH, reflux, 73%; (c) NH₂OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 80%.

Scheme 2. Synthesis of HDAC Inhibitor CF-L02

Reagents and conditions: (a) m-CPBA, DCM, rt, 89%; (b) 4-bromo-2-methylpyridine, KOH, DMSO, 75 °C; (c) Concentrated H₂SO₄, EtOH, reflux, 54%; (d) NH₂OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 82%.
Scheme 3. Synthesis of HDAC Inhibitor CF-L03

Reagents and conditions: (a) ethyl hydrogen pimelate, HATU, DIEA, DMF rt, 56%; (b) NH$_2$OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 72%.

Scheme 4. Synthesis of HDAC Inhibitor CF-L04

Reagents and conditions: (a) 8-Methoxy-8-oxooctanoic acid, HATU, DIEA, DMF rt, 43%; (b) NH$_2$OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 69%.

Scheme 5. Synthesis of HDAC Inhibitor CF-L05

Reagents and conditions: (a) Oxepan-2-one, KOH, DMSO, 75 °C; (b) o-Phenylenediamine, HATU, DIEA, DMF rt, 41%; (c) Concentrated H$_2$SO$_4$, EtOH, reflux, 73%; (d) NaOH, THF/H$_2$O (1/1), rt, 35%. 
Scheme 6. Synthesis of HDAC Inhibitor CF-L06

Reagents and conditions: (a) m-CPBA, DCM, rt, 89%; (b) 4-bromo-2-methylpyridine, KOH, DMSO, 75 °C; (c) o-Phenylenediamine, HATU, DIEA, DMF rt, 43%; (d) Concentrated H₂SO₄, EtOH, reflux, 54%; (e) NaOH, THF/H₂O (1/1), rt, 48%.

Scheme 7. Synthesis of HDAC Inhibitor CF-L07

Reagents and conditions: (a) ethyl hydrogen pimelate, HATU, DIEA, DMF rt, 56%; (b) NaOH, THF/H₂O (1/1), rt, 58%; (c) o-Phenylenediamine, HATU, DIEA, DMF rt, 48%.

Scheme 8. Synthesis of HDAC Inhibitor CF-L08

Reagents and conditions: (a) 8-Methoxy-8-oxooctanoic acid, HATU, DIEA, DMF rt, 43%; (b) NaOH, THF/H₂O (1/1), rt, 65%; (c) o-Phenylenediamine, HATU, DIEA, DMF rt, 51%.
Scheme 9. Synthesis of HDAC Inhibitor CF-L09

Reagents and conditions: (a) Oxepan-2-one, KOH, DMSO, 75 °C; (b) tert-butyl (3-amino-[1,1'-biphenyl]-4-yl)carbamate, HATU, DIEA, DMF rt, 80%; (c) Concentrated H$_2$SO$_4$, EtOH, reflux, 73%; (d) NaOH, THF/H$_2$O (1/1), rt, 35%. (e) 4M HCl in dioxane, rt, 63%.

Scheme 10. Synthesis of HDAC Inhibitor CF-L10

Reagents and conditions: (a) m-CPBA, DCM, rt, 89%; (b) 4-bromo-2-methylpyridine, KOH, DMSO, 75 °C; (c) tert-butyl (3-amino-[1,1'-biphenyl]-4-yl)carbamate, HATU, DIEA, DMF rt, 75%; (d) Concentrated H$_2$SO$_4$, EtOH, reflux, 54%; (e) NaOH, THF/H$_2$O (1/1), rt, 48%. (f) 4M HCl in dioxane, rt, 60%.
Scheme 11. Synthesis of HDAC Inhibitor **CF-L11**

Reagents and conditions: (a) ethyl hydrogen pimelate, HATU, DIEA, DMF rt, 56%; (b) NaOH, THF/H₂O (1/1), rt, 58%; (c) tert-butyl (3-amino-[1,1'-biphenyl]-4-yl)carbamate, HATU, DIEA, DMF rt, 93%; (d) 4M HCl in dioxane, rt, 64%.

Scheme 12. Synthesis of HDAC Inhibitor **CF-L12**

Reagents and conditions: (a) 8-Methoxy-8-oxooctanoic acid, HATU, DIEA, DMF rt, 43%; (b) NaOH, THF/H₂O (1/1), rt, 65%; (c) tert-butyl (3-amino-[1,1'-biphenyl]-4-yl)carbamate, HATU, DIEA, DMF rt, 86%; (d) 4M HCl in dioxane, rt, 51%.
Scheme 13. Synthesis of HDAC Inhibitor CF-L13

Reagents and conditions: (a) 8-Methoxy-8-oxooctanoic acid, HATU, DIEA, DMF rt, 46%; (b) NH$_2$OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 39%.

Scheme 14. Synthesis of HDAC Inhibitor CF-L14

Reagents and conditions: (a) 8-Methoxy-8-oxooctanoic acid, HATU, DIEA, DMF rt, 82%; (b) NH$_2$OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, quantitative yield; (c) 1M HCl in EtOAc, rt. quantitative yield.
Scheme 15. Synthesis of HDAC Inhibitor CF-L15

Reagents and conditions: (a) 8-Methoxy-8-oxooctanoic acid, HATU, DIEA, DMF rt, 83%; (b) NH₂OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 96%; (c) 1M HCl in EtOAc, rt. quantitative yield.

Scheme 16. Synthesis of HDAC Inhibitor CF-L16

Reagents and conditions: (a) Methyl 7-aminoheptanoate hydrochloride, HATU, DIEA, DMF rt, 88%; (b) tert-butyl (2-aminoethyl)carbamate, NaBH₄, MeOH, rt, 89%; (c) NH₂OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 67%; (d) 1M HCl in EtOAc, rt. 92%.
Scheme 17. Synthesis of HDAC Inhibitor CF-L17

Reagents and conditions: (a) Ethyl 7-bromoheptanoate, K$_2$CO$_3$, ACN, reflux, 54%; (b) tert-butyl (2-aminoethyl)carbamate, NaBH$_4$, MeOH, rt, 91%; (c) NH$_2$OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 75%; (d) 1M HCl in EtOAc, rt, 92%.

Scheme 18. Synthesis of HDAC Inhibitor CF-L18

Reagents and conditions: (a) Methyl (E)-3-(4-formylphenyl)acrylate, NaBH$_4$, MeOH, rt; (b) NH$_2$OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 28% overall yield
Scheme 19. Synthesis of HDAC Inhibitor CF-L19

Reagents and conditions: (a) Ac₂O, TEA, DCM, rt, overnight, 80%; (b) Fuming HNO₃, Ac₂O, DCM, 0 °C, 1 h, 84%; (c) NaOH, MeOH, rt, 84%; (d) 48% HBr, reflux, 6 h, 74%; (e) Boc₂O, NaOH, THF, rt, overnight, 87%; (f) methyl acylate, Pd(OAc)₂, Ph₃P, TEA, anhydrous ACN, 90 °C, 20 hr, 51%; (g) 1M HCl in EtOAc, rt. overnight, 86%; (h) ACN, K₂CO₃, reflux, overnight, 69%; (i) Fe powder, NH₄Cl, EtOH/H₂O (2/1), reflux, 54% (j) NH₂OH (50 wt% in water), NaOH, DCM/MeOH (1/2), rt, 25%
APPENDIX B: NMR SPECTRA DATA

$^1$H NMR (600 MHz, D$_2$O)

$^1$H NMR spectrum of TCPP in D$_2$O

*D$_2$O solvent residual at 25 °C
$^{13}$C NMR (151 MHz, D$_2$O)

$^{13}$C NMR spectrum of TCPP in D$_2$O

*D$_2$O solvent residual at 25 °C
$^{195}$Pt NMR (129 MHz, D$_2$O)

$[^{195}\text{Pt NMR spectrum of TCPP in D}_2\text{O}]$
$^1$H NMR spectrum of Pt-1 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
\(^{13}\)C NMR spectrum of Pt-1 in DMF-d\(_7\)

*DMF-d\(_7\) solvent residual at 25 °C

\(^{13}\)C NMR spectrum of Pt-1 in DMF-d\(_7\)
\(^{195}\text{Pt} \text{ NMR spectrum of } \text{Pt-1} \text{ in DMF-d}_{7}\)
$^1$H NMR spectrum of Pt-2 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR spectrum of $\text{Pt-2}$ in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{195}$Pt NMR spectrum of **Pt-2** in DMF-\text{d}_7
$^1$H NMR spectrum of Pt-3 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR spectrum of Pt-3 in DMF-d$_7$

*DMF-d$_7$: solvent residual at 25 °C

$^{13}$C NMR spectrum of Pt-3 in DMF-d$_7$
$^{195}$Pt NMR spectrum of Pt-3 in DMF-d$_7$
$^1$H NMR spectrum of Pt-4 in DMF-$d_7$

$^1$H NMR (600 MHz, DMF-$d_7$)

*DMF-$d_7$ solvent residual at 25 °C
\[ ^{13}\text{C NMR spectrum of Pt-4 in DMF-d}_{7} \]

*DMF-d\(_7\) solvent residual at 25 °C
$^{195}$Pt NMR spectrum of Pt-4 in DMF-d$_7$
$^1$H NMR spectrum of Pt-5 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C

$^1$H NMR spectrum of **Pt-5** in DMF-d$_7$
$^{13}$C NMR spectrum of Pt-5 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
HMOC NMR spectrum of Pt-5 in DMF-d$_7$ ($^{13}$C δ 30.81, 30.87 overlaps with solvent residual peak)

*DMF-d$_7$ solvent residual at 25 °C
\[ \text{\(^{195}\)Pt NMR spectrum of Pt-5 in DMF-d7} \]
$^1$H NMR spectrum of Pt-6 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR (151 MHz, DMF-d$_7$)

*DMF-d$_7$ solvent residual at 25 °C

$^{13}$C NMR spectrum of Pt-6 in DMF-d$_7$
$^{195}$Pt NMR spectrum of \textbf{Pt-6} in DMF-d$_7$
$^{1}$H NMR spectrum of Pt-7 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR spectrum of Pt-7 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{195}$Pt NMR spectrum of Pt-7 in DMF-d$_7$
$^1$H NMR spectrum of Pt-8 in DMF-d$_7$

*DMF-d$_7$: solvent residual at 25 °C
$^{13}$C NMR spectrum of Pt-8 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{195}\text{Pt NMR}$ (129 MHz, DMF-d$_7$)

$^{195}\text{Pt NMR}$ spectrum of **Pt-8** in DMF-d$_7$
$^1$H NMR spectrum of Pt-9 in DMF-d$_7$

$^1$H NMR (600 MHz, DMF-d$_7$)

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR (151 MHz, DMF-$d_7$)

Pt-9

$^{13}$C NMR spectrum of Pt-9 in DMF-$d_7$

*DMF-$d_7$ solvent residual at 25 °C
HMOC NMR spectrum of Pt-9 in DMF-d$_7$ ($^{13}$C $\delta$ 24.21, 24.17 overlap)

*DMF-d$_7$ solvent residual at 25 °C
$^{195}$Pt NMR spectrum of Pt-9 in DMF-d$_7$
$^{1}H$ NMR spectrum of Pt-10 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR (151 MHz, DMF-d$_7$)

$^{13}$C NMR spectrum of Pt-10 in DMF-d$_7$

*DMF-d$_7$: solvent residual at 25 °C
$^{195}$Pt NMR (129 MHz, DMF-d$_7$)

Pt NMR spectrum of **Pt-10** in DMF-d$_7$
$^1$H NMR spectrum of Pt-11 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR spectrum of Pt-11 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
HMQC NMR spectrum of Pt-11 in DMF-d$_7$ ($^{13}$C $\delta$ 154.00, 127.53 represents 2 aromatic $^{13}$C respectively)

*DMF-d$_7$ solvent residual at 25 °C
$^{195}$Pt NMR spectrum of Pt-11 in DMF-$d_7$
$^1$H NMR spectrum of Pt-12 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25°C
$^{13}$C NMR (151 MHz, DMF-$d_7$)

$^{13}$C NMR spectrum of **Pt-12** in DMF-$d_7$
HMOC NMR spectrum of Pt-12 in DMF-d$_7$ (The $^{13}$C peak signals between 127.30 and 130.15 ppm represent 6 aromatic $^{13}$C)
$^{195}$Pt NMR spectrum of **Pt-12** in DMF-d$_7$
$^1$H NMR spectrum of Pt-13 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C
$^1$H NMR spectrum of Pt-14 in DMSO-d$_6$

$^1$H NMR (600 MHz, DMSO-d$_6$)

*DMSO-d$_6$ solvent residual at 25 °C

$^1$H NMR spectrum of Pt-14 in DMSO-d$_6$
$^1$H NMR (600 MHz, DMSO-d$_6$)

Pt-15

*DMSO-d$_6$ solvent residual at 25 °C

$^1$H NMR spectrum of Pt-15 in DMSO-d$_6$
$^1$H NMR spectrum of Pt-16 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C*
$^1$H NMR spectrum of CF-L01-2 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C*
C NMR spectrum of CF-L01-2 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C

$^{13}$C NMR spectrum of CF-L01-2 in CDCl$_3$
$^1$H NMR spectrum of CF-L01 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L01 in CD$_3$OD

*CD$_2$OD solvent residual at 25 °C
$^1$H NMR spectrum of CF-L02-3 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L02-3 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^1$H NMR spectrum of CF-L02 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C

$^1$H NMR spectrum of **CF-L02** in CD$_3$OD
$^{13}$C NMR (151 MHz, CD$_3$OD) of CF-L02 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C

$^{13}$C NMR spectrum of **CF-L02** in CD$_3$OD
$^1$H NMR spectrum of CF-L03-1 in CDCl$_3$

*NCDCl$_3$ solvent residual at 25 °C*
$^{13}$C NMR spectrum of **CF-L03-1** in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C*
$^{1}$H NMR spectrum of CF-L03 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C
\[^{13}\text{C} \text{NMR spectrum of } \text{CF-L03 in DMSO-d}_6\]

* DMSO-d$_6$ solvent residual at 25 °C
$^1$H NMR spectrum of CF-L04-1 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L04-1 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C

$^{13}$C NMR spectrum of CF-L04-1 in CDCl$_3$
$^1$H NMR spectrum of CF-L04 in DMSO-d$_6$

* DMSO-d$_6$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L04 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C

$^{13}$C NMR spectrum of CF-L04 in DMSO-d$_6$
$^1$H NMR spectrum of CF-L05-1 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C

$^1$H NMR spectrum of CF-L05-1 in DMSO-d$_6$
$^{13}$C NMR spectrum of CF-L05-1 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C*
$^1$H NMR spectrum of CF-L05 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C

$^1$H NMR spectrum of CF-L05 in CD$_3$OD
$^{13}$C NMR spectrum of CF-L05 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C
$^1$H NMR spectrum of CF-L06-1 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L06-1 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C
$^1$H NMR (600 MHz, CD$_3$OD)

*CD$_3$OD solvent residual at 25 °C

$^1$H NMR spectrum of CF-L06 in CD$_3$OD
$^{13}$C NMR spectrum of CF-L06 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C*
\(^1\)H NMR spectrum of CF-L07-1 in DMSO-d\(_6\)

*DMSO-d\(_6\) solvent residual at 25 °C

\(^1\)H NMR spectrum of CF-L07-1 in DMSO-d\(_6\)*
$^{13}$C NMR spectrum of CF-L07-1 in DMSO-$d_6$
$^1$H NMR spectrum of CF-L07 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C

$^1$H NMR spectrum of CF-L07 in CD$_3$OD
$^{13}$C NMR (151 MHz, CD$_3$OD)

$^{13}$C NMR spectrum of **CF-L07** in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C*
1H NMR spectrum of CF-L08-1 in DMSO-d6

*DMSO-d6 solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L08-1 in DMSO-d$_6$
$^1$H NMR spectrum of **CF-L08** in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C*
$^{13}$C NMR spectrum of CF-L08 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C
H NMR spectrum of CF-L09 in CD$_3$OD

$^1$H NMR spectrum of **CF-L09** in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C*
$^{13}$C NMR spectrum of CF-L09 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C
*CD$_2$OD solvent residual at 25 °C

$^1$H NMR spectrum of CF-L10 in CD$_3$OD
$^{13}$C NMR spectrum of **CF-L10** in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C*
$^1$H NMR spectrum of CF-L11 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C
$^{13}$C NMR spectrum of **CF-L11** in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C*
$^1$H NMR spectrum of **CF-L12** in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C*
$^{13}$C NMR spectrum of CF-L12 in CD$_3$OD

*CD$_2$OD solvent residual at 25 °C
$^1$H NMR spectrum of CF-L13-1 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L13-1 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^1$H NMR spectrum of CF-L13 in DMSO-$d_6$
$^{13}$C NMR spectrum of CF-L13 in DMSO-$d_6$
\(^1\)H NMR spectrum of CF-L14-1 in DMSO-d\(_6\)

\(^\text{*DMSO-d}_6\) solvent residual at 25 °C

\(^1\)H NMR spectrum of CF-L14-1 in DMSO-d\(_6\)
$^{13}$C NMR spectrum of CF-L14-1 in DMSO-d$_6$

* DMSO-d$_6$ solvent residual at 25 °C
$^1$H NMR spectrum of CF-L14-2 in DMSO-d$_6$.
$^{13}$C NMR spectrum of CF-L14-2 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C
$^1$H NMR spectrum of CF-L14 in DMSO-$d_6$
\textsuperscript{13}C NMR spectrum of \textbf{CF-L14} in DMSO-d\textsubscript{6}

*DMSO-d\textsubscript{6} solvent residual at 25 \degree C

\textsuperscript{13}C NMR spectrum of \textbf{CF-L14} in DMSO-d\textsubscript{6}
$^1$H NMR spectrum of CF-L15-1 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L15-1 in DMSO-$d_6$

*DMSO-$d_6$ solvent residual at 25 °C*
$^1$H NMR spectrum of CF-L15-2 in DMSO-d$_6$.

* DMSO-d$_6$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L15-2 in DMSO-$d_6$
$^1$H NMR spectrum of CF-L15 in DMSO-$d_6$

*DMSO-$d_6$ solvent residual at 25 ºC*
$^{13}$C NMR spectrum of CF-L15 in DMSO-d$_6$
$^1$H NMR (600 MHz, CDCl$_3$)

$^1$H NMR spectrum of **CF-L16-1** in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C*
$^{13}$C NMR spectrum of CF-L16-1 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^1$H NMR spectrum of CF-L16-2 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L16-2 in DMSO-d$_6$
HMOC NMR spectrum of CF-L16-2 in DMSO-d$_6$ ($^{13}$C δ 39.95 overlaps with solvent residual peak)

*DMSO-d$_6$ solvent residual at 25 °C*
$^1$H NMR spectrum of CF-L16-3 in DMSO-d$_6$

*DMSO-d$_6$ solvent residual at 25 °C
$^{13}$C NMR (151 MHz, DMSO-$_d_6$)

*DMSO-$_d_6$ solvent residual at 25 °C

$^{13}$C NMR spectrum of CF-L16-3 in DMSO-$_d_6$
HMOC NMR spectrum of CF-L16-3 in DMSO-d$_6$ ($^{13}$C $\delta$ 39.12, 39.97 overlaps with solvent residual peak)

* DMSO-d$_6$ solvent residual at 25 °C
$^1$H NMR spectrum of CF-L16 in DMSO-d$_6$+ D$_2$O (2-3 drops)

*DMSO-d$_6$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L16 in DMSO-$d_6$+D$_2$O (2-3 drops)

*DMSO-$d_6$ solvent residual at 25 °C
HMQC NMR spectrum of CF-L16 in DMSO-\textsubscript{d6}+ D\textsubscript{2}O ($^{13}$C $\delta$ 39.30 overlaps with solvent residual peak)

*DMSO-\textsubscript{d6} solvent residual at 25 °C
$^1$H NMR spectrum of CF-L17-1 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^{13}$C NMR spectrum of **CF-L17-1** in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C*
$^1$H NMR (600 MHz, DMSO-$d_6$)

*BocHN

CF-L17-2

*DMSO-$d_6$ solvent residual at 25 °C

$^1$H NMR spectrum of CF-L17-2 in DMSO-$d_6$
$^{13}$C NMR spectrum of CF-L17-2 in DMSO-$d_6$

*DMSO-$d_6$ solvent residual at 25 °C
HMQC NMR spectrum of CF-L17-2 in DMSO-d$_6$ + D$_2$O ($^{13}$C δ 39.93 overlaps with solvent residual peak)

*DMSO-d$_6$ solvent residual at 25 °C
$^1$H NMR (600 MHz, DMSO-$d_6$)

*DMSO-$d_6$ solvent residual at 25 °C

$^1$H NMR spectrum of **CF-L17-3** in DMSO-$d_6$
$^{13}$C NMR spectrum of CF-L17-3 in DMSO-d$_6$
HMOC (DMSO-d$_6$)

* DMSO-d$_6$ solvent residual at 25 °C

HMOC NMR spectrum of **CF-L17-3** in DMSO-d$_6$ ($^{13}$C δ 39.95 overlaps with solvent residual peak)
$^1$H NMR (600 MHz, D$_2$O)

$^1$H NMR spectrum of **CF-L17** in D$_2$O

*D$_2$O solvent residual at 25 °C*
$^1$H NMR (600 MHz, D$_2$O)

*D$_2$O solvent residual at 25 °C

$^{13}$C NMR spectrum of CF-L17 in D$_2$O
*D₂O solvent residual at 25 °C

HMOC NMR spectrum of CF-L17 in D₂O

H₂N

CF-L17

H₂N

O

H₂N

H

H

OH
$^1$H NMR spectrum of CF-L18 in CD$_3$OD

*CD$_3$OD solvent residual at 25 °C
$^{1}$H NMR (600 MHz, CDCl$_3$)

$^1$H NMR spectrum of **CF-L19-1** in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C*
$^{13}$C NMR spectrum of CF-L19-1 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
\[ ^1\text{H NMR spectrum of CF-L19-2 in CDCl}_3 \]

*CDCl\(_3\) solvent residual at 25 °C*
13C NMR spectrum of CF-L19-2 in CDCl₃

*CDCl₃ solvent residual at 25 °C
\(^1\)H NMR spectrum of CF-L19-3 in DMSO-d\(_6\)

*DMso-d\(_6\) solvent residual at 25 °C

\(^1\)H NMR spectrum of CF-L19-3 in DMSO-d\(_6\)
$^{13}$C NMR spectrum of CF-L19-3 in DMSO-$d_6$

* DMSO-$d_6$ solvent residual at 25 °C

$^{13}$C NMR spectrum of CF-L19-3 in DMSO-$d_6$
$^1$H NMR spectrum of CF-L19-4 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L19-4 in CDCl$_3$

*CDCl$_3$ solvent residual at 25 °C
$^1$H NMR spectrum of 2-(4-bromophenyl)pyrrolidine in DMSO-d$_6$ (couldn’t differentiate enantiomers)

*DMF-d$_6$ solvent residual at 25 °C
$^{13}$C NMR (151 MHz, DMSO-$d_6$) (couldn’t differentiate enantiomers)

2-(4-bromophenyl)pyrrolidine

*DMSO-$d_6$ solvent residual at 25 °C

$^{13}$C NMR spectrum of 2-(4-bromophenyl)pyrrolidine in DMSO-$d_6$ (couldn’t differentiate enantiomers)
$^1$H NMR spectrum of CF-L19-5 in DMSO-d$_6$ (two sets of signals indicate diastereomers)

*DM$$^1$$SO-d$_6$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L19-5 in DMSO-$d_6$ (two sets of signals indicate diastereomers)

*DMSO-$d_6$ solvent residual at 25 °C
$^1$H NMR spectrum of CF-L19-6 in CDCl$_3$ (two sets of signals indicate diastereomers)
$^{13}$C NMR spectrum of CF-L19-6 in CDCl$_3$ (two sets of signals indicate diastereomers)

*CDCl$_3$ solvent residual at 25 °C*
$^1$H NMR spectrum of CF-L19-7 in D$_2$O

*D$_2$O solvent residual at 25 °C

$^1$H NMR spectrum of CF-L19-7 in D$_2$O
$^{13}$C NMR spectrum of CF-L19-7 in D$_2$O
$^1$H NMR spectrum of CF-L19-8 in DMSO-$d_6$

*DMSO-$d_6$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-L19-8 in DMSO-d$_6$ (EtOAc peaks also exist)
$^1$H NMR spectrum of CF-L19 in DMSO-d$_6$

*DMso-d$_6$ solvent residual at 25 °C

$^1$H NMR spectrum of CF-L19 in DMSO-d$_6$
\(^1\)H NMR spectrum of CF-101 in DMF-d\(_7\)

\(^*\)DMF-d\(_7\) solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-101 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{103}$Pt NMR (129 MHz, DMF-d$_7$)

CF-101

$^{195}$Pt NMR spectrum of CF-101 in DMF-d$_7$
$^1$H NMR spectrum of CF-102 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-102 in DMF-d$_7$

*DMF-d$_7$: solvent residual at 25 °C
HMOC NMR spectrum of CF-102 in DMF-d$_7$ ($^{13}$C $\delta$ 153.78, 115.72 represents 2 aromatic $^{13}$C respectively)

*DMF-d$_7$ solvent residual at 25 °C
$^{195}$Pt NMR spectrum of CF-102 in DMF-d$_7$
$^1$H NMR spectrum of CF-103 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-103 in DMF-d$_7$

*DMF-d$_7$, solvent residual at 25 °C
HMOC NMR spectrum of **CF-103** in DMF-d$_7$ ($^{13}$C δ 26.17 represents two $^{13}$C)
$^{195}\text{Pt NMR}$ spectrum of CF-103 in DMF-d$_7$
$^1$H NMR (600 MHz, DMF-d$_7$)

$^1$H NMR spectrum of CF-104 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
$^{13}$C NMR spectrum of CF-104 in DMF-d$_7$

*DMF-d$_7$, solvent residual at 25 °C
*DMF-d$_7$ solvent residual at 25 °C

**HMQC NMR spectrum of CF-104 in DMF-d$_7**
$^{195}$Pt NMR spectrum of CF-104 in DMF-d$_7$
$^1$H NMR spectrum of CF-201 in DMF-$d_7$.

*DMF-$d_7$-solvent residual at 25 $^\circ$C
$^1$H NMR spectrum of CF-202 in DMF-d$_7$

*DMF-d$_7$ solvent residual at 25 °C
APPENDIX C: MASS SPECTRA DATA

ESI-MS mass spectrum of TCPP
ESI-AccuTOF mass spectrum of Pt-1
ESI-AccuTOF mass spectrum of Pt-2
ESI-AccuTOF mass spectrum of **Pt-3**

- Formula: **Pt-3**
- Mass: 441.0277 \([M+Na]^+\)
- Mass: 859.0569 \([2M+Na]^+\)
ESI-AccuTOF mass spectrum of **Pt-4**
ESI-AccuTOF mass spectrum of **Pt-5**
ESI-AccuTOF mass spectrum of **Pt-6**
ESI-AccuTOF mass spectrum of **Pt-7**
ESI-AccuTOF mass spectrum of **Pt-8**
ESI-AccuTOF mass spectrum of **Pt-9**
ESI-AccuTOF mass spectrum of Pt-10
ESI-AccuTOF mass spectrum of **Pt-11**
ESI-AccuTOF mass spectrum of **Pt-12**
ESI-AccuTOF mass spectrum of **Pt-14**
ESI-AccuTOF mass spectrum of Pt-15
DART-AccuTOF mass spectrum of **CF-L01-2**

![Diagram of CF-L01-2 molecule and mass spectrum]
DART-AccuTOF mass spectrum of **CF-L01**
DART-AccuTOF mass spectrum of CF-L02-3
DART-AccuTOF mass spectrum of **CF-L02**
DART-AccuTOF mass spectrum of **CF-L03-1**
DART-AccuTOF mass spectrum of **CF-L03**
DART-AccuTOF mass spectrum of **CF-L04-1**
DART-AccuTOF mass spectrum of CF-L04
DART-AccuTOF mass spectrum of **CF-L05-1**
DART-AccuTOF mass spectrum of CF-L05
DART-AccuTOF mass spectrum of **CF-L06-1**
DART-AccuTOF mass spectrum of **CF-L06**
DART-AccuTOF mass spectrum of **CF-L07-1**
DART-AccuTOF mass spectrum of **CF-L07**
DART-AccuTOF mass spectrum of **CF-L08-1**
DART-AccuTOF mass spectrum of **CF-L08**
DART-AccuTOF mass spectrum of **CF-L09**
DART-AccuTOF mass spectrum of **CF-L10**
DART-AccuTOF mass spectrum of **CF-L11**
DART-AccuTOF mass spectrum of **CF-L12**
DART-AccuTOF mass spectrum of CF-L13-1
DART-AccuTOF mass spectrum of **CF-L13**
DART-AccuTOF mass spectrum of CF-L14-1
DART-AccuTOF mass spectrum of CF-L14-2
ESI-AccuTOF mass spectrum of CF-L14-2
ESI-AccuTOF mass spectrum of CF-L14
DART-AccuTOF mass spectrum of **CF-L15-1**
DART-AccuTOF mass spectrum of **CF-L15-2**
ESI-AccuTOF mass spectrum of CF-L15-2
DART-AccuTOF mass spectrum of **CF-L15**
ESI-AccuTOF mass spectrum of **CF-L15**
DART-AccuTOF mass spectrum of **CF-L16-1**
DART-AccuTOF mass spectrum of CF-L16-2
DART-AccuTOF mass spectrum of CF-L16-3
DART-AccuTOF mass spectrum of **CF-L16**
DART-AccuTOF mass spectrum of **CF-L17-1**
DART-AccuTOF mass spectrum of **CF-L17-2**
DART-AccuTOF mass spectrum of CF-L17-3
ESI-AccuTOF mass spectrum of CF-L17
Varian 320 ESI mass spectrum of **CF-L18**
DART-AccuTOF mass spectrum of **CF-L19-1**
DART-AccuTOF mass spectrum of **CF-L19-2**
DART-AccuTOF mass spectrum of CF-L19-3
DART-AccuTOF mass spectrum of **CF-L19-4**

![Mass spectrum graph](image)

**Formula:**

H₂N₃\[O₂N\]Br

**Charge:** [M+H]⁺

**Molecular Weight:** 244.5903
DART-AccuTOF mass spectrum of **CF-L19-5**

- McLafferty rearrangement (loss of isobutylene)
  
  ![Chemical Structure](image)

- McLafferty rearrangement + Decarboxylation (loss of isobutylene + CO₂)

- \[ \text{[M} - \text{C}_4\text{H}_8 + \text{H}]^+ \]

- \[ \text{[M} - \text{C}_4\text{H}_8 - \text{CO}_2 + \text{H}]^+ \]

- \[ \text{[M} + \text{H}]^+ \]

- \[ 114.0563 \]

- \[ 226.0066 \]

- \[ 270.0067 \]

- \[ 326.0659 \]

\[ m/z \]
DART-AccuTOF mass spectrum of **CF-L19-6**
DART-AccuTOF mass spectrum of **CF-L19-7**
DART-AccuTOF mass spectrum of CF-L19-8
DART-AccuTOF mass spectrum of **CF-L19-9**
ESI-AccuTOF mass spectrum of CF-L19
ESI-AccuTOF mass spectrum of **CF-101**
ESI-AccuTOF mass spectrum of CF-102
ESI-AccuTOF mass spectrum of CF-103
ESI-AccuTOF mass spectrum of **CF-104**
APPENDIX D: X-RAY DATA

X-ray structure of TCPP

X-ray structure of Picoplatin

X-ray structure of Pt-2

X-ray structure of Pt-3
X-ray structure of Pt-4  

X-ray structure of Pt-5  

X-ray structure of Pt-12
X-ray structure of CF-L09

X-ray structure of CF-L10
APPENDIX E: BIOSTUDY DATA

A2780 cells (20 ×) with round shape morphology

A2780cis cells (20 ×) with fibroblastic morphology
Thermal ESI-LTQ mass spectrum of pure DNA with 7 negative charges.
Thermal ESI-LTQ mass spectrum of DNA-cisplatin adduct with 7 negative charges.
Thermal ESI-LTQ mass spectrum of **DNA-Pt-1** (picoplatin) adduct with 7 negative charges.
Thermal ESI-LTQ mass spectrum of DNA-Pt-3 adduct with 7 negative charges.
Thermal ESI-LTQ mass spectrum of DNA-Pt-4 adduct with 7 negative charges.
Thermal ESI-LTQ mass spectrum of DNA-CF-101 adduct with 7 negative charges.
**HCT-116 colon cancer cell line**

IC$_{50}$ curve of CF-L01 to CF-L12 in HCT-116

**A549 lung cancer cell line**

IC$_{50}$ curve of CF-L01 to CF-L12 in A549
DNA gel electrophoresis of cisplatin, **Pt-1, Pt-2, Pt-3** and **Pt-4** (left to right) with three runs for each.

DNA gel electrophoresis of cisplatin, **Pt-5, Pt-6, Pt-7** and **Pt-8** (left to right) with three runs for each.
DNA gel electrophoresis of cisplatin, **Pt-9, Pt-10, Pt-11** and **Pt-12** (left to right) with three runs for each.

DNA gel electrophoresis of cisplatin and **CF-101** (left to right) with three runs for each.
DNA gel electrophoresis of cisplatin, **CF-102, CF-103, CF-104** and SAHA (left to right) with three runs for each.